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I. List of abbreviations 
°C Degree Celsius  
µ Micro 
3R  Replace, Reduce, Refine 
5HT 5-Hydroxytryptamine (Serotonine) 
a/d analogue-digital 
AAALAC Association for assessment and accreditation of laboratory animal care 
AD Alzheimer's disease 
ADMA Asymmetric dimethylarginine 
ADME Absorption, distribution, metabolism, excretion 
ADR Adverse drug reaction 
AE Adverse Event 
AED Anti-epilepsy drug 
Arg Arginine 
AUC Area under the curve 
aVF Augmented voltage foot (Goldberger ECG deviation) 
aVL Augmented voltage left (Goldberger ECG deviation) 
aVR Augmented voltage right (Goldberger ECG deviation) 
AZ  "Aktenzeichen"/ file reference number 
BCS Body conditioning score 
BL Baseline 
bpm Beats per minute 
BSP Burst suppression pattern 
C Central (electrode position) 
C Carbon atom 
ca. circa 
cc cubic centimeter 
Cfree Free concentration in plasma 
CLC Communication link controller 
Cmax Maximum plasma concentration 
CNS Central nervous system  
CRI Constant rate infusion  
CRO Contract research organization 
CSF Cerebrospinal fluid 
CT  Computer tomography  
D Dopamine 
D. rerio Danio rerio, Zebrafish 
DMA Dimethylarginine 
DMPK Drug metabolism and pharmacokinetics 
DMSO Dimethylsulfoxid 
DNA  Desoxyribonucleinic acid  
DSITM Data Science International 
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DSS Data and Statistical Science 
e.g. for example 
ECG Electrocardiogram 
ECoG Electrocorticogram  
EDTA Ethylene diamine tetraacetic acid 
EEG  Electroencephalogram 
EMA  European Medicines Agency  
EMG Electromyogram 
EOG Electrooculogram 
EPSP Excitatory post-synaptic potential 
et al. et alii 
etc. et cetera 
EU European Union 
F  Frontal (electrode position) 
FDA Food and Drug Administration  
FEAB Fentanyl-etomidate-anesthetized beagle 
FELASA Federation for Laboratory Animal Science Associations 
FFT Fast Fourier transformation 
FHD First human dose 
FIH First in human 
FOB Functional observation battery 
Fp Fronto-polar (EEG electrode position) 
Fu (p) Fraction unbound (in plasma) 
GABA Gamma-aminobutyric acid 
GHB Gamma-hadroxybutyrate 
GLP Good laboratory practice  
GV-Solas GV = Gesellschaft für Versuchstierkunde  
Solas = Society for laboratory animal sciences 
HPMC Hydroxypropylmethylcellulose 
hr hour 
HR Heart rate 
Hz Hertz 
i.v.  intravenous 
ICH International Committee on Harmonization of technical requirements for 
registration of pharmaceuticals for human use  
IE  Idiopathic epilepsy  
IED Interictal epileptic discharge 
iEEG intracranial Electroencephalography  
ILAE International League Aganist the Epilepsies 
Inc. Incorporation  
ISPS Inhibitory post synaptic potential 
JET Jacketed external telemetry 
kg Kilogram 
LA left arm (Einthoven ECG deviation) 
LF  Left foot (Einthoven ECG deviation) 
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LFP Local field potential 
LOAEL Lowest observed adverse effect level 
LOEL Lowest observed effect level 
MEA Micro electrode array 
MES Maximal electroshock test 
MEST Maximal electroshock threshold test 
Met Methionine 
mg Milligram 
min minute 
miRNA Micro ribonucleinic acid  
ml Milliliter 
MRI Magnetic resonance imaging  
MTD Maximum tolerated dose 
n Nano 
NaCl Natrium (engl. sodium)-chloride, saline 
NCE New chemical entity  
NOAEL No observed adverse effect level 
NPS Neuropsychiatric symptoms 
NSAID Non-steroidal anti-inflammatory drug 
O  Occipital (electrode position) 
OECD Organization for economic cooperation and development 
P Parietal (electrode position) 
p.o. per os  
PC Phosphatidylcholine 
PD Pharmacodynamics 
PI Principal Investigator 
PK Pharmacokinetic 
PoE Power over Ethernet 
PPB Plasma protein binding 
PTZ Pentylenetetrazole  
RA Right arm (Einthoven ECG deviation) 
RF Radio-frequency 
RR Respiratory rate 
s.c. subcutaneous 
SD Standard deviation 
SDMA Symmetric dimethylarginine 
SE Status epilepticus 
SM Sphingomyelin 
SNE Subdermal needle electrode 
SOP Standard operation procedure 
SUD Substance use disorders  
SWD Spike-wave discharge 
SWS  Seizure warning system 
T Temporal (EEG electrode position) 
t 1/2 Half-life  
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TI Therapeutic index 
TierSchG “Tierschutzgesetz” (German law on animal welfare) 
TierSchHuV “Tierschutzhundeverordnung” (German law on dog welfare) 
TierSchVersV „Tierschutzversuchsverordnung“ (German law on animal experiments) 
TK Toxicokinetic 
Tmax  Time of maximal plasma concentration 
TRH Thyreoid releasing hormone 
TRX DIS's digital transcievers  
TSH Thyroid stimulating hormone 
Tyr Tyrosine 
USA United States of America 
V Volts 
V. Vena 
z zero 
α Alpha-Frequency 
β Beta-Frequency 
γ Gamma-Frequency 
δ Delta-Frequency 
θ Theta-Frequency 
ς Sigma-Frequency 
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II. Introduction 
Neurological liabilities are a major concern during drug development and seizures especially 
are considered a severe adverse effect (Zaccara et al., 1989; Easter et al., 2007; Easter et al., 
2009; Fonck et al., 2015). Not only can they progress into convulsions but repeated seizures 
can cause lasting damage to the brain (Walker & Kovac, 2015). Drugs of different 
pharmaceutical classes and therapeutic indications can have the potential to induce 
seizures, but the highest risk are compounds from central-nervous-system (CNS) indications 
(Easter et al., 2009; Authier et al., 2016).  
Preclinical detection of seizure risk is important to guarantee the safety of participants in 
clinical trials and ultimately human and animal patients. In preclinical drug development, 
seizure liability is often a chance finding in toxicological studies at high doses (Easter et al., 
2009; Backes, 2016). In clinical studies symptoms of non-convulsive seizures such as 
dizziness, hallucinations, blurred vision and mood changes have been reported. Detecting 
such symptoms in animals and relating them to seizures is challenging (Metea et al., 2015). 
Clinical observations of animals are only conducted at pre-defined time points and therefore 
frank convulsions may also be missed (Metea et al., 2015; Backes, 2016). In addition, there 
are often no clear clinical forewarning signs preceding convulsions (Elander, 2013). 
Dedicated studies to explore CNS effects of drug candidates fall within the field of safety 
pharmacology and different models for assessment of seizure liability exist. As it is the only 
method to reliably capture non-convulsive seizures, the current gold-standard for seizure 
liability assessments is video – electroencephalography (EEG) (Easter et al., 2009; Authier et 
al., 2014b). In human medicine, the EEG is a valuable tool for diagnosis of neurologic or 
psychiatric disease. In veterinary medicine, EEG is more challenging as strongly developed 
masticatory muscles cause a higher degree of artefacts as compared to human EEG 
recordings. Moreover, animals do not always tolerate the procedure, and diagnostic 
activation techniques are not easily adapted (Brauer et al., 2011).  
In regulatory safety studies, the dog is the standard non-rodent species and the goal of this 
thesis was to evaluate the use of dog EEG for assessments of neurological symptoms, 
especially seizure liability, in drug development. The design of such studies should enable a 
maximized detection of neurological symptoms and their correlation to drug plasma 
concentrations and biomarkers, while minimizing animal numbers and distress.  
Paroxysmal EEG activity prior to clinical convulsions has been reported during a period that 
could be sufficient for prophylactic anticonvulsive treatment (Dürmüller et al., 2007). This 
could provide a basis for refinement of seizure liability testing in mammals. In addition, 
clinical symptoms occurring at the same time as abnormal, drug induced, EEG patterns are 
also of interest to identify reliable premonitory signs of convulsions. 
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Six adult beagle dogs, three from each gender, were implanted with telemetric EEG 
transmitters. Three of them already had cerebrospinal fluid (CSF) ports, and feasibility to 
combine the two implant types was explored. To this aim, a set of reference compounds was 
tested first. When compatibility of implants was confirmed, three in-house model-
compounds were selected. It is a general belief that the dog is more sensitive for 
neurological symptoms than other species. Still, it has successfully been used in EEG seizure 
studies (Dürmüller et al., 2007; van der Linde et al., 2011b; Authier et al., 2014b; Authier et 
al., 2015; Authier et al., 2016). From the selected previous drug candidates, data was already 
available from rodent and non-rodent safety studies, so that further evaluation of species-
specific sensitivity for neurological symptoms was possible.  
Also, a shortened experimental time could potentially reduce the distress of animals used for 
research. Use of the intravenous route of administration could be a way to achieve this. 
Reducing experimental time would also enable continuous clinical observations thereby 
increasing symptom detection rate and allowing immediate veterinary treatments in case of 
severe symptoms. In addition, sample collection during presence of symptoms could lead to 
an improved correlation of drug plasma concentration to clinical effects, thereby enabling a 
better calculation of safety margins. Dose levels for toxicology studies could be adapted 
accordingly and occurrence of severe neurological symptoms in a larger subset of animals 
could be prevented. In the development of compounds that have a high risk to induce such 
symptoms exploratory pilot studies as investigated here could help to refine regulatory 
toxicological studies. 
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III. Literature 
1 Seizure and Convulsion Liability Assessments in Drug Development 
A thorough evaluation of the adverse effect profile of novel drugs is a major pillar of drug 
development. The aim of safety assessment studies is risk identification in relation to 
exposure. This allows calculation of safety margins that ensure patient safety. If a sufficient 
safety window (therapeutic index, TI) cannot be established, further development is 
stopped. Early detection of adverse effects is important to guide project decisions for 
selection of the best development candidate (Easter et al., 2009; Butler et al., 2017). Seizure 
liability is a dangerous adverse CNS effect, but Easter et al. (2009) observed that it is often 
only investigated after convulsions have been observed in toxicology studies. Later 
discontinuation of a project implies that more animals have been used without creating a 
benefit for patients. Attrition is especially high in certain indications and one of them is 
neuroscience (Mead et al., 2016). Many companies have stopped investing in this field, 
reducing the chance to close therapeutic gaps in diseases like Alzheimer’s diseases (AD) or 
schizophrenia (Pangalos et al., 2007). The complexity of the nervous system, with many 
pathways not being completely understood, is one reason for this (Scott et al., 2013). Both, 
drugs that target the CNS and drugs that do not, have been related to seizure induction 
(Zaccara et al., 1989; Easter et al., 2007; Easter et al., 2009; Fonck et al., 2015). Easter et al. 
(2009) retrospectively evaluated investigative drugs from AstraZeneca (1999-2008) with 
preclinical findings of seizure liability and found that 50% of them were not from CNS 
indications. As with other adverse effects, seizure liability needs to be evaluated in relation 
to exposure (FDA, 2001) and therapeutic range (Löscher, 2009; Backes, 2016) in order to 
determine the appropriate safety margin. Convulsions are a severe finding and regulators 
require a high safety margin of additional 10x from the no observed effect level (NOAEL) for 
animals (Elander, 2013). Determination of exposure levels at the time point of seizures or 
convulsions therefore is beneficial for calculation of safety margins.  
 
 Definitions: Seizures and Convulsions 1.1
In literature, the terms seizure and convulsion are often used interchangeably (Elander, 
2013). According to Fisher et al. (2005), “an epileptic seizure is a transient occurrence of 
signs and/ or symptoms due to abnormal excessive or synchronous neuronal activity in the 
brain.” (Fisher et al., 2005) and a convulsion can potentially be a clinical symptom of this 
(Easter et al., 2007; Easter et al., 2009). A convulsion is defined as an episode of abnormal 
and pronounced muscle contractions (Blume et al., 2001; Fisher et al., 2005; Easter et al., 
2009). Its quality can be tonic, clonic or tonic-clonic (Blume et al., 2001; Fisher et al., 2005; 
Fonck et al., 2015). “Tonic” describes an increase in muscle tone for a few seconds to 
minutes (Blume et al., 2001). Repetitive prolonged myoclonic muscle contractions are 
referred to as clonic convulsion or rhythmic myoclonus (Blume et al., 2001). According to 
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Löscher (2009), convulsions are an unspecific symptom of many developmental drugs. The 
relation between seizures and convulsions is expressed in the, according to Metea et al. 
(2015), frequently used formulation: “not all seizures result in behavioral convulsions and 
not all apparent convulsions are related to seizures” (Metea et al., 2015).  
Historically, seizures were first defined in the context of human epilepsy in 1964 by the 
“International League Against the Epilepsies”(ILAE) (Berendt et al., 2015). They first 
introduced a unified classification scheme for seizures in the variants of human epilepsy in 
1969 (Gastaut, 1969). This classification scheme differentiates main categories of seizures 
according to their mode of onset (partial, generalized, unclassified) and classifies each one 
into different subgroups. It has then been subject to multiple revisions, e.g. (Merlis, 1970; 
Angeles, 1981; Dreifuss, 1989; Fisher et al., 2005; Engel, 2006; Berg et al., 2010).  
In veterinary medicine, the “international veterinary epilepsy task force” adapts the human 
terminology to animal epilepsy to provide a common language for veterinary neurologists 
and create consensus between animal and human epilepsy understandings (Berendt et al., 
2015). Their first proposal has been published in 2015 (Berendt et al., 2015). In veterinary 
medicine, Fischer et al. (2013) considered the clinical value of a classification scheme for 
seizures as limited, due to multiple causes: first, diagnosis often is based on descriptions or 
video recordings provided by the patient owners only, instead of on EEG recordings (Fischer 
et al., 2013). Treatment options in animal epilepsy are limited, so the scheme is not needed 
to guide selection of anti-seizure-drugs (Fischer et al., 2013). Lastly, there are differences in 
progression and severity of epilepsy between dog breeds and some epilepsy syndromes are 
unique to certain breeds (Fischer et al., 2013). 
Walker & Kovac (2015) pointed out that the ILAE definition of a seizure is not 
comprehensive, neither to describe epileptic seizures in humans nor when applied to 
pharmacological research. According to them, it is important to consider that not all seizure 
activity results in signs or symptoms visible for an external observer and that preclinical 
assessment of seizure liability is done in different in vitro assays, e.g. hippocampal slices, and 
in animal models (Walker & Kovac, 2015). Therefore, their proposal for the definition of a 
seizure was: “A seizure is the escalating synchronization of neurons originating from the CNS 
[thereby including its occurrence in cell cultures or other in vitro assays]. In vivo, a seizure 
may elicit specific symptoms like, for example convulsions, depending on the affected brain 
region or species” (Walker & Kovac, 2015).  
 
 Causes of Seizures: Symptomatic and Reactive Seizures  1.2
The mechanisms that cause the occurrence of a seizure or a convulsion cannot always be 
identified (Delanty et al., 1998; Elander, 2013). Synchronous firing of neurons is generated if 
the balance between inhibitory and excitatory neurotransmission is disrupted (Delanty et al., 
1998; Fonck et al., 2015). This can happen as a consequence of structural abnormalities of 
the CNS, metabolic disturbances or drug actions (Delanty et al., 1998). Epilepsy is defined by 
Literature 
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the occurrence of at least two spontaneous seizures (Fischer et al., 2013). In the diagnosis of 
epilepsy, primary (or idiopathic), secondary (or symptomatic) and reactive seizures are 
differentiated. Idiopathic seizures are the “true epileptic” form, resulting from a functional 
impairment of the brain, whereas “symptomatic” applies if other diseases are causative 
(Podell et al., 1995; Fischer et al., 2013). In cases in which the origin of the disorder cannot 
be identified, “epilepsy with unknown cause” is diagnosed, (Fischer et al., 2013). “Reactive” 
seizures are induced in a normal brain by external causes, mainly toxins or metabolic 
alterations (Podell et al., 1995; Fischer et al., 2013). Drug-induced seizures thereby fall in this 
latter category. According to Podell et al. (1995), recurrence of reactive seizures does not 
justify the diagnosis of epilepsy, as they are reactions of a normal brain without structural or 
functional abnormalities. 
 
 Symptoms of Seizures 1.3
Symptoms of a seizure can be variable depending on extent and localization within the CNS 
(Easter et al., 2009; Elander, 2013; Fischer et al., 2013). As described in human medicine, 
signs of non-convulsive seizure, both generalized or focal, range from mood changes or 
impaired vision (Easter et al., 2009), over headache to hallucinations. In non-convulsive 
status epilepticus, alterations in mental state of different degrees are an always present 
symptom (Husain et al., 2003). These alterations “can range from mild confusion to 
profound impairment of consciousness” (Husain et al., 2003). In epileptic patients it has 
been shown that electrophysiological seizure activity can be present hours in advance of a 
visible manifestation (Litt et al., 2001). 
In animals, signs of non-convulsive seizures induce unspecific or subtle behavioral changes 
that are difficult to detect and even more challenging to interpret (Baird et al., 2015; Metea 
et al., 2015). Alterations in the level of consciousness in animals can be expressed in reduced 
or abnormal activity, like tail-chasing or aggressiveness (Dodman et al., 1996). Myoclonic 
twitches or muscle rigidity can also be signs of seizures, both drug induced (Metea et al., 
2015) and epileptic (Fischer et al., 2013). Also, autonomic signs like increased salivation, 
vocalization and ocular abnormalities can be symptoms of seizures (Fischer et al., 2013). 
In drug development, such signs might not be recognized as ongoing seizure activity by the 
study personnel (Easter et al., 2009; Metea et al., 2015) and it is challenging to judge them 
as potential premonitory signs for convulsions (Elander, 2013; Metea et al., 2015). Also, due 
to their short duration or occurrence at times when the animals are not observed (e.g. at 
night), seizures and seizure-related convulsions can be missed (Metea et al., 2015; Backes, 
2016). 
The ultimate detection of a seizure is with the EEG (Privitera et al., 1994; Podell et al., 1995; 
Elander, 2013; Fonck et al., 2015). EEG signs that precede seizures, and thereby indicate a 
lowered seizure threshold, are a general increase in synchrony, isolated or repetitive sharp 
waves, isolated spikes or isolated spike-waves (Metea et al., 2015; Authier et al., 2017). 
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Seizures in the EEG consist of mainly spike-wave-complexes as spike trains. “The ictal nature 
of observed EEG abnormalities” can also be indicated by “other EEG forms such as 
paroxysmal spikes, fast ripples, or postictal depression” (Fonck et al., 2015). In cases of 
convulsive seizures, it can be determined via EEG whether the convulsion was centrally or 
peripherally mediated (Elander, 2013).  
 
 Preclinical Seizure Liability Assessments: Methods in Drug Development 1.4
 In silico Methods 1.4.1
Computational prediction of a drug’s pharmacological profile, especially its capability to 
penetrate the blood-brain-barrier, can help to calculate the risk of a new chemical entity 
(NCE) (Easter et al., 2009; Butler et al., 2017). Computers can match a compound’s structure 
to pathways known to be related to seizure generation. Easter et al. have identified 53 
targets with potential seizure risk and based on this, Zhang et al. (2011) developed a support 
vector machine method that detects seizure liability with an accuracy of 86.9%1. The 
foundation of computational tools is a thorough review of the literature. In general, 
literature research is one of the first steps in target safety assessments (Butler et al., 2017). 
Limitation of computational approaches, as concluded by Easter et al. (2009), is the lack of 
ultimate understanding of seizure generation.  
 
 In vitro Methods 1.4.2
In vitro profiling can reveal a candidate drug’s affinity for a receptor or interaction with other 
CNS pathways known to be involved in seizure generation (Easter et al., 2009; Elander, 
2013). Affinity studies detect binding potential, whereas functional in vitro assays bring 
further information on the consequent effects, like interaction with neurotransmitters or 
action as either agonist or antagonist (Easter et al., 2009; Elander, 2013). According to Scott 
et al. (2013), “Patch clamp electrophysiology is the gold standard method of detecting 
compounds that perturb electrical activity”; usually one ion channel is investigated at a time 
so they are less suited as general screening tools.  
Culturing neuronal cells, mixed with glia cells, on microelectrode arrays (MEA) is possible 
with cells of different origin to test influences on different pathways in the neuronal network 
(Scott et al., 2013). In vitro methods can be conducted as early screening methods at low 
costs, have a high throughput and usually low compound needs (Easter et al., 2009; 
Markgraf et al., 2014). However, according to Scott et al. (2013), investigation of CNS effects 
is “challenging to study in vitro due to the large number of cell types that exist in the brain 
and the complex anatomical and functional networks that underlie human behaviors” (Scott 
et al., 2013). In addition, in vitro methods do not allow determination of systemic influences 
on seizure generation (Cole et al., 2002). 
                                                     
1 Currently, the link to this tool is corrupt and the author was contacted to investigate whether this is due to 
technical or scientific reasons  
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1.4.3 Ex vivo Methods 
For assessment of seizure liability ex vivo, brain slice preparations, most commonly the rat 
hippocampal brain slice assay, have been developed (Easter et al., 2009; Elander, 2013; 
Markgraf et al., 2014). Predictability for the performance of 16 reference compounds was 
89% in the rat hippocampal slice assay (Easter et al., 2009). Easter et al. (2009) note that the 
use of slices originating from other brain areas and multi-electrode arrays could increase 
assay performance. Fonck et al. (2015) add, that “the most appropriate preparation is likely 
to be dependent on the exact mechanism of drug induced seizure” (Fonck et al., 2015).  
 
1.4.4 In vivo Zebrafish Locomotor Assay 
Early in vivo screening of drug candidates can be done in the larval zebrafish (Danio rerio) 
locomotor assay (Winter et al., 2008; Easter et al., 2009; Koseki et al., 2014; Cassar et al., 
2017). Larval zebrafish are exposed to the test compound souled in fish water and their 
swimming behavior is tracked (Winter et al., 2008; Easter et al., 2009). Within this assay, 
reference compounds have a good predictivity in different laboratories: Winter et al. (2008) 
report 72% predictivity and Cassar et al. (2017) achieved 70% sensitivity, 100% specificity, 
100% positive predictive value and 57% negative predictive value (Cassar et al., 2017). With 
drug candidates with known preclinical seizure liability, assay performance was poor: 
Despite exposure levels comparable to reference compounds, 2 out of 9 candidates were 
false negative (22% sensitivity, 100% specificity, 100% positive predictive value and 46% 
negative predictive value) (Cassar et al., 2017).  
 
1.4.5 In vivo Rodent and Non-Rodent Methods  
Convulsive drug action can possibly be detected in rodent behavioral observation assays. For 
improved detection or further characterization, specialized tests have been developed. Most 
of them are based on induction of convulsions in different animal models and derive from 
efficacy testing of anti-epileptic drugs (Easter et al., 2009). In general, the candidate drug is 
administered in connection with a convulsive stimulus and the latency to convulsions or the 
dose necessary to induce them is compared to controls. To induce convulsions, either 
chemicals (e.g. pentylenetetrazole, PTZ) or electricity can be applied. Repeated electrical 
stimulation is also used to permanently lower the seizure threshold (kindling effect) to 
increase the animals’ sensitivity for proconvulsive agents (Potschka et al., 2000). Alternatives 
to kindled animals are genetically seizure-prone animals (Löscher, 2009). EEG recordings 
from these animals can be included to further increase the sensitivity of this approach 
(Elander, 2013). 
The gold standard for seizure detection is the video-EEG (Easter et al., 2009). It allows 
seizure classification and detection of absence or non-convulsive seizures (Russo et al., 2011; 
Hamdam et al., 2013) as well as it can preclude seizure activity in cases of unclear symptoms 
(Easter et al., 2009). In addition, the EEG can show CNS effects at low doses and improve 
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calculation of safety margins (Elander, 2013). EEG seizure liability studies have been 
successfully performed in rodents (Easter et al., 2009; Markgraf et al., 2014; Authier et al., 
2016), as well as in non-rodents (Braitman & Sparenborg, 1989; Dürmüller et al., 2007; 
Authier et al., 2009; van der Linde et al., 2011a; van der Linde et al., 2011b; Authier et al., 
2016). Hamdam et al. (2013) describe video-EEG an “emerging technique”, as ”simultaneous 
assessments of new compounds on behavior (via video), seizure liability and disruption of 
sleep patterns (via EEG)” has been facilitated (Hamdam et al. (2013), referring to Authier et 
al. (2009)). A safety pharmacology animal model that uses the EEG to investigate CNS 
symptoms is the fentanyl-etomidate-anesthetized beagle (FEAB) (Van Deuren et al., 2009; 
van der Linde et al., 2011a; van der Linde et al., 2011b). According to the authors, its 
advantages are the possibility to simultaneously evaluate central-nervous, cardiovascular 
and respiratory parameters (van der Linde et al., 2011b). Disadvantages of anesthetized 
animal models are potential pharmacodynamic and pharmacokinetic interactions between 
the anesthetic and the test compound. Also, anesthetics themselves influence CNS activity 
and pro- or anticonvulsive effects have been described (Reddy et al., 1993; Baraka & Aouad, 
1997).  
 
1.5 Preclinical Seizure Liability Assessments: Current Practice in the Pharmaceutical 
Industry  
It has been pointed out that an early detection of seizure risk is advantageous to enable 
chemical modification of the molecule and guide the project strategy on an early stage 
(Pugsley et al., 2008; Easter et al., 2009; Hamdam et al., 2013). Early-stage screening 
methods (computational, in vitro, ex vivo, rodent behavioral observations) do not guarantee 
detection of seizure liability and the first adverse findings are convulsions in advanced-state 
toxicology studies (Easter et al., 2009). At this stage of the development process, many 
resources and animals already have been used and the finding of a convulsion can 
complicate and potentially stop further development of a drug candidate (Easter et al., 2009; 
Elander, 2013; Fonck et al., 2015). In addition, the requirements by the ICH S7A are not 
specific, so no standardized approach for seizure liability testing is established (Porsolt et al., 
2002; Easter et al., 2009; Markgraf et al., 2014; Fonck et al., 2015; Metea et al., 2015). 
Currently, there is no single method that guarantees adequate assessment of seizure liability 
or proconvulsive action, so usually a combination of methods is used (Easter et al., 2009; 
Löscher, 2009; Elander, 2013). Experience from previous interactions with regulatory 
authorities can guide the strategy to advance the program (Authier et al., 2013).  
Elander (2013) assembled parameters that need to be considered after the occurrence of 
convulsions. Before choosing follow-up tests, a detailed description is needed referring to 
duration, quality (tonic, clonic, tonic-clonic), loss of consciousness and recovery (Elander, 
2013). Concomitant stress factors that might lower the seizure threshold like noise, handling 
or altered clinical chemistry parameters should be considered as well (Elander, 2013). Also, 
impurities of the test compound have to be excluded (Elander, 2013). At necropsy, 
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additional histopathological methods, like special stains, can be used to identify astrocyte 
and microglial changes or neurodegeneration that have been linked to convulsions (Elander, 
2013). A dedicated seizure liability study should allow “determination of drug plasma levels 
at the time of symptoms and confirm the NOAEL, identify premonitory signs that can be 
translated to clinical trials, confirm that the seizure is self-limiting and can be treated with 
standard anticonvulsants” (Authier et al., 2013; Authier et al., 2014b). Also, the therapeutic 
indication and the targeted patient population are factors that need to be considered for a 
thorough risk assessment (Fonck et al., 2015).  
 
1.5.1 Species Selection for in vivo Seizures Liability Studies  
Rodents are the routine species used as long as no pharmacological indication necessitates 
the use of a non-rodent species (Authier et al., 2009; Authier et al., 2014b; Authier et al., 
2016). There are ethical concerns about the use of animals in drug development and 
especially the use of non-rodents is often questioned in the scientific community and the 
general public (Spielmann & Gerbracht, 2001; Bailey et al., 2013). So far use of rodents and 
non-rodents remains a regulatory requirement (FDA, 2005) and several authors showed 
better translatability of results from non-rodent than from rodent testing (Broadhead et al., 
2000; Olson et al., 2000; Spielmann & Gerbracht, 2001). 
In regular safety testing, the dog is often referred to as the standard non-rodent species 
(Broadhead et al., 2000; Hasiwa et al., 2011; Bailey et al., 2013) and next to the rat, it is the 
most commonly used species in toxicology (Easter et al., 2009). One advantage of the dog as 
a preclinical species is that it has long been a companion animal to humans. Due to this close 
relation, dogs show symptoms more reliably than animals with a lesser degree of 
domestication and study personnel is accustomed to interpreting dog behavior (Backes, 
2016). Appropriate housing conditions can be offered to dogs in a research facility, and 
handling is in general well tolerated. Providing good conditions for research animals is 
demanded for ethical and legal reasons as well as it is the base for good results (Clark & 
Pomeroy, 2010). An extensive literature background exists on dogs (Clark & Pomeroy, 2010) 
and authorities worldwide accept data generated in this species. Physiological parameters 
compare well to humans, and therefore the dog has been used as a model for many human 
diseases, including genetic diseases (Reid et al., 1996; Clark & Pomeroy, 2010).  
Dogs are generally believed to be overly sensitive to convulsions (Redman & Weir, 1969; 
Edmonds et al., 1979; Easter et al., 2009; Hasiwa et al., 2011) and that they are therefore 
less suited as a relevant model to assess human seizure liability (Authier et al., 2014b). On 
the other hand, authorities require testing drug effects in the most sensitive species (FDA, 
2005) and therefore, according to Authier et al. (2013), the use of the dog can be specifically 
requested. Easter at al. (2009) hypothesized that the increased susceptibility of the dog for 
seizures is due to its genetic predisposition to epilepsy. This disease is the most common 
neurologic disorder in dogs (Volk, 2015) and currently it is estimated that 0.5-1% of the 
population is affected (Fischer et al., 2013). The incidence of idiopathic epilepsy is higher in 
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certain breeds (Fischer et al., 2013; Hülsmeyer et al., 2015) and the beagle dog, that is most 
often used in pharmaceutical research, is amongst them (Bielfelt et al., 1971; Fischer et al., 
2013). Canine epilepsy is very comparable to the human disease: the incidence is similar, 
many drugs are effective in both species and EEG recordings from human and dog epileptics 
show the same characteristics (Berendt et al., 1999; Potschka et al., 2013). As a result, the 
epileptic dog has also been discussed as a natural model of the human disease (Potschka et 
al., 2013). Limitations of canine epilepsy as a natural disease model are the lack of routine 
EEG investigations in the characterization of dog epilepsy (Brauer et al., 2011) and the very 
limited documentation of temporal lobe epilepsy in the veterinarian literature. Also, species 
differences in pharmacokinetics, e.g. the shorter elimination time in dogs compared to 
humans (Potschka et al., 2009), are drawbacks of the canine model in the testing of novel 
anti-epileptic drugs (Potschka et al., 2013).  
Considering species similarities of dogs and humans with regards to epileptic seizures and 
the concomitant experience with seizures in dogs (detection, literature references, and 
treatment options), the dog can be considered as a model for seizures liability studies in 
drug development. Also, Olson et al. demonstrated that results from dog studies predict 
human toxicities to a higher degree (63%) compared to rodents (43%) (Olson et al., 2000). 
One disadvantage of the use of rodents compared to dogs is the smaller size that does not 
account for detection of some signs related to non-convulsive seizure liability like 
nystagmus. Retrospective analysis of internal data could not confirm a higher convulsion 
susceptibility of the dog compared to the NHP (Backes, 2016) and this mitigates concerns 
about false positive results.  
The background incidence of spontaneous seizures should be considered in any dedicated 
seizure liability study (Easter et al., 2009; Elander, 2013) as spontaneous convulsions have 
not only been observed in beagles (Edmonds et al., 1979) but also in rats (Nunn & 
Macpherson, 1995) and for some strains of NHPs natural occurrence of epilepsy with 
photosensitivity is also known (Meldrum et al., 1975; Szabó et al., 2005).  
 
1.6 Clinical Seizure Liability  
In a clinical setting, it is very rare that the occurrence of a seizure in a patient can be related 
to a single drug (Murphy & Delanty, 2000). There are many factors that can promote seizure 
risk. Only to mention a few, there are interactions with other drugs or alcohol, a special 
predisposition due to the illness itself, inherited neurological disorders or other 
comorbidities (Delanty et al., 1998; Murphy & Delanty, 2000; Löscher, 2009; Fonck et al., 
2015). The risk for drug-induced seizures is higher with epilepsy patients (Fonck et al., 2015) 
and in other conditions with a reduced seizures threshold (Dickey & Morrow, 1990), e.g. 
with an impaired blood-brain barrier (Fonck et al., 2015). The probability that a new-onset 
generalized seizure in humans is drug – induced was estimated to be 6.1% (Pesola & 
Avasarala, 2002).  
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Evaluation of results acquired in the course of clinical trials can be of special value to 
estimate seizure liability of released drugs. In contrast to case reports, they are assessed in 
controlled conditions (Rosenstein, 1993). If a seizure occurs in the course of a clinical study 
as an adverse event (AE), which is seldom the case, its relation to the study drug is examined 
thoroughly by the principal investigator (PI) and by physicians from both, pharmaceutical 
company and FDA (Food and Drug Administration) (Alper et al., 2007). The overall safety of 
first-in human doses seems to be guaranteed, as shown in a retrospective analysis by Bayer 
(Wensing et al., 2010). This report covers the years 2000-2005 but reflects, as to the authors, 
experience from a longer period: the most frequent symptom in phase I studies was 
headache and none of the adverse effects required hospitalization or led to lasting 
impairments (Wensing et al., 2010). Still, the recent example of BIA-10247 in which 5 healthy 
volunteers suffered from irreparable brain damage, in one case leading to death (Kaur et al., 
2016) implicates “that drug development will always have risks” and that “It is not possible 
to identify all ‘high-risk’ compounds that need elevated risk assessment” (Eddleston et al., 
2016). 
The definite safety profile of a drug can only be defined after its release, when it has been 
used by a larger number of patients, in a more of more diverse population and potentially in 
off-label or multiple-drug use conditions (Fung et al., 2001; McNaughton et al., 2014). 
Reports about seizures occurring post – marketing can be found with drugs from all kinds of 
pharmaceutical classes and fields of indication (Dickey & Morrow, 1990). Fonck et al. (2015) 
observed that seizures in relation with use of a marketed compound generally occur at 
(brain) exposure levels exceeding the recommended limits. The highest risk is reported for 
drugs which directly access the CNS, e.g. antidepressants or neuroleptics (Dickey & Morrow, 
1990; Easter et al., 2009; Kumlien & Lundberg, 2010). Among neuroactive compounds, 
antidepressants seem to imply a specifically high risk, being the leading cause of seizures 
reported to poison control centers in 1988-1989 (29%, (Olson et al., 1993)) and in 2003 (49% 
(Thundiyil et al., 2011)). 31% of drugs withdrawn for safety reasons from the market 
between 1960 and 1999 were from CNS indications (Fung et al., 2001). The safety issues that 
were causative of this were not seizures but mainly hepatic and hematologic liabilities, 
followed by cardiovascular, dermatologic and carcinogenic; often, multiple toxicities were 
the cause (Fung et al., 2001). Neurologic reasons contributed to only 4.1% of withdrawals, 
followed by psychiatric and abuse (Fung et al., 2001).  
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2 The Electroencephalogram 
An electroencephalogram is a recording of the spontaneous electric activity of the brain 
(Kirschstein, 2008) measured by electrodes placed above different brain regions. Cortical 
pyramidal neurons are the main generators of the EEG (Teplan, 2002; Kirschstein, 2008). 
Glial cells also contribute to the EEG as they have close electrical coupling between each 
other, thereby amplifying the neuronal signal (Holliday & Williams, 1999). To be exact, the 
term EEG only refers to recordings derived from scalp electrodes, whereas an 
electrocorticogram (ECoG) is measured directly from the cortical surface and an electrogram 
is a recording from depth electrodes (Teplan, 2002). In literature however, the term EEG is 
frequently used for any recording of electric brain activity, regardless of the recording 
technique.  
The electric activity is generated at synapses, when the action of different neurotransmitters 
induces either an inhibitory (IPSP) or excitatory (EPSP) potential at the postsynaptic neuron 
through changes in the local distribution of ions (Holliday & Williams, 1999; Kirschstein, 
2008). Action potentials in the axons do not significantly influence the EEG due to their 
multi-directional course relative to the surface that results in a net potential equaling zero 
(Holliday & Williams, 1999).  
Cortical neurons function as a dipole, so depending on the site of the electric excitation, 
mainly its distance to the recording electrode, the signal measured on the skull can either be 
positive or negative (Kirschstein, 2008). An ESPS in deep sites will induce positivity below a 
surface electrode whereas an EPSP just below that electrode will cause negativity (Holliday & 
Williams, 1999). A single post-synaptic potential is too small to be recorded but pyramidal 
cells have a multitude of synapses that fire with some synchrony, sum up and facilitate 
recording with an EEG electrode (Holliday & Williams, 1999).  
The anatomic organization of the brain in gyri and sulci has the effect that the electric 
currents that run horizontally below the electrode are not completely captured (Kirschstein, 
2008). The recorded signal is the sum of all inhibitory and excitatory postsynaptic potentials, 
predominantly from cells on the top of one gyrus (Kirschstein, 2008). Thereby, the signals 
acquired via EEG are field potentials that have no definite direction like muscle potentials, 
that pass through a fiber in a direction relative to an electrode (Holliday & Williams, 1999). 
 
2.1 The Electroencephalogram in Veterinary Medicine 
 Historical Overview  2.1.1
The British physiologist R. Caton was the first person to measure electric brain activity from 
animals in 1875 (Caton, 1875; Brass, 1959; Teplan, 2002). Brass (1959) reviewed the 
consequent research activities using animals that where then initiated to expand the 
knowledge about the electric currents of the brain (Brass, 1959). According to him, the first 
term for this novel technique, “electrocerebrogram”, was introduced in a review on electric 
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brain activity by Práwdicz-Neminski in 1925 (Brass, 1959). He was also the first to 
comprehensively describe spontaneous electric activity of the dog’s brain; for this, dogs 
were immobilized with curare and their EEG was measured invasively through holes in the 
skull (Brass, 1959). In 1924, Hans Berger was first to record the human scalp EEG (Teplan, 
2002). For linguistic reasons (not to mix Greek and Latin), he introduced the term 
“electroencephalogram” in 1929 (Berger, 1929; Haas, 2003). Berger described the distinct 
EEG waveforms and their changes in different vigilance and disease states (Brass, 1959).  
Animal EEG was mostly used for experimental, not diagnostic, purposes (Brass, 1959). Fields 
of interest were experimentally induced epilepsy or investigation of drug substance 
influences on the EEG, mainly of anesthetics (Brass, 1959). The first introduction of the EEG 
as a diagnostic technique in clinical veterinary medicine was by Brass (Brass, 1959; Schütt-
Mast & Stephan, 1996; Holliday & Williams, 1999). He established EEG reference values by 
collecting data from healthy dogs and comparing them to recordings from patient dogs, 
using five electrodes. He concluded that the main application of EEG in veterinary medicine 
is for localization of focal pathologies as hematomas, neoplasms or inflammatory processes 
and their differentiation to epileptic seizures to guide treatment decisions or surgery 
planning (Brass, 1959). 
One year after Brass’ first description of the use of the EEG in the veterinary clinic, McGrath 
published a textbook with guidelines for neurologic examination of dogs that that included a 
description of the EEG as diagnostic tool in veterinary medicine as well (McGrath, 1960). In 
1962, Croft described electroencephalography as a “young and growing science” and already 
noted the lack of standardization of recording and interpretation techniques in veterinary 
medicine (Croft, 1962). Croft contributed to the knowledge of pathological EEG patterns like 
the flat EEG in encephalitis (Croft, 1970a) or spike-wave patterns in epilepsy (Croft, 1962), 
changes after head trauma (Croft, 1970b), in cerebrovascular diseases (Croft, 1971), and 
space-occupying lesions (Croft, 1972). Like Brass, Croft and other clinicians at that time 
preferred recording EEGs from un-anesthetized animals with different degrees of 
mechanical restraint (Brass, 1959; Croft, 1962; Redding, 1964).  
While Brass and Croft used needle electrodes (Brass, 1959; Croft, 1962), Redding proposed 
the use of alligator clamps in veterinary medicine and described new recording coordinates 
(Redding, 1964). Advantage of alligator clamps over needle electrodes is that clipping of the 
hair, to which some owners might oppose, is not necessary for proper fixation (Redding, 
1964). He used local anesthetics to anesthetize the facial muscles to both, prevent artefacts 
and block pain induced by the clamps (Redding, 1964). Redding also published the “Atlas of 
Electroencephalography in the Dog and Cat” in 1984 (Redding & Knecht, 1984). 15 years 
later, Holliday published a comprehensive review on clinical EEG focusing on the dog 
(Holliday & Williams, 1999). Recently, Hasegawa reviewed methods in veterinary neurology 
and proposed a standard montage and sedation protocol in veterinary medicine (Hasegawa, 
2016).  
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The first EEGs were obtained using paper-bound polygraphs (Holliday & Williams, 1999). The 
introduction of computers for recording and storing EEG data brought eminent progress 
regarding interpretation (e.g. by allowing digital change of montages), computational 
analysis, data storing and data sharing among physicians (Bergamasco et al., 1999), 
(Kellinghaus, 2013). Computerization of the bioelectrical signal from the brain enables to 
analyze data in different ways: in the time, the frequency or in the space domain 
(Bergamasco et al., 1999). 
An early report on quantitative electroencephalography (qEEG) in veterinary medicine has 
been published by Klemm (Klemm, 1969), and since then this technique has been used by 
several other veterinarian clinicians and researchers, e.g. (Greene et al., 2002; Bergamasco 
et al., 2003; Jeserevics et al., 2007). This technique enables characterization of background 
activity beyond visual interpretation. It can be used for example to obtain objective criteria 
for the central action of anesthetics (Greene et al., 2002). Guidelines for quantitative EEG 
analysis in dogs have been proposed by Bergamasco et al. in 2003 (Bergamasco et al., 2003). 
However, the clinical use of quantitative EEG parameters is confounded by a lack of 
reference values and standardized protocols (Jeserevics et al., 2007). Quantitative EEG data 
have been described for some breeds like Labrador retrievers (Moore et al., 1991) or beagle 
dogs (Jones & Greufe, 1994). Another variable is anesthesia which has either been avoided 
(Jones & Greufe, 1994) or induced by different drugs like isoflurane (Moore et al., 1991), 
medetomidine (Itamoto et al., 2001), (Jeserevics et al., 2007) or propofol (Bergamasco et al., 
2003). Anesthetics themselves can have proconvulsive effects (Reddy et al., 1993; Baraka & 
Aouad, 1997), thereby influencing the EEG and especially qEEG parameters. 
 
 Status Quo and Comparison to Human Medicine 2.1.2
In 1968, Klemm reviewed methods so far described for animal EEG recording in veterinary 
medicine and tried to standardize them (Klemm, 1968; Steiss, 1988). He recommended a 
first-line montage and compared different electrode types and restraint methods (Klemm, 
1968). In human medicine, the EEG recording technique had already been harmonized by 
the introduction of the „ten-twenty-system“(10-20) system in 1958 (Jasper, 1958; Klem et 
al., 1999; Milnik, 2009).  
 
Electrode Number and Positions  
In human EEG recordings, electrode placement considers anatomical structures of the skull 
that can be reliably identified in different individuals (nasion, inion, preauricular points) and 
relative to individual skull size (Jasper, 1958; Klem et al., 1999; Milnik, 2009) (compare Figure 
1 and Figure 2). Electrode names refer to the brain area they monitor: frontopolar (Fp), 
frontal (F), central (C), parietal (P), occipital (O) and temporal (T). Assignment to the right or 
left hemisphere is done by adding even (right hemisphere) or odd (left hemisphere) 
numbers. The second letter “z” indicates electrodes along the midline (“zero”) (Milnik, 
2009).  
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Figure 1 and Figure 2: Topographical illustration of electrode positions according to the 10-20 system  
Even numbers indicate electrodes on the right side, odd numbers stand for electrodes on the left 
side. All electrodes are placed within 10% or 20% of the total (100%) distance between anatomical 
structures or electrodes,the midline e.g. connects inion and nasion: nasion + 10% = Fpz; +20% =Fz: 
+20%=Cz; +20%= Pz, +20%= Oz, +10% = Inion  Drawings adapted from Milnik (Milnik, 2009) and 
Jasper (Jasper, 1958), (Klem et al., 1999). 
 
Coordinates for electrode placement in veterinary medicine are adapted from the 10-20 
system (Pellegrino & Sica, 2004; Bunford et al., 2017). Steiss found that in 1988, the most 
common maontage was according to or adapted from the one described in the atlas of 
electroencephalography by Redding and Knecht (see (Redding & Knecht, 1984), Steiss, 
1988). Examples of alternative placements in dogs that have been described are shown in 
Table 1. One reason for this variability is the anatomy of different species and different 
breeds, especially in case of the dog (Pellegrino & Sica, 2004; Bunford et al., 2017). In 
humans, at least 16 electrodes are commonly placed (Bunford et al., 2017). In dogs, usually a 
lesser number is used (compare Table 1) which is due to the smaller size of the head and 
stronger developed muscle layer covering the skull (Bunford et al., 2017). 
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Reference Indication for EEG 
Electrode 
type, 
number 
Fixation type Dogs 
(Brass, 1959) ME  SNE (steel), 
n=5 
training, dark quiet 
room; n.s. 
Healthy dogs; 
patients, n = n.s. 
(Redding, 1964) ME Alligator 
clamps 
Mechanical restraint normal dogs 
(Herin et al., 1968)  SNE, n=8 Gallamine triethiodide n.s., n=40 
(Moore et al., 
1991) 
MD qEEG SNE, n=21 Isoflurane Healthy Labrador 
Retrievers, n=8 
(Kersten, 1993) MD SNE, n=8 n.s. Healthy and patient 
dogs, n = n.s. 
(Morita et al., 
2002) 
Epilepsy SNE, n=12 s.c. lidocaine; i.m. 
Xylazine 
Epileptic Shetland 
Sheep dogs, n=11 
(Bergamasco et al., 
2003) 
MD qEEG SNE, n=16 Propofol Healthy beagle dogs, 
n=10 
(Pellegrino & Sica, 
2004) 
Epilepsy SNE, n=8 Xylazine Normal dogs n=50, 
epileptic dogs, n=9 
(Jeserevics et al., 
2007) 
Epilepsy SNE, n=16  Medetomidine (dark, 
quiet room) 
Healthy (n=16) and 
epileptic (n=15) 
Finnish Spitz dogs  
(Raith et al., 2010) Status 
epilepticus 
SNE, n=5 
 
Propofol or 
pentobarbital infusion 
Patient dogs (n=7) 
and cats (n=3) 
(James et al., 2011) ME for long 
term 
recording 
SNE, SWE, 
GCE 
none Epilepsy patients 
(Davis et al., 2011) ME iEEG Intracranial, 
n=16 
none Epilepsy patients  
(Cauduro et al., 
2017) 
 
Seizures SNE, n=12  
 
Dexmedetomidine, 
propofol 
Patient dogs (n=200) 
n.s. 
Table 1: Examples of indications, electrodes, restraint methods and subjects from the veterinary 
literature. SNE = Subcutaneous needle electrode; SWE = Subdermal wire electrode; GCE = Gold-cup 
electrode; ME = Method establishment; MD = Method description; n.s. not specified; iEEG = 
intracranial Electroencephalogram; n = number; SE = Status epilepticus. 
 
Electrodes  
Different electrode types are used in human medicine, e.g. needle electrodes, disposable gel 
electrodes or reusable disk electrodes (Teplan, 2002). For veterinary medicine, Steiss (1988) 
found that in 1988, the most commonly used electrode was the subdermal needle electrode 
(SNE). One alternative, as mentioned above, is the alligator clamp, introduced by Redding 
(Redding, 1964). Most new publications from the field of veterinary EEG describe the use of 
needle electrodes, too (compare Table 1). James et al. compared applicability of subdermal 
needle electrodes, subdermal wire electrodes and gold cup electrodes for long-term 
recordings in dogs and concluded, that the differences found “may not be clinically relevant” 
(James et al., 2011).  
 
Literature 
 
- 21 - 
 
Artefacts  
Two categories of artefacts can be differentiated which are physiological artefacts and 
technical artefacts. Physiological artefacts originate from the recorded subject and technical 
artefacts are caused by the equipment or external sources (Milnik, 2011).  
Amongst physiological artefacts, muscle artefacts are a frequent finding in dog EEGs. As 
opposed to humans, dogs have a prominent muscle layer between electrodes and skull 
which causes a comparably higher level of artefacts (Brass, 1959; Bunford et al., 2017). 
Another cause of artefacts in dog EEGs are ear movements (Brass, 1959). Even in 
anesthetized dogs, activity from temporal muscles transiently occurs (Klemm, 1968) and 
therefore the proposal made by Bunford et al. (2017) to record EEGs from sleeping dogs only 
would not completely solve that issue. Another approach to reduce artefacts (and 
simultaneously block pain from electrode application) is injection (Redding, 1964), (Itamoto 
et al., 2001; Morita et al., 2002) or topic application (Ward et al., 2016) of local anesthetics. 
Not only facial muscles are sources of artefacts, but “the EEG is extremely sensitive to any 
other source of electrical activity, including muscle, cardiovascular and ocular activity of the 
patient” (Wrzosek, 2016). Ocular and cardiovascular activity can be monitored with the help 
of additional electrodes, which is commonly done in human EEG recordings and has also 
been adapted by veterinarians in the literature, e.g. (Holliday & Williams, 1999).  
In human medicine, movement, muscle and ocular artefacts can be reduced by instructing 
the patient accordingly. In veterinary medicine, this is not possible, and some animals need 
to be sedated or anesthetized to tolerate the procedure. Whereas the earliest reports on 
EEG in veterinary medicine describe the use of trained animals (Brass, 1959), mechanical 
restraint (Redding, 1964) or muscle relaxants (Herin et al., 1968), the majority of veterinary 
neurologists seem to routinely use sedation or anesthesia when recording an EEG. The use 
of different protocols contributes to the low level of standardization of 
electroencephalographic proceedings in veterinary medicine (compare Table 1). Holliday et 
al. (1999) recommend sedation rather than anesthesia, as the confounding effect on EEG is 
smaller and different vigilance states can still be captured.  
The high level of artefacts makes interpretation of animal EEGs challenging, especially as 
there are no established quantitative procedures for automated artefact rejection in dog 
studies as for human EEGs (Bunford et al., 2017). In human EEG recordings, the use of a large 
number of electrodes allows changing the montage in various ways. Thereby, the “logical 
filed distribution” of EEG signs can be controlled to distinguish between artefact or real 
symptom (Milnik, 2011). Using a sufficient number of recording electrodes, despite of the 
different anatomy of the dog compared to the human, therefore also helps artefact 
identification in veterinary medicine.  
 
 
Literature 
 
- 22 - 
 
Activation techniques  
Standard activation techniques are well established in human medicine like the “Berger 
reaction”, photic stimulation, sleep deprivation, anti-epileptic drug (AED) withdrawal or 
hyperventilation. They are used to provoke occurrence of epilepsy-typical potentials within 
interictal recordings and thereby increase the diagnostic value of the EEG. Their adaption to 
veterinary medicine is challenging and has rarely been investigated (Brauer et al., 2011; 
Brauer et al., 2012; Wrzosek et al., 2017). Neither did passive hyperventilation during 
general anesthesia (Brauer et al., 2012) nor did photic stimulation in medetomidin-sedated 
dogs increase the frequency of epileptic discharges (Wrzosek et al., 2017). One exception is 
the naturally activating nature of sleep, as this state has been found to increase the 
incidence of epileptic discharges (Holliday & Williams, 1999; Wielaender et al., 2017). A 
pharmacological activation technique to increase the probability of recording epileptic EEG is 
the intravenous administration of chlorpromazine, eventually combined with photic 
stimulation (Holliday et al., 1970; Holliday & Williams, 1999).  
 
Indications  
Like in human medicine, seizures of unknown origin are the most common reason to write 
an EEG from animals (Holliday & Williams, 1999). It is also used for monitoring and 
treatment control of status epilepticus in dogs and cats (Raith et al., 2010). Quantitative 
analysis of EEGs of epileptic dogs before and after phenobarbital treatment showed 
comparable changes in relative power of delta, alpha, theta and beta activity in two different 
studies (Jeserevics et al., 2007; Bocheńska et al., 2014). This could be used in monitoring the 
effects of antiepileptic treatment apart from clinical symptoms (Bocheńska et al., 2014).  
Long-term EEG monitoring of the epileptic brain in human medicine is done for different 
reasons: in the preparation of epilepsy surgery, for treatment monitoring or automated 
seizure forewarning. This is done with the help of portable EEG devices which can either be 
non-invasive or involve chronic implantation of electrodes. A non-invasive EEG device for 
ambulant monitoring of epileptic dogs has only recently been described in the veterinary 
literature which enables capturing rare seizures for accurate diagnosis and enables diagnosis 
of myoclonic seizures and absence seizures in veterinary clinics (James et al., 2011; James et 
al., 2017; Wielaender et al., 2017; Wielaender et al., 2018). So far, recordings from epileptic 
patient dogs were mostly acquired in the interictal state, with few exceptions (Raith et al., 
2010; Davis et al., 2011; Coles et al., 2013; James et al., 2017; Wielaender et al., 2017; 
Wielaender et al., 2018). For human patients with refractory epilepsy surgical resection of 
the epileptic focus can be the only remaining treatment option (Davis et al., 2016; 
Hasegawa, 2016) and this has also been considered for dogs with drug-resistant epilepsy 
(Hasegawa, 2016). Implantation of intracerebral electrodes for exact determination of the 
epileptic focus in the pre-surgical workup is then commonly done in humans (Hasegawa, 
2016). In animals, cortical or depth electrodes have mostly been used experimentally 
(Hasegawa, 2016), e.g. for investigation of a stereotactic system for implantation of 
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stimulating and recording depth electrodes in dogs (Long et al., 2014). One exception were 
studies by Davis et al. (2011) and Coles et al. (2013): They tested an algorithm-based device 
that predicts seizure occurrence in dogs with naturally occurring epilepsy (Davis et al., 2011) 
and then confirmed feasibility in pet dogs (Coles et al., 2013). 
Applications of EEG beyond assessment of seizures is monitoring of anesthetic depth which 
is frequently done in humans (Teplan, 2002; Bruhn et al., 2006). Commercially available 
devices for humans have been tested in animals (March & Muir Iii, 2003; March & Muir, 
2005; Bollen & Saxtorph, 2006; Ribeiro et al., 2008) but the authors concluded that further 
validation would be needed for clinical use.  
 
Commonness  
According to James et al., “most veterinary neurologists” use the EEG (James et al., 2011). 
She refers, however, to a survey dating back to 1988 that indicated that 17 out of the 19 
participants used the EEG (Steiss, 1988). Other authors claim that the EEG has not the status 
of a routinely used technique in veterinary medicine (Brauer, 2010; De Risio et al., 2015; 
Wrzosek, 2016). No newer surveys on the frequency at which EEG recordings are made in 
veterinary medicine today were found but Brauer (2010) states that there is a demand for 
the technique, especially in the diagnosis of epilepsy (Brauer, 2010). Currently, availability of 
EEG equipment is limited to specialized institutes which leads to an on average restricted 
knowledge of this method among veterinarians (Jeserevics et al., 2007).  
It has been assumed that use of the EEG has decreased in veterinary medicine since imaging 
methods have become widely available (Brauer, 2010). In human medicine, innovations in 
the field of imaging techniques have not markedly reduced the amount of 
electroencephalographic examinations and an EEG remains a standard tool in the diagnosis 
of seizure patients (Milnik, 2010). Compared to other methods, it has advantages in humans: 
the EEG can be easily obtained in a non-invasive fashion without any risk for the patient, 
repeated recordings can be made, e.g. for treatment monitoring, and the costs are 
comparably low (Milnik, 2010).  
In human medicine, the EEG has been combined with other methods to increase the 
diagnostic value of both methods. One example is EEG-triggered fMRI that relates cerebral 
oxygen consumption to epileptic EEG activity (Hasegawa, 2016). As this can be performed in 
anesthetized animals, this method could be used in future in the diagnostic workup of 
epileptic animal patients (Hasegawa, 2016). Other EEG-derived disciplines in human 
medicine are the study of evoked potentials, brain computer interfaces and EEG biofeedback 
(see (Teplan, 2002)).  
It can be concluded that Klemm’s attempt to standardize EEG recording techniques in 
veterinary medicine (Klemm, 1968) was not successful, which is also mentioned by several 
authors (Pellegrino & Sica, 2004; Jeserevics et al., 2007; Brauer, 2010; Hasegawa, 2016; 
Bunford et al., 2017). This lack of standardization, the introduction of other diagnostic 
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methods in neurology and limited availability of recording equipment are reasons why it is 
seldom used. However, the EEG is a recognized technique also in veterinary medicine. Main 
interest in this method in the veterinary clinic is for characterization and treatment of 
epileptic disorders (Hasegawa, 2016).  
 
2.2 EEG in Drug Development 
In drug development, EEG studies are not required from regulators, but they can be included 
as safety or efficacy biomarker. In safety studies, main applications of the EEG are, according 
to Authier et al. (2016), sleep and seizure studies. For both endpoints, it is considered the 
current gold standard (Authier et al., 2014a; Authier et al., 2014b). EEG symptoms are 
generally considered to have a high degree of translatability between species, including 
humans (Fonck et al., 2015). Concerning efficacy studies, EEG has been proposed as a 
translational biomarker in various disorders like schizophrenia, Alzheimer’s disease, 
depression or attention-deficit disorders (for a review, see Leiser et al. (2011)) or as a PD 
biomarker (Wilson et al., 2014). Quantitative EEG is used to confirm a drugs central 
bioavailability and determine duration of central drug action (Irwin, 1982; Porsolt et al., 
2002).  
Especially in the development of antiepileptic drugs, the EEG has also played an important 
role: first in the characterization of animal models of epilepsy (e.g. (Grossman, 1963; Girgis, 
1978; Opdam et al., 2002; Szabó et al., 2005)) and second in the testing of antiepileptic 
treatments in these models (e.g. (Lockard et al., 1975; Turski et al., 1984; Akman et al., 
2011)). Anxiolytic drugs have also been characterized in the EEG (Krijzer & Van der Molen, 
1987).   
Another application of the EEG has been the testing of anti-pain medications. In minimally 
anesthetized animals, noxious stimuli are reflected in the EEG and thereby efficacy of drugs 
can be evaluated (LeBlanc et al., 2016). This model has also been used in veterinary medicine 
to evaluate pain during surgical procedures (Haga et al., 2001; Kaka et al., 2015; Kaka et al., 
2016).  
In pharmaceutical research, electrodes are mostly implanted into the skull (Authier et al., 
2016). Mounted EEG caps with the data storage medium directly connected to the 
electrodes, tethered EEG or telemetry can be used. Telemetry with internalized implants 
facilitates long term recordings in freely moving animals, which has several advantages. It 
allows that animals can be grouped housed and exhibit their normal behaviors, increases the 
chance of detecting rare events with unpredictable onset and the quality is higher than with 
EEGs from restraint animals (Morton et al., 2003; Authier et al., 2014b). However, forms of 
restraint, e.g. the use of a sling, have still been used in order to minimize artefacts or to 
allow continuous infusion (Dürmüller et al., 2007). Only few authors describe the use of non-
invasive EEG measurements in drug safety testing (Authier et al., 2015).  
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2.3 Technical Definitions  
The difference in the electric activity that is recorded beneath two electrodes is termed a 
“derivation” and is displayed in one “channel” of the recording (Holliday & Williams, 1999). 
In a “reference montage”, one electrode is placed over electrically active brain tissue 
(“active electrode” or “exploring electrode”) and compared to that of an “indifferent” – or 
“reference” – electrode placed over electrically inactive sites (Holliday & Williams, 1999). A 
reference electrode over active brain tissue can also be chosen and then, the montage is 
called ”bipolar” (Holliday & Williams, 1999). A third ground electrode “is needed for getting 
differential voltage by subtracting the same voltages showing at active and reference points” 
(Teplan, 2002). In order to record the activity from different brain areas, multiple electrodes 
are compared amongst each other. Therefore, they are arranged in transversal or 
longitudinal chains over the skull (Holliday & Williams, 1999). In a bipolar montage, each 
electrode is used twice: in two adjacent channels, it is used once as reference electrode and 
once as active electrode (Holliday & Williams, 1999). In clinical neurophysiology, differential 
amplifiers that potentiate the difference in voltage between two connected electrodes are 
used (Holliday & Williams, 1999; Kellinghaus, 2013). By international definition, electrodes 
should be connected with the amplifier in a way, that a negative signal from the electrode 
that is named first in the derivation is displayed upwards (Holliday & Williams, 1999). The 
amplifier transforms the “microvolt signals into the range where it can be digitized 
accurately” (Teplan, 2002) and therefore, sensitivity of the amplifier should be highest in the 
range of the electrical brain activity (0.5Hz to 70Hz) (Holliday & Williams, 1999). After signal 
amplification, an analogue-digital converter (A/D) enables storing the EEG on a computer 
(Teplan, 2002). According to the Nyquist theorem, half the sampling rate is the highest 
reliably presentable frequency in the EEG (Kellinghaus, 2013).  
 
2.4 Visual EEG Analysis 
Traditionally, the first step of EEG interpretation is visual analysis (Holliday & Williams, 
1999). A trained and experienced interpreter is required for this in contrast to automatic 
analysis that uses definite computer settings (Holliday & Williams, 1999).  
The graphic display of the EEG is a change of voltage with time (Klemm, 1969). The term 
“spontaneous EEG” is used when there is no intentional external stimulation of the activity 
of the brain (Klemm, 1969). Different waveforms, each defined by a certain frequency (unit: 
Hertz (Hz)) and amplitude (unit microvolts (µV)), can be visually identified (alpha, beta, delta, 
theta and gamma). They form the appearance of the ongoing background activity, which first 
indicates different stages of vigilance. The background activity varies between the different 
regions of the brain (Roesche, 2012) and changes with age (Pampiglione, 1963; Holliday & 
Williams, 1999; Milnik, 2010; Roesche, 2012). 
Upon this background activity, different transient patterns can be superimposed (Holliday & 
Williams, 1999). They can be characteristic for different stages of vigilance or neurologic 
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diseases. Examples of transient EEG patterns are sleep spindles and K-complexes that are 
present in drowsiness or sleep, or spike-wave complexes characteristic for epileptic 
disorders. Artefacts can be mistaken for symptomatic EEG changes, as their nature is 
transient as well (Holliday & Williams, 1999). The duration of transient events is usually less 
than a few seconds (Holliday & Williams, 1999). Automated analysis of paroxysmal EEG 
patterns is possible with software solutions, e.g. detection of spike wave patterns or spike 
trains.   
 
2.5 Quantitative EEG Analysis 
Quantitative analysis of the EEG (qEEG) brings information on the amount of the individual 
spectral components that form the EEG signal (Bergamasco et al., 1999; Holliday & Williams, 
1999). This can be used to investigate changes in background activity that would not be 
evident upon visual analysis alone (Bergamasco et al., 2003) but does not provide 
information on specific graphoelements as paroxysmal activity or artefacts (Bergamasco et 
al., 1999; Holliday & Williams, 1999).  
Quantitative analysis is achieved by applying the Fast Fourier Transformation (FFT) to 
selected episodes (Bergamasco et al., 1999). These episodes need to be cleaned from 
artefacts as these highly impact the result of frequency analysis (Bergamasco et al., 1999). 
Also, vigilance state needs to be controlled for correct application of qEEG (Porsolt et al., 
2002; Wilson et al., 2014). Parameters that need to be defined are the lower and upper 
limits of the frequency bands and usually, the common EEG rhythms are selected (delta, 
theta, sigma, alpha, beta and gamma) but the exact bandwidths are differently defined in 
literature. Results of quantitative analysis can be displayed in absolute (µV2) or relative (%) 
values. The absolute power is calculated from the square of the amplitudes of each 
frequency band (Moore et al., 1991). Relative power is defined as the absolute power of one 
band, divided by the power of the entire spectrum and then multiplied with 100 to express 
the result as percentage (Jeserevics et al., 2007).  
For dogs, Kis et al. (2014; 2017) report that absolute power is variable between individuals 
as a consequence of varying skull size and skull thickness in different breeds (Kis et al., 2014; 
Bunford et al., 2017; Kis et al., 2017). Relative ratios between the power bands are less 
variable and have therefore often been preferred for comparison (Bergamasco et al., 1999), 
(Kis et al., 2014; Kis et al., 2017). Bunford et al. (2017) also point out that calculation of 
relative power is “common practice in human EEG studies because absolute EEG power is 
less psychometrically sound than relative EEG power” (Bunford et al., 2017). 
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3 Reference Compounds for Validation of a Telemetry EEG System 
For establishment of a seizure liability assay, selection of a set of positive and negative 
reference compounds from literature is a possible approach and has been chosen for 
validation of mouse EEG (Easter et al., 2007), hippocampal brain slices (Easter et al., 2007), 
the zebrafish locomotor assay (Winter et al., 2008) and a computational support vector 
machine (Zhang et al., 2011). For the establishment of dog EEG for seizure liability 
assessments, the use of PTZ has been described by e.g. Dürmüller et al. (2007) and Baird et 
al. (2015). In rodent models (e.g.(Irwin, 1968)) for evaluation of CNS effects of drug 
candidates however, other reference compounds are commonly used. For identification of 
sedative effects, diazepam, haloperidol and morphine are often chosen (Roux et al., 2004). 
For hyperexcitability, the use of D-amphetamine is commonly described (Roux et al., 2004). 
Other reference compounds exist, and the testing protocols vary between laboratories 
(Authier et al., 2016).  
 
3.1 Midazolam 
Midazolam is a benzodiazepine and belongs to the same chemical class as diazepam. In 
rodent CNS tests, diazepam is more commonly used (Roux et al., 2004). However, 
midazolam has been reported to be superior in the treatment of convulsions via other 
routes than the intravenous one (McMullan et al., 2010; Schwartz et al., 2013) especially as 
intramuscular diazepam administration is not feasible (Schwartz et al., 2013). Midazolam 
also is the standard anticonvulsant for the treatment of drug-induced convulsions in 
toxicological studies. Therefore, this drug was also selected for treatment of convulsions in 
the following experiments with in-house compounds. In the veterinary clinic, it is also used 
as anticonvulsant, as well as a sedative or as premedication for induction of general 
anesthesia (Reves et al., 1985). Concerning EEG effects, benzodiazepines have been well 
characterized: According to Wilson et al. (2014), who reviewed applications of pharmaco-
EEG in animals and men, benzodiazepine-induced EEG changes are best described in 
literature. These changes include mainly an increase in beta and a reduction in alpha power 
(Porsolt et al., 2002; Wilson et al., 2014). In dog EEG, midazolam was described in 
combination with medetomidine (Itamoto et al., 2002), flumazenil (Artru, 1989) and 
lidocaine-induced seizures (Horikawa et al., 1990).  
 
3.2 Propofol 
Propofol is not commonly used in rodent CNS tests, but its effects on dog EEG have been 
well described in the literature (Artru et al., 1992; Kusters et al., 1998; Bergamasco et al., 
1999; Bergamasco et al., 2003; Lopes et al., 2008; Ribeiro et al., 2008; Akos et al., 2012). 
Also, results of quantitative EEG analysis of beagle dogs have been published (Bergamasco et 
al., 2003). This enabled comparison of results with literature data. Propofol is well tolerated 
in healthy dogs (Bergamasco et al., 2003) and therefore, it is also widely used in veterinary 
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medicine for induction and maintenance of general anesthesia. (Hall & Chambers, 1987; 
Watkins et al., 1987; Morgan & Legge, 1989). It is administered intravenously, and then has a 
fast onset of action. Through rapid hepatic metabolism, it does not accumulate and narcotic 
depth can therefore be easily adjusted. It has also been described that spikes in the EEG 
could appear in propofol anesthesia (Reddy et al., 1993; Baraka & Aouad, 1997). This would 
allow EEG pattern recognition without causing severe distress to the research dogs.  
 
3.3 Apomorphine 
In the veterinary clinic, apomorphine is commonly used to induce emesis when poisoning is 
suspected. Apomorphine is an unselective D1 and D2 receptor agonist. In drug development, 
apomorphine is known as a stimulant reference compound that induces stereotyped 
behavior in different species, namely lip-smacking and chewing movements in NHP 
(Meldrum et al., 1975; Korsgaard et al., 1985) and rodents (Kropf et al., 1989). The 
“apomorphine-induced climbing and stereotypies test” in rodents is used in the testing of 
antipsychotic drugs (Bardin et al., 2006). There is a dose-dependency to this effect: lower 
doses (0.05 - 0.1 mg/kg) of apomorphine were reported to block non drug-induced 
stereotypies whereas higher doses (0.25 - 1.0 mg/kg) induce them (Korsgaard et al., 1985). 
An increase in motor activity was also frequently described after apomorphine injection with 
a concomitant increase in EEG artefacts from muscle activity (Meldrum et al., 1975).  
Apomorphine effects on the EEG were investigated in epileptic baboons (Meldrum et al., 
1975), rats (Kropf et al., 1989; Sebban et al., 1999) rabbits (Brücke et al., 1957) and healthy 
volunteers (Luthringer et al., 1999). No reports on its effects on dog EEG were found. Wilson 
et al. (2014) compared results of a study that explored effects of apomorphine on the rat 
EEG (Wilson et al., 2014) to a study of a low dose (0.75 mg total) in healthy human 
volunteers (Luthringer et al., 1999; Wilson et al., 2014). They stressed the importance to 
control the vigilance state to exclude an influence of natural changes in the level of 
wakefulness on EEG results (Wilson et al., 2014). Visually assessable changes in the EEG after 
apomorphine administration had the characteristics of an “arousal reaction”, namely a 
decrease in amplitude and rise in frequency (Brücke et al., 1957; Meldrum et al., 1975). 
 
3.4 Quinpirole 
Quinpirole is, as D-amphetamine, known to have an EEG stimulating effect in rodents (Arnt 
et al., 1987). Clinical signs in rodents are “dose dependent hyperactivity (locomotion, 
sniffing, head movements and rearing), whereas licking/ biting was only seen occasionally.” 
(Arnt et al., 1987). Also, it is a selective D-2 agonist, and testing quinpirole enabled 
comparison of selective agonists on different dopamine receptors (D2 and D3). 
Pharmacologic properties of quinpirole in dogs were investigated by Whitaker & Lindstrom 
with a 0.2 mg/kg dose: They found that excretion was mostly via urine (94% of the dose), 
and only a minor part was detected in the feces (3%) within 72 hours (Whitaker & Lindstrom, 
Literature 
 
- 29 - 
 
1987). They chose the intravenous route as the substance class is known to induce emesis in 
dogs (Whitaker & Lindstrom, 1987). EEG effects of quinpirole were investigated in rats by 
Sebban et al. (1999). They discovered that the effects of D2 agonists on EEG power are dose-
dependent, with an increase of power at low (0.01 mg/kg) and a decrease at higher (0.5 
mg/kg) doses (Sebban et al., 1999). 
 
4 In-House Compounds  
Substances available for the EEG studies were developed for the treatment of 
neuropsychiatric diseases, being schizophrenia (compound 1 and 2) and neuropsychiatric 
disorders in AD and related dementias (compound 3). Modes of action varied between 
compounds, so the use of the EEG under different conditions could be evaluated. Molecular 
targets were the dopamine-receptor 3 (D3), glycine-transporter 1 (GlyT1) and the serotonin 
(5HT) receptor, subtype 2c (5HT2c).  
It was known from previous studies that these compounds induce different neurological 
symptoms in preclinical species at high doses. Pre-existing rodent and non-rodent data were 
available and for two of them (compound 1 and compound 3) data from NHP infusion 
studies existed. Route of administration was the same as intended for the EEG studies and 
therefore, comparison of exposure related to neurological symptoms across species was 
enabled. Neurological symptoms, mode of action and indication are summarized in Table 2.  
 
Compound 
Code Mode of Action  Indication 
Symptoms in non-
rodent preclinical 
studies 
Symptoms in rodent 
preclinical studies 
1 D3 receptor agonist 
schizophrenia, 
substance abuse 
Dogs: ataxia, jerks, 
emesis, convulsions 
Sedation, decreased 
activity 
2 
Glycine 
transporter 1 
agonist 
schizophrenia 
Dogs: Head tremor 
NHPs: stereotypies, 
aggressiveness, ataxia, 
tremor, twitches 
decreased activity, 
palpebral closure, 
walking on toes 
ataxia, sedation, 
convulsions 
3 5HT2c receptor agonist 
neuropsychiatric 
disorders in AD 
and related 
dementias 
NHP: Decreased 
activity, emesis, 
salivation, tremors, 
nystagmus, 
convulsions 
decreased activity, 
tremors, convulsions, 
ataxia 
Table 2: Overview on in-house compounds. Mode of action, indication and neurological symptoms in 
preclinical species are shown. 
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4.1 Compound 1 
Convulsions were a symptom seen in dogs in the previous toxicology studies with compound 
1 and they occurred at a maximal plasma concentration (Cmax) of 7875 ng/mL. In rodent CNS 
safety assessments, a dose dependent decrease in spontaneous locomotor activity was seen 
at doses higher than 300 mg/kg corresponding to a mean total Cmax of 24660 ng/mL (plasma 
protein binding rat: 87.1%). In the PTZ test for evaluation of pro- or anticonvulsant activity 
statistically significant increases in latency to tonic convulsions were observed in rats 
receiving oral doses between 30 (corresponding to a mean total Cmax of 5740 ng/mL) and 
300 mg/kg. At 10 mg/kg, no anticonvulsive effects were observed. Compound 1 had already 
been used as a model compound to explore species-specific sensitivity to convulsions in a 
NHP infusion study (Backes, 2016) and to establish a zebrafish locomotor assay (Cassar et al., 
2017).  
 
4.2 Compound 2 
With regards to compound 2, this drug candidate induced a distinct symptom in the dog, 
which was a tremor predominantly affecting the head. As the cause of this observation was 
unclear, one goal of the thesis was to explore whether the tremor was an expression of 
seizure activity by use of the EEG. From clinical observation, it was suspected that underlying 
seizures were not the cause, as the level of consciousness of dogs was not or only mildly 
affected and as the head tremor was unresponsive to midazolam treatment. The NOAEL for 
dogs was set at a dose of 3 mg/kg, which corresponded to a Cmax of 294 ng/mL and an AUC0-
24 hr of 3872 ng*hr/mL. In NHPs no head tremor or convulsions were observed and the 
NOAEL was higher. Neurological symptoms induced by compound 2 in NHPs were 
stereotypic (gnawing, circling, grooming, and forepaw padding) and aggressive behavior, 
occasional ataxia, tremor and twitching. The NOAEL for NHPs in a 2 week study was 100 
mg/kg/day for males and females corresponding with an AUC0-24 of 34200ng*hr/mL and a 
Cmax of 6620 ng/mL. In rats, decreased activity, palpebral closure, walking on toes and ataxia 
were main clinical signs. At doses equal to or greater than 300 mg/kg severe sedation, 
hunched posture and clonic convulsions (at 600 mg/kg) were observed. The NOAEL in rats 
was defined for male and female rats differently: 665 ng/mL was set for male rats, whereas 
1290 ng/mL was determined for female rats.  
 
4.3 Compound 3 
In safety pharmacology studies in rodents, compound 3 produced a range of CNS/ 
neurobehavioral effects: decreased spontaneous locomotor activity, reduced grooming 
behavior and convulsions (oral dose 300 mg/kg, total plasma exposure 2000 ng/mL). In the 
PTZ seizure assay in rats, proconvulsant activity was observed at 10 mg/kg (660 ng/mL). 
Toxicology studies with compound 3 were conducted in rats and NHP (cynomolgus (macaca 
fascicularis)). Symptoms observed in rats were ataxia (≥20 mg/kg/day), tremors (≥60 
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mg/kg/day), reduced food consumption and mortality at 120 mg/kg/day. In NHP toxicology 
studies, convulsions were seen and the lowest exposure related to this finding was 1030 
ng/mL. Other symptoms in NHPs were tremors, emesis and increased salivation. A 
neurological symptom of special interest in this species was nystagmus. To explore if it was a 
potential premonitory sign for convulsions, a dedicated infusion study was conducted. In this 
study, convulsions were observed at plasma drug levels between 1500 and 2000 ng/mL and 
nystagmus could be observed in all animals prior to convulsions. A dedicated rat EEG study 
was also designed to explore seizure liability and it was found that spike-wave discharges 
were present in the EEG in the absence of clinical symptoms preceding clinical convulsions.  
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IV.Materials and Methods 
1 Leading Questions 
1. Can electroencephalographic premonitory signs of convulsions be identified that 
facilitate prophylactic anticonvulsive treatment and avoid the occurrence of 
convulsions in toxicology studies, thereby reducing the burden of animals? 
 
2. Is combination of two procedures possible to enable simultaneous EEG recording and 
CSF sampling for analysis of potential biomarkers of seizure liability? 
 
3. Can intravenous administration of escalating doses reduce inter-animal variability so 
that use of fewer animals is justified? 
 
4. Is the dog a relevant animal model for seizure liability assessments and how does the 
dog’s sensitivity for neurological symptoms compare to other preclinical species? 
 
5. Can quantitative and automated analysis of dog EEG support investigation of CNS 
effects of development drugs?  
 
2 Literature Research 
Literature from Public Resources 
The literature research was conducted using the following search engines: PubMed®, go3R®, 
Google Scholar® Key words were “EEG dog”, “Seizure dog”, “EEG preclinical safety”, “EEG 
safety pharmacology”, “EEG sleep”, “EEG veterinary medicine”, “epilepsy dog”, “drug 
induced seizures”, “drug induced convulsions”, “seizure classification”, “EEG changes drugs”, 
“seizure prediction”, “seizure liability methods”, “zebrafish seizure”, “guidelines safety 
testing”, “species selection”, “drug induced neurological symptoms”, “EEG apomorphine”, 
“EEG propofol”, “EEG quinpirole”, “EEG midazolam”, “dog apomorphine”, “dog quinpirole” 
and variations of them. The database Pharmapendium® was used to search for reports on 
preclinical seizure liability of various reference compounds in the context of establishment of 
a zebrafish locomotor assay and knowledge from this research was also used for the 
selection of reference compounds. 
The reference lists of relevant publications were additionally searched to find further 
references. The first review of the literature was done in June 2015. Ongoing literature work 
was conducted throughout working on this thesis. 
 
Literature from Internal Resources 
Internal databases that were used with the same key words as listed above were Pro Quest 
Dialogue® and ClinicalKey®. Data from toxicological studies with in-house compounds were 
originally collected in the Prestima Production tool (different versions; current version 6.4). 
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After termination of a study, all collected data were uploaded and stored in the eDocs 
system. This database was accessed using the current version (eDocs 4). Also, the project-
specific folders stored on AbbVie servers were searched.  
 
3 Animal Welfare 
3.1 Animal Research Allowance 
An animal research allowance was approved by the responsible authority 
(Landesuntersuchungsamt Rheinland-Pfalz, Referat 23, Mainzer Straße 112, 56068 Koblenz). 
Title of this permit translates as “Investigating non-rodent species-selection in neuroscience: 
species-specific sensitivity of the dog for neurological symptoms” (“Untersuchungen zur 
Speziesauswahl beim Nichtnager im Bereich Neurowissenschaften: Speziesspezifische 
Sensitivität des Hundes für neurologische Symptome”. It was approved in 2014 under the 
reference number AZ: 23177-07/G14-9-081 (G2/14). EEG recording was requested as an 
extension to the original permit and approval was granted in September 2015.  
Study design and conduct were in accordance with the EU directive 2010/63/EU and the 
following acts from the legislation of the Federal Republic of Germany:  
x Ordinance on the protection of animals used for experimental or scientific purposes 
published on 1st August 2013 (German implementation of EU directive 2010/63; 
BGBl. I S. 3125, 3126) [TierSchVersV] 
x Commission Recommendation 2007/526/EC on guidelines for the accommodation 
and care of animals used for experimental and other scientific purposes published on 
18 June 2007 
x The German Animal Welfare Act as published on 18 May 2006, amended according to 
Art. 20 G from 9 December 2010; amended by Art. 1G from 4 July 2013; amended by 
Art. 141 from 29. March 2017. [Deutsches Tierschutzgesetz, TierSchG] 
x Act on the Welfare of Dogs published on 2nd May 2001; amended by Art 3 on 12. Dec. 
2013 [Deutsche Tierschutz-Hunde-Verordnung, TierSchuHuV] 
Also, AbbVie is certified by the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) and participates in a rehoming-program.  
 
3.2 Study Plans  
To align study procedures internally, two study plans were written according to internal 
standards. Study plans define the housing conditions according to species, responsibilities 
(e.g. study director, deputy study director, lead technician, veterinarians etc.) and timelines. 
Also, details on the test item (formulation, storage conditions, and dose) are assembled. All 
data that need to be collected during the study (body weights, food consumption, plasma 
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samples for PK, etc.) are defined, together with the corresponding methods (e.g. preparation 
and storage of samples) and timelines. The first plan defined proceedings of the surgical 
implantation of EEG transmitters; the second study plan determined the procedure for the 
testing of reference and in-house compounds. If changes were made to the original study 
plan, these were announced in “Amendments” and shared latest on the day of study 
conduct. Additional “Study Communications” containing updates on the current status of an 
experiment, were sent via eMail. All information related to an ongoing study is stored 
internally on a shared drive and in print in a raw data folder.  
 
3.3 Veterinary Care 
On days without experiments, laboratory animals were supervised by animal care 
technicians with at least one attending veterinarian on site on week days. During the 
weekends, one veterinarian was on-call.  
During experiments, at least two veterinarians were present. The surgical implantation of 
EEG transmitters was done by a trained veterinary surgeon, invited solely for this purpose.  
General veterinarian examinations were done during animal selection, prior to and after 
surgery and prior to and after all EEG experiments. A neurological examination was done at 
animal selection, after surgery and after experiments with in-house compounds. Clinical 
pathology and hematology was controlled prior to surgery, after surgery, prior to the testing 
of in-house compounds and after the testing of compound 2. Clotting parameters were 
controlled prior to surgery.  
In addition, a regular health check with control of clinical chemistry and hematology 
parameters is done for all dogs kept at the research facility every six months. Once a year, an 
examination according to FELASA standards is conducted. Dogs are vaccinated according to 
current recommendations by the “German Committee of Clinical Veterinarians” [free 
translation of “Bundesverband praktizierender Tierärzte”]. 
Veterinary treatments during the experiments to treat neurological or other clinical 
symptoms were allowed by the study plan. They consisted of intravenous midazolam 
(Midazolam-ratiopham®, 15mg/3mL), subcutaneous metoclopramide (Emeprid® Injection, 
Cewa) or maropitant (Cerenia maropitant, 10mg/mL Zoetis Belgium SA) and subcutaneous 
metamizole (Metamizol Natrium, 500mg/ml, WDT). Details are described in the section of 
the respective experiment.  
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4 Animal Selection, Housing and Identification 
4.1 Animal Selection  
Adult intact Beagle dogs (4 males, 3 females; Marshall Bio Resources, North Rose, USA.) 
were selected from the in-house colony. Inclusion criteria of dogs were pre-implanted CSF 
ports, mild temperament, a normal general and neurologic veterinary examination and 
normal clinical chemistry and hematology parameters. Age of selected dogs varied between 
30 and 48 months at the start of the experiment. Only male dogs with pre-implanted CSF 
ports were available. The method of CSF port implantation was described by M. Wilsson-
Rahmberg et al. (1998). Ports are especially designed screws with a central opening. For CSF 
collection, a cannula with a stylet is inserted first through the covering skin and then through 
the port. Each dog requires cannulas with specific lengths. The dogs selected for this study 
had their ports implanted in 2013 for pharmacokinetic (PK) studies. They were not naïve but 
had been used in PK studies with very low compound doses and a minimal distress level. 
Wash-out time after PK studies is at least one month in general, and has been longer for 
selected dogs. For the pilot study, in which compatibility of CSF ports and EEG electrodes 
was explored, one dog with CSF ports that had lost patency was selected.  
 
 
Figure 3: X-ray of a dog with CSF port.  Two implants pointing 
in the direction of the lateral ventricles are fixed in the skull.  
 
Mean age of selected dogs was 3.25 years which is according to Fischer et al. (2013) within 
the range of onset of idiopathic epilepsy. Changes in the thyroid hormone levels have been 
reported to indicate idiopathic epilepsy (von Klopmann et al., 2006) and therefore, they 
were evaluated. Genetic predisposition to epilepsy was of interest as well, so the breeder of 
the research dogs was contacted for information on the incidence of epilepsy in their colony. 
The Marshall beagle® is a purpose-bred dog breed and its genetic background should be well 
known to guide selection of parent animals. Unfortunately, no answer to this request was 
received. However, epilepsy was not observed in any of the dogs during the study and in the 
whole colony for the past years.  
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4.2 Animal Housing and Enrichment  
Dogs were group housed with males and females being kept separately in kennels with 
outdoor runs. Single housing of dogs was done during feeding or whenever warranted by 
veterinary advice or study design needs. Dogs were kept on a standard diet (Ssniff Hd Ereich, 
Extrudat: Ssniff Spezialdiäten GmbH, Ferdinand-Gabriel-Weg 16, 59494 Soest, Germany) 
which was offered once daily. Changes were made in the feeding regime only for conduction 
of experiments and are described later. Unfiltered tab water was available ad libitum at all 
times.  
Lighting in the animal rooms consisted of daylight with additional artificial light provided in a 
12 hours light cycle from 6 a.m. to 6 p.m.. Inside temperature averaged 22 +/- 4°C and was 
controlled together with air exchange rate and air humidity. All indoor and outdoor kennels 
were cleaned daily. As enrichment, dog toys, claws and chewing bones were offered. 
 
4.3 Animal Identification and Group Assignment  
All dogs had a microchip implanted and an individual number tattooed in the right ear. 
Individual cage cards that were kept in the animal rooms provided additional information 
about e.g. breeder, date of birth, responsible personnel, study number, allowance reference 
number etc. Male dogs were identified by odd study numbers (1001, 2001, 3001), females 
received even study numbers (1002, 2002, 3002). Animal assignment to the different 
experiments was randomly and based on animal weight, substance availability, and wash-
out times and is shown in Table 3. In between experiments the washout-time was at least 
two weeks and minimum 5 half-lives of the respective test compounds. 
 
Animal number Sex Compound 
1001 Male Midazolam, Apomorphine, Compound 2 
1002 Female Midazolam, Apomorphine, Compound 2 
2001 Male Propofol, Quinpirole, Compound 1 
2002 Female Propofol, Quinpirole, Compound 3 
3001 Male Compound 3 
3002 Female Compound 1 
Table 3: Dog assignment to EEG experiments. As the same person was responsible for study 
planning, study conduct and EEG interpretation, blinding was not performed in these pilot studies.  
 
5 Implantation of EEG Transmitters  
A complete list of the material and medication used is provided in Appendix 1 and 2. Prior to 
surgery, the functioning of the each transmitter was controlled and a protocol was created 
in the recording program to facilitate intra-surgical recording of EEG to control compatibility 
of CSF and EEG implants, correct electrode placement and reconfirm implant functioning. A 
trained veterinary surgeon (invited for this purpose), one sterile and one non-sterile 
assistant performed the surgery, while one or two additional veterinarians and a veterinary 
Materials and Methods 
 
- 37 - 
 
nurse prepared the next dog, given multiple surgeries on one day, and supervised recovery 
from anesthesia.  
 
5.1 Preparation of Dogs for Implantation 
General health of dogs was assessed by evaluation of hematology and clinical chemistry 
parameters and a general veterinary examination. 
Antibiotic treatment (Baytril® Flavour, Bayer Vital GmbH, 5 mg/kg p.o.) was started on the 
day prior to surgery and continued for a total of seven days. Together with the antibiotics, 
dogs received oral doses of caprofen (Rimadyl®, Zoetis Deutschland GmbH, 4 mg/kg p.o.) 
once daily. On the day of surgery, buprenorphine (Buprenovet®, Bayer Vital GmbH, 0.02 
mg/kg, i.m.) was administered and subsequent doses were given every six hours for two to 
three days following surgery, depending on the individual dog’s clinical appearance. 
Additional premedication was midazolam (Midazolam-ratiopharm® 15 mg/3ml, 0.1 mg/kg, 
i.v.). 
Dogs were fasted overnight prior to surgery. General anesthesia was induced with 
intravenous propofol (Propovet™ Multidose, Abbott Laboratories Ltd, 4 mg/kg for induction 
of anesthesia; subsequent doses of approximately 1 mg/kg with regards to clinical effect, 
i.v.) administered via catheter placed in the right vena cephalica. Prior to moving the dog 
from the preparation to the surgery room, it was intubated and its head and neck where 
shaven. Eye lubricant (Bephanthen® Augen – und Nasensalbe) was administered to both 
eyes. Inside of the surgery room, the dog was placed on a heating pad with the extremities 
supported by towels. A local anesthetic (lidocaine; Xylocaine® Pumpspray, AstraZeneca 
GmbH, one pump spray) was administered into the ear canals prior to insertion of the 
stereotaxic ear bars. Then the dog’s head was placed in a stereotaxic frame (Figure 4). 
Surgical fields were prepared with Braunoderm® (B. Braun Melsungen AG), Braunol® 
(B.Braun Melsungen AG) and Kodan® (Schülke & Mayr GmbH). Dogs were covered with 
sterile foil. Anesthesia was maintained with inhalant isofluran (1.5-2.3% Isofloran CP, 
1mL/mL, CP Pharma GmbH). During surgery, intravenous fluids were administered (Ringer-
Lactat nach Hartmann B. Braun; B. Braun Melsungen AG, 10mL/kg/h i.v.). Vital parameters 
(ECG, heart rate, respiratory rate, SpO2, CO2, temperature) were monitored (LifeVet®, 
Eickemeyer®), observed continuously and recorded in a protocol by the non-sterile assistant. 
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Figure 4: Stereotaxic frame used for implantation of EEG 
transmitters in dogs.  Scaling on the three axes (x, y, z) enables the 
surgeon to localize exact positions for implantation. Stereotaxic 
coordinates for implantation were chosen by the surgeon (after 
external consultation). Ear bars (not shown here) are used to 
stabilize the animals head for an exact localization of the 
stereotaxic coordinates. The hand piece of the drill is attached to 
the stereotaxic as well (1). The drill enters the bone only in a pre-
defined depth (“brake” on the stereotaxic (2)).  
 
 
 
 
 
 
5.2 Pilot Study to Explore Compatibility of EEG and CSF Implants  
After placing the dog for the pilot study in the stereotaxic frame, the surgical field on the 
head was aseptically prepared, as described above. A second field over the hip was also 
prepared, as it was not known whether a bone graft would be required after CSF port 
removal.  
An incision was performed over the midline and muscle tissue was bluntly dissected from 
the skull. Positions for screw placement were determined using the stereotaxic frame and 
marked with a sterile skin marker (Mediware Skin Marker, servoprax GmbH). For this dog 
(and the following dogs with CSF ports), the screws that served as EEG electrodes (0-80X1-8, 
Plastics one) were placed 17-20 mm rostral from the inter-aural line and 10 mm on either 
side from the midline in the frontal bone. Prior to drilling, intravenous dexamethasone (1 
mg/kg Dexamethasone Injektionslösung ad us. vet. 2mg/mL; i.v.) was administered. Then, 
the hand piece of the drill (Foredom®, H.30) was attached to the stereotaxic and the holes 
were carefully drilled. The drill bit was rinsed with sterile saline (NaCl 0.9% B. Braun 
Melsungen AG) by an assistant to prevent overt heating of tissue. The stereotaxic had an 
automated stop to prevent the drill from entering the cranial cave. One implant (DSITM 
PhysioTel® Digital implants M-01) was removed from its sterile package and rinsed in sterile 
saline. The first centimeter of isolation was removed from both biopotential cables, bent and 
inserted into the holes in the skull. The screws then were manually drilled in. Thereby, the 
tips of the cables enrolled themselves around the screws. 
The implant was turned on and identified by the software to record approximately five 
minutes of intra-surgical EEG. The EEG was evaluated by two persons. After the recording 
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was complete, EEG electrodes and CSF implants were removed in this dog. No bone graft or 
other sealing methods were deemed necessary. The wound was closed via subcutaneous 
absorbable stitches and skin staples.  
 
5.3 EEG-Transmitter Implantation 
The procedure for permanent implantation was the same in most aspects with the following 
exceptions: An additional field on the left side of the neck was shaven and aseptically 
prepared. The coordinates on the head were determined as described above and the holes 
were drilled. Coordinates for dogs with CSF ports were the same as used in the pilot 
experiment. For dogs without CSF ports, screws were inserted 5 mm rostral from inter-aural 
line and 10 mm on either side from the median line. Then, an incision was made in the neck 
and the biopotential leads were tunneled subcutaneously by using a trocar to the incision 
side on the head. The lengths of the leads were determined according to the individual dog’s 
size. After the recording of control EEG, screws were drilled in and a pouch was created 
between the neck muscular layers to hold the telemetry transmitter. Topic bupivacaine 
(bupivacaine 0.25% Jenapharm® Mibe GmbH Arzneimittel) was used as an additional 
analgesic on muscle layers. Cables were then fixed on the skull using surgical glue (Surgibond 
tissue adhesive, SMI AG). Screws were covered using bone cement (Smartset GHV, DePuy 
CMW, Johnson+Johnson). Then, both wounds were closed with subcutaneous stitches and 
skin staples.  
 
5.4 Recovery  
After wound closure, isoflurane was discontinued. Spontaneous respiration was controlled in 
the wake up period. As the first swallowing was observed, the intratracheal tubus was 
removed and the dog was transferred to a heated box. Fluids were discontinued and the dog 
was continuously observed until it was able to maintain an upright position. Oxygen was 
provided via mask and in some dogs an additional heat source (3MTM, Bair HuggerTM) was 
used. When dogs were alert and able to walk, they were transferred to their home kennels. 
Nutri-Cal® (Albrecht GmbH) paste and canned food (Hill’sTM, a/dTM Restorative Care) were 
then offered. Clamps were removed 14 days after surgery. Hematology and clinical 
chemistry parameters were controlled for each dog three days after surgery.  
 
5.5 Maintenance of Asepsis during Multiple-Day Surgeries  
Establishment of aseptic conditions was challenging, as not all parts of the material could be 
autoclaved. This included parts of the stereotaxic frame and the drill. The hand piece of the 
drill was sent to an external company for ethylendioxide-sterilization, kept in an autoclaved 
bag from which it was only removed by the surgeon during surgery. The power cable was 
covered with sterile plastic tubes (Medical Technologies GmbH; camera cover folded with 
paper insertic aid, 13x242cm, sterile). Drilling was controlled with a foot piece, so there was 
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no need to touch the motor of the drill. An additional sterile hand piece was kept separate in 
case of potential disruption of sterile conditions that would necessitate exchanging the 
device. Parts of the stereotaxic frame that could not be autoclaved were bathed in a strong 
disinfectant (Cidex® OPA; Advanced Sterilization Products®, Johnson + Johnson) prior to 
surgery and then rinsed with AMPUWA. Potency of the disinfectant solution was controlled 
with Cidex®OPA test stripes and exchanged accordingly.  
 
6 Setup of the Video-EEG recording Unit 
For recording telemetric EEG with synchronized video, two normal dog home-kennels were 
equipped with custom-made attachments to hold the necessary hardware (described 
below). Special attention was paid to ensure that all components were out of the animals’ 
reach and did not hinder daily cleaning procedures. Also, to avoid interferences with the 
signal, the metal bars of the dogs’ kennels were partially replaced with a polycarbonate 
window. 
 
6.1 DSITM PhysioTel Digital Implants, M series, type M-01  
The DSITM PhysioTel Digital Implants are able to record one biopotential (one channel bipolar 
EEG recording), body temperature and activity. Probes for temperature and activity 
recording are internalized in the device. Each implant has a unique identification number to 
allow assignment of signals to the respective animal. Lashes around the transmitter allow its 
fixation during surgery. Its small size with a volume of 11 cc and a weight of 13.7 g implies 
minimal impairment of the animals. Usability of the implants is limited to their battery life 
that allows 40 days of constant measuring. Implants can be switched on by swiping a magnet 
over them; turning off is possible either by another magnet swipe or via software.  
 
 
Figure 5: DSITM PhysioTel Digital 
Implants M-01. blue circle: 
biopotential leads; green circle: 
antenna. Arrow: screw electrodes.  
 
1 
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6.2 DSITM PhysioTel Digital Transcievers (TRX-1) 
Inside of the kennel, the TRX is needed for the reception of the radio – frequency (RF) signals 
from the implants and for their transmission to the “Communication Link Controller” (CLC). 
To enable acquisition, different premises have to be met: the minimum distance between 
the animal and the transceiver cannot be less than 40 centimeters, maximal distance is 3-5 
meters. In order to obtain best quality signals, the recommended 90° angle between two 
transceivers was realized (see Figure 6 and Figure 7). 
 
  
Figure 6 and Figure 7: Two digital transcievers;  a 90° angle was chosen to realize optimal signal 
transmission. One is hung from the ceiling the other is at one side of the recording kennel. Metal bars 
have been replaced with a polycarbonate plate to minimize interferences.  
 
 
6.3 The Communication Link Controller (CLC) 
One CLC is able to receive signals from up to four implants via the TRX-1. It transfers them to 
the acquisition computer but also works bidirectional and thereby allows implant 
management (e.g. determination of recording properties, switching implants off).  
 
6.4 Additional Network Components 
A common router (CISCO®) was used to create the network in which the different 
components of the video telemetry recording unit communicate. To enable adding the 
multiple components to the network while minimizing use of cables, a switch, which 
provides power over Ethernet (PoE), was used.  
The video recording unit consisted of color cameras (Axis®, P1365). They were connected to 
the network via switch to allow synchronization of video and EEG. Two cameras were placed 
in each kennel to allow 360° view of the animal.  
To verify that the magnetic swipe has turned the implants on, a PhysioTelTM “Digital Power-
On Detector” was used. Upon implant activation, this device gives a light and sound signal.  
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6.5 Setup of an EEG Protocol 
EEG and video data were collected on a mobile workstation (Dell Inc. Precision M4800) with 
the DSITM software Ponemah (Version 5.20) and the Noldus Media Recorder (Version 2).  
The hardware needs to be assembled in a certain order: First, the router has to be powered 
up. Then it can be connected to a non-PoE on the switch. Next, the computer is started and 
connected to a second non-PoE port on the switch. The transceivers are connected to the 
CLC before the CLC is linked with the router, using a PoE port. The cameras are individually 
connected to the switch. Then, the Ponemah software (with the license dongle inserted) is 
started and identifies the different components. With the help of the software, a scan 
detects the individual implants to enable assigning them to a CLC. Then, a protocol needs to 
be created that defines the correct assembly of the hardware components as well as 
technical parameters for recording and details about the individual study. Settings that need 
to be adjusted prior to EEG acquisition are listed in Table 4.  
The option to synchronize two videos with one EEG signal does not exist in Ponemah. A 
work-around was developed: an additional not implanted transmitter was used to enable 
recording from the second angle. In the protocol, a second group was created and assigned 
to this camera. 
 
Parameters in the Ponemah study protocol 
Definition of 
information 
submitted per 
implant 
Each implant can record one bio-potential, activity and temperature. In addition, 
information on battery life (recording days left, remaining battery capacity) can 
be submitted to the computer. To increase battery life, channels that are not of 
interest for the current study can be switched off. In the experiments described 
here, biopotential, temperature and activity were always sampled.  
Sampling Rate  Sampling rate is chosen for biopotential, temperature and activity separately. 
500 Hz were chosen for the EEG, making it priority. Secondary sampling rate for 
temperature and activity was 50 Hz.  
Group 
assignment  
Each implant is assigned to one group automatically. One group consists of the 
three channels (biopotential, temperature and activity) submitted by one 
implant. The video camera corresponding to one animal needs to be assigned to 
one group for synchronization.  
Experimental 
protocol 
Optional: Information on the individual study can be entered like: date, test 
substance, dosage, animal number, animal sex, responsible scientist etc. 
 
Note: Care must be taken that group name and animal identifier are the same. 
Otherwise, the video will not be saved for offline-analysis in DSITM Neuroscore.  
Definition of 
events 
Events can be defined and added during the acquisition. Examples for events are: 
“Jumping”, “Emesis”, “Dosing”, “Animal is drinking” etc.  
This tool was not used in the experiments described here. Instead, all events 
were noted in a separately written protocol. 
Table 4: Setup of a protocol in DSITM Ponemah. 
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7 EEG Experiments  
7.1 Baseline and Sleep Recording 
The functioning of the system was controlled two weeks after surgery. Baseline recordings of 
20 minutes were obtained from all dogs. The EEG from only one animal at a time was 
recorded in the first control EEGs. To further evaluate if the setup was suitable to visualize 
alterations in the EEG signal, normal sleep was recorded. Two of the three grouped housed 
male dogs were recorded simultaneously, starting at 6 p.m. in the evening. The recording 
was continued until 7 a.m. on the next day.  
 
7.2 EEG Recording with Subcutaneous Needle Electrodes 
A telemetry transmitter was connected to stainless-steel needles to test whether this would 
enable to record minimal-invasive EEGs with the same equipment as used with the 
implanted telemetry. One female dog with implanted EEG transmitters was chosen for this 
experiment and the signals sampled by the implanted and the non-implanted transmitter 
were recorded simultaneously. 
The dog was fastened overnight and electrodes were placed under propofol (Propovet™ 
Multidose, Abbot Laboratories) anesthesia. 4 mg/kg were initially administered, with 
subsequent doses of about 1 mg/kg after effect to keep the dog anesthetized for a period of 
20 minutes. Eye lubricant was administered on both eyes (Bepanthen® Augen- und 
Nasensalbe, Bayer) and the dog was placed on a mattress in lateral recumbence. A local 
anesthetic (Lidocainhydrochloride 2%, 2 x 1 mL s.c.) was injected subcutaneously. The two 
needle electrodes were then inserted subcutaneously above the implanted screw electrodes 
(5 mm rostral from inter-aural line and 10 mm on either side from the median line). Needle 
electrodes were fixed with tape (Hansaplast® Fixierpflaster Classic). A net bandage with 
holes cut for the ears was used to further stabilize the electrodes and hold the transmitter 
body at the side of the neck. The one-channel EEG was recorded for a period of 20 minutes 
under propofol anesthesia from implanted and not-implanted electrodes. Propofol 
administration was then discontinued and the dog was allowed to recover from anesthesia. 
Recording was continued for 15 minutes before the needle electrodes were removed.  
 
7.3 Reference Compounds  
A set of reference compounds was selected from literature for different purposes: the first 
aim was to explore whether drug effects can be differentiated from normal baseline activity 
with bilaterally implanted electrodes in dogs with and without CSF ports. Then, the technical 
readiness of the telemetry equipment could be evaluated under real study conditions. Lastly, 
the testing of relatively harmless reference compounds provided an option for training the 
processes of an EEG study and EEG interpretation. This included the induction of symptoms 
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often seen in toxicology studies, like emesis, and their differentiation from neurological 
symptoms. 
To avoid testing a substance like PTZ that would induce severe symptoms and limit the reuse 
of dogs, compounds and doses were selected that were considered to be well tolerated. Two 
CNS stimulants, apomorphine and quinpirole, and two CNS depressants, midazolam and 
propofol, were chosen after reviewing the literature. Selection was limited to some degree, 
as the use of e.g. morphine or d-amphetamine is legally restricted. 
Doses for reference compounds were based on the manufactures prescription (midazolam, 
propofol, apomorphin) or on literature reports (quinpirole, (Whitaker & Lindstrom, 1987)).  
One male and one female dog were chosen for each experiment with reference compounds. 
A general veterinary examination was conducted prior to all experiments. Prior to dosing, 20 
minutes of baseline EEGs were recorded. All experiments were performed in the morning, 
with compound administration between 8.00 and 12.00. Catheters for intravenous 
administration were inserted into the right V. cephalica in the respective experiments 
(midazolam, propofol, quinpirole). The investigator was not blinded to treatment or dose.  
 
7.3.1 Midazolam 
Midazolam was administered intravenously as ready-to use formulation (Midazolam-
ratiopharm® 15mg/3ml) at a dose of 0.2 mg/kg. The EEG was then recorded for 20 minutes. 
Clinical symptoms were observed by two observers and recorded via video. Due to wrong 
protocol setup, the video was not saved and was not available for offline analysis. The 
second dog was dosed after the recording of the first one was finished on the same day.  
 
7.3.2 Propofol 
The dogs selected for this experiment were fasted overnight. Propofol (Propovet™ 
Multidose, Abbot Laboratories) was administered via catheter, placed in the right V. 
cephalica. After intravenous injection of a starting dose (4 mg/kg), subsequent doses 
(approx. 1 mg/kg) were administered by the attending veterinarian based on clinical signs to 
maintain anesthesia for 20 minutes. During this time, the dog was placed in lateral 
recumbence and covered with a towel. Eye lubricant was administered on both eyes 
(Bepanthen®, Augen- und Nasensalbe, Bayer). After propofol was discontinued, the EEG was 
recorded until the dog was awake and walking. The dogs were recorded in the morning on 
two different days. Clinical signs were controlled by two veterinarians and recorded with 
video.  
 
7.3.3 Apomorphine 
Emesis is a common finding in dog toxicology studies; therefore the potential EEG artefacts 
related to this symptom were of interest. As one of the available in-house compounds was a 
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D3 agonist, comparison of EEG effects of unselective and selective agonists was of interest as 
well. The two dogs were given a third of their usual amount of food half an hour prior to the 
start of the experiment. This was done as the effects of emesis on the EEG should be 
evaluated by injecting apomorphine and vomiting on an empty stomach was considered 
more stressful. Apomorphine was administered subcutaneously (0.8 mg/kg; Emedog, 1 
mg/mL, Laboratoire TVM, s.c.). After 30 minutes, dogs were treated with metoclopramide (1 
mg/kg, Emeprid® cewa, s.c.). EEG recording was then discontinued. Dogs were under 
veterinary observation until emesis stopped. They were fed normally after the experiment. 
EEGs of both dogs were recorded on the same day, one after the other.  
 
7.3.4 Quinpirole 
Quinpirole (Quinpirole-hydrochloride, Sigma-Aldrich) for intravenous administration was 
prepared freshly at the day of each experiment. It was initially dissolved in sterile saline 
(NaCl 0.9%, B. Braun) at a concentration of 6.6 mg/mL and sterile filtered through a 0.22 μm 
Sterivex®-GP, Millipore polyethersulfone (Merck Millipore) under a laminar flow hood.  
After intravenous administration of quinpirole, clinical observations and EEG recordings 
were continued for the duration of symptoms. Both dogs were recorded on separate days. 
The male received a dose of 0.2 mg/kg which was lowered for the female dog to 0.1 mg/kg. 
Dogs received subcutaneous metoclopramide (1 mg/kg; Emeprid®, cewa) 30 minutes after 
Quinpirole administration. Total recording time was seven hours for the male and four hours 
for the female dog.  
 
7.4 In-House Compounds  
The use of drug candidates from the field of neuroscience enabled evaluation of the EEG for 
assessment of seizure liability under real-life conditions. The selected compounds had 
different modes of action (see Literature, chapter 4). The investigator was not blinded to 
treatment in the experiments and was also responsible for offline EEG analysis.  
 
 Compound 1  7.4.1
Experiments with compound 1 were conducted on two separate days, each starting in the 
morning at 9 a.m.. On each day, one male and one female dog received escalating 
intravenous doses of compound 1.  
 
Dose Selection 
Doses were selected based on pre-existing data from toxicology studies in dogs and NHPs. 
Previous studies in dogs used the oral route of administration, whereas NHPs had received 
escalating intravenous infusions. Neurological symptoms were seen in both species. Dose 
selection was based on the following goal: the first dose targeted plasma concentrations not 
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correlated with neurological symptoms. The two subsequent escalating doses targeted 
plasma concentrations associated with the occurrence of neurological symptoms. To 
determine which dosages would be needed to reach these levels, pharmacokinetic modeling 
experts were consulted. They established a computational two-compartment model using 
Phoenix software (Phoenix 64; Build 6.4.0.768), based on data from a toxicology dog study 
with oral administration and from a DMPK study with intravenous and oral dosing. The 
calculated doses were the following: 12 mg/kg (from 0-10 minutes) to target an initial mean 
Cmax of 2.5 µg/mL; 27 mg/kg (from 30-40 minutes) to target a mean Cmax of 7.5 µg/mL; 29 
mg/kg (from 60-70 minutes) to target a mean Cmax of 11.5 ug/mL and 30 mg/kg (from 90-100 
minutes) for target mean Cmax of 15 µg/mL (Figure 8). 
Based on experiences from the first experiment with the male dog, the protocol was 
adapted for the female dog to reduce the overall duration and the burden of the procedure 
for the animal: The number of dosing steps was reduced to doses of 30 mg/kg for a target 
exposure of 7.5 µg/mL and 40 mg/µL for 11.5 µg/mL.  
 
Figure 8: Dosing scheme 
Compound 1:  Doses were 
modeled to achieve increasing 
target exposures. 
 
 
Formulation 
Compound 1 (succinate) was initially dissolved in DMSO (5 DMSO : 95 saline: NaCl 0.9% B. 
Braun) at a concentration of 20 mg/mL. The solution was then stirred in an ultrasound bath 
at 37°C until visually clear. Next, sterile saline was added to achieve the desired 
concentration of 15 mg/mL. This was done on the day before the study. Overnight, the 
solution was kept in a glass bottle with screw cap at 4°C. Aseptic filtering was done freshly 
on the next day by the pharmaceutical lab. The solution was sterile filtered through a 0.22 
µm Minisart High-Flow syringe Filter (PES Sartorius 16532) under a laminar flow hood using 
aseptic techniques. Final concentration was determined and found to be 16.9 mg/ mL in the 
first and 15.9 mg/mL in the second experiment. Infusion rates were adapted accordingly 
(Table 5). Until administration, the solution was kept at room temperature. 
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Dog Dose (mg/kg) 
Conc. 
(mg/mL) Dosing Scheme 
Sample 
Time 
(min) 
Target Plasma 
Concentration
(µg/mL) 
Volume 
(mL) 
Infusion 
Rate 
(mL/h) 
M 
12 
 16.9 
10 min infusion + 
20 min observation 12 2.5 
7.1 42.4 
27 
 16.9 
10 min infusion + 
20 min observation 42 7.5 
15.9 95.4 
29 16.9 10 min infusion + 20 min observation 72 11.5 
17.15 102.9 
30 16.9 10 min infusion + 20 min observation 102 15 n/a n/a 
F 
30* 15.9 10 min infusion + 20 min observation 12 
7.5 16.98 102 
40* 15.9 10 min infusion + 20 min observation 42 
11.5 22.64 135 
Table 5: Experimental design compound 1  M = male, f = female; * = adjusted dosages, based on 
experience from experiment 1. 
 
Study Design 
After 20 minutes of baseline recording, administration of the test compound was started 
using an infusion pump (B.Braun Perfusor FM, B. Braun Melsungen AG). During the time of 
infusion, one person was in the dog kennel and described all clinical symptoms. They were 
recorded by a second person who also observed the EEG trace. The handwritten records 
were transferred to Excel (Microsoft Office 2010) for later evaluation after the experiment. 
Heart rate and other physiological parameters were assessed at irregular intervals by a 
veterinarian during infusions and in the observation time in between. After administration of 
the calculated dose was finished, the infusion line was removed. Two minutes later, the dog 
was taken out of the kennel for collection of blood samples. For the remaining 18 minutes of 
this 20 minutes observation time, the dog was left in the recording kennel and supervision 
was continued from the outside. After these 20 minutes, the second and third doses were 
administered following the same procedure. A CSF sample was collected from the male dog 
through the implanted CSF port 100 minutes after the start of the experiment. Recording 
was continued for both dogs as long as clinical symptoms were present for five more hours 
after administration of the last dose. A control-EEG with duration of 30 minutes was 
recorded from the male dog to confirm recovery two days after the experiment.  
 
 Compound 2 7.4.2
Dose Selection  
Doses were derived from previous oral toxicology studies (Table 6). There, doses >10 mg/kg 
induced the head tremor and resulted in a Cmax of 1208 ng/mL and 1086 ng/mL for males 
and females respectively. Doses up to 30 mg/kg were well tolerated. Mean oral 
bioavailability of compound 2 in dogs was 78.4% and t1/2 (after an oral dose of 1 mg/kg) was 
5.4 hours. Modeling of doses for intravenous administration was done, but only the free 
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base form of the compound was available. Due to poor solubility, this form was not suitable 
for intravenous administration and therefore, the oral route was chosen. The calculated 
intravenous dose necessary to reach a target plasma concentration of 1000 ng/mL would 
have been 2 mg/kg. The following dose of 3 mg/kg would have reached the next target 
concentration of 2000 ng/mL. Each dose would have been administered over a period of 10 
minutes with 20 minutes of observation time in between. An oral dose of 14 mg/kg was 
selected based on earlier studies. Pharmacokinetic parameters are shown in Table 6 and 
Figure 10.  
 
 
Figure 9: Modeling of intravenous doses of 
compound 2.  Due to poor solubility, the oral 
route was chosen. 
 
Sex Dose Capsule (mg/ kg/day) Cmax (ng/mL) AUC (ng x hr/mL) T½ (hrs) 
Male 10 1208.0 9335.4 5.5 
Female 10 1086.0 12689.2 6.0 
Table 6: Plasma exposure in earlier toxicology studies with compound 2.  Male and female dogs 
received oral doses of 3, 6, 10 and 30 mg/kg. Head tremor was observed with oral doses >6 mg/kg.  
 
. 
Figure 10: Plasma concentration of compound 2 after 
oral administration (10 mg/kg) to male and female dogs.  
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Formulation 
Compound 2 was prepared freshly on the day of the experiment. The substance was 
dissolved in 0.2% HPMC (10 mg/mL) and then stirred continuously until administration. For 
administration, the appropriate volume based on actual body weight (10 mL for the female, 
15.4 mL for the male) was filled in gelatin capsules to achieve the selected dose of 14 mg/kg.  
 
Study design 
After 30 minutes of baseline recording, compound 2 was administered p.o. via capsule (14 
mg/kg). The EEG equipment was installed outside of the animal room and observations were 
primarily via video. The animal room was entered for collection of blood (30, 50, 120 
minutes and at 6 and 24 hours after dosing) and veterinary examinations. One CSF sample 
was collected from the male dog 50 minutes after dosing. All study events like the time of 
dosing or the onset of symptoms were documented. As the male dog had not resumed 
normal behavior in the evening, the recording was interrupted for 10 minutes for data 
saving before it was restarted and continued overnight until 6 a.m. on the following day.  
 
 Compound 3 7.4.3
Dose Selection  
Dosages of compound 3 were calculated by AbbVie pharmacokinetic modeling experts based 
on data from two individual DMPK studies with intravenous dosing in dogs. The modeling 
software was Phoenix 64 (Build 6.4.0.768) and a fitted PK two compartment model with 
population parameters V, V2, Cl, Cl2 was applied. Selection of target exposures was based on 
target exposures previously chosen for the NHP infusion study (500 ng/mL, 1000 ng/mL, 
1500 ng/mL and 2000 ng/mL) under consideration of species specific protein binding. No 
previous experience existed with high doses of this compound in dogs. In oral NHP 
toxicology studies, individual animals had convulsions after single doses at lower plasma 
levels of 1030 ng/mL and 1390 ng/mL. Figure 11 shows the exposure simulation that 
determined intravenous doses of 8 mg/kg, 6 mg/kg and 9.5 mg/kg to result in target 
exposures of 750 ng/mL, 1000 ng/mL and 1600 ng/mL. 
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Figure 11: PK modeling of the dosing scheme for 
compound 3  Intravenous doses: 8.0, 6.0 and 9.5; 
target exposures: 750, 1000, 1600 ng/mL.   
 
For the second experiment with compound 3, the model was adapted by considering the 
plasma concentrations measured in the first experiment. Also, higher total plasma 
concentrations were targeted. The first dose of 16.5 mg/kg was calculated to result in a total 
plasma concentration of 1500 ng/mL and the second dose of 11.0 mg/kg should reach an 
exposure of 2000 ng/mL (Figure 12). The male dog from the first experiment was selected 
based on higher sensitivity compared to the female due to the CSF ports. 
 
 
Figure 12: Second simulation for compound 3.  
First dose: 16.5 mg/kg (target 1500 ng/mL); 
second dose: 11.0 mg/kg (target 2000 ng/mL).  
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Dog  Dosage Target Exposure 
(µg/mL) 
Volume (mL) Infusion Rate 
(mL/h) 
3001 8.0 750 14.54 87.27 
3001 6.0 1000 10.9 65.45 
2002 8.0 750 9.69 56.0 
2002 6.0 1000 7.27 43.63 
Table 7: Infusion rate calculation for the first experiment with compound 3. 
 
Dog  Dosage Target Exposure 
(µg/mL) 
Volume (mL) Infusion Rate 
(mL/h) 
3001 16.5 1500 32.0 196.2 
3001 11.0 2000 22.0 132.0 
Table 8: Infusion rate calculation for the second experiment with compound 3. 
 
Formulation  
Compound 3 was initially dissolved in D5W (5% Glucose, Deltaselect®) at a concentration of 
6 mg/mL. The pH was measured with a pH meter (inoLab, pH720, WTW) and adjusted to 7.4 
using 0.1 mM NaOH or HCl. Then, osmolality was controlled with an osmometer (OM 815, 
Typ M 10/25 µl, Löser) to ensure that the compound was suitable for intravenous 
administration. Osmolality was adapted to physiological conditions (290 +/- 10 mosmol) 
using AMPUWA® (Fresenius Kabi Deutschland GmbH). On the experimental day, the solution 
was sterile filtered using a 0.22 µm Sterivex® filter. 
 
Study Design 
After 20 minutes of baseline recording, the male dog received the two consecutive 
intravenous doses of 8 mg/kg and 6 mg/kg over 10 minutes, with a 20 minutes observation 
time in between. Blood samples were taken at 12 and 32 minutes, two minutes after 
termination of each infusion step respectively. A CSF sample was collected from the male 
dog 50 minutes after dosing. The EEG of the female dog was also recorded during the 
experiment with the male dog, so the baseline was extended by 60 additional minutes. After 
termination of the experiment with the first dog, dosing scheme was repeated with the 
female dog. Clinical observations of the dogs were recorded during the time of the 
experiment and transferred to an Excel sheet (Microsoft® Excel 2010). Additional blood 
samples were collected 24 hours after the start of dosing for both dogs individually.  
 
ECG Recording and Analysis 
EEG recording and infusion scheme were the same for the second experiment with 
compound 3. In addition ECG recording was performed to monitor effects of compound 3 on 
the cardiovascular system that had been observed in the first study. For this measurement, a 
jacketed external telemetry system was used (DSITM JET – jacketed external telemetry, Prior 
to initiation of this experiment, the dog was habituated to wearing the jacket (Lomir 
Biomedical Inc.). The setup consisted of the recording laptop computer (Dell Inc., Latitude 
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E66440) the ECG transmitter (Model JET-3ETA-BP), a Bluetooth receiver (Bluegiga 
Technologies Inc., WRAP Access ServerTM) and commercially available adhesive electrodes 
(ConMed® Corporation, Softrace® Medium repositionable ECG electrodes). The recording 
software was, as for the EEG, Ponemah (DSITM). As described for the EEG, a protocol had to 
be configured prior to recording. For parallel EEG and ECG recordings, two computers were 
necessary, so ECG time synchronization was not automatic via software. As the individual 
computer times differ from each other, exact starting and stopping times of the recording 
were documented to enable relating both signals with each other. The dog’s hair was clipped 
in places where the electrodes were applied. Then, the skin was cleaned with alcohol to 
enable secure hold of the electrodes. Electrodes were placed at the right (RA = right arm 
electrode, red) and left (LA = left arm electrode, yellow) forelimb and at the left hind limb (LF 
= left foot electrode, green). The ground electrode was positioned at the right hind limb. 
Electrodes were then connected with the transmitter which is stored in a pocket on the 
outer layer of the jacket. The inner layer consists of softer fabric and protects the electrodes. 
Ponemah (DSITM) records the ECG according to Einthoven (I., II, and III deviation) and 
Goldberger (aVR (augmented voltage right), aVL (augmented voltage left) and aVF 
(augmented voltage foot). Sampling rate was 500 Hz and epoch time was five seconds. First, 
ECG recordings were visually evaluated. The recording software Ponemah (DSITM) extracts 
HR and QTcv automatically and the derived data can be copied to Excel for further analysis. 
Prolongation of the QT interval is used as an indicator for pro-arrhythmic drug effects (El 
Amrani et al., 2016). QTcv means that the QT interval is mathematically corrected by heart 
rate (Van de Water et al., 1989; Prior et al., 2009; El Amrani et al., 2016). Graph Pad Prism 
(Version 5) was used to calculate median HR and QTcv. 
 
7.5 Visual Video-EEG Analysis 
Visual analysis of EEG was done during the experiment in Ponemah and then retrospectively 
using DSITM Neuroscore (Version 3.2). In this program, a 1 Hz high-pass filter and a 50 Hz 
power-line filter were used on all EEG recordings.  
All recordings were split into a baseline period and a period covering the time after 
substance administration. If multiple doses were administered, further divisions were made.  
Recordings were visually examined in 10 second windows. Artefacts and episodes with signal 
drop-outs were identified visually and marked. Background activity was evaluated by 
considering wave morphologies, frequency and amplitude. Episodes at which the animal was 
asleep were marked accordingly as well as transient abnormal EEG patterns. Video was 
displayed simultaneously with the EEG trace during both, online- and offline viewing.  
Due to the limited animal numbers, no statistical evaluation of EEG data was done. The 
interpreter was not blinded to animal or treatment. 
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7.6 Automatic Seizure Detection 
DSITM’s Neuroscore software (Version 3.2) was extended with a module for automatic 
seizure detection. For internal validation of this seizure detection module, EEG data from 
mice that had received intraperitoneal PTZ was used. There are two possibilities by which 
the program identifies seizures and both were explored. The first option is to set an absolute 
threshold. In order to do this, the mean amplitude of the background activity has to be 
determined. The program then identifies all discharges with a higher voltage. Additional 
parameters can be defined to refine the automated detection, e.g. maximum voltage, which 
eliminates the detection of high-amplitude artefacts or signal drop-outs. The identifiers of 
spike-trains can also be defined manually through minimal spike-train duration and minimal/ 
maximal distance between spikes. The second option for automatic seizure detection is to 
define a dynamic threshold, which is useful in recordings with an unstable baseline.  
 
7.7 Quantitative EEG Analysis  
After artefacts and episodes with altered vigilance state had been visually identified and 
marked, a quantitative analysis of EEG was done in Neuroscore. Epoch time was set to two 
seconds for all recordings and relative EEG power was calculated for the frequency ranges 
defined in Table 9. Calculation was done by using Fast-Fourier Transformation (FFT), which is 
a build-in feature of the Neuroscore software.   
 
Frequency band Spectrum (Hz) Color code  
Delta 0.5-4 Light blue  
Theta 4-8 Dark Blue  
Alpha 8-12 Green  
Sigma 12-16 Violet  
Beta 16-24 Orange  
Gamma 24-50 Yellow  
Table 9: Power bandwidths selected for quantitative EEG analysis via FFT.  
 
Relative power [%] of EEG frequencies was then displayed in a signal grid in Neuroscore. 
Artefact coverage [%] was calculated for each 2 seconds epoch. Also, episodes with reduced 
vigilance were marked in the recording and coverage of sleep markers was calculated and 
added to the signal grid as well. This table was then exported to Excel (Microsoft Office 
2010) where lines with an artefact or sleep marker coverage >0% were deleted.  
50 to 100 artefact-free two-second-epochs were selected in Excel (Excel 2010, Microsoft®) 
from the baseline period and around TK sampling time points. Further data processing was 
done using Graph Pad Prism (version 5). For each experiment, scatter plots that show 
changes in the single power bands from baseline to post treatment (see supplementary 
data) were created. Within the scatter plots, means +/- standard deviation (SD) are shown. 
To investigate changes in relative power bands in the baseline period and after treatment 
between dogs, the median of each power band was calculated. One plot was created for 
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each experiment respectively showing the median power changes in each frequency band of 
two dogs from baseline to post treatment. Due to the small animal numbers, results are 
presented in a descriptive way.  
 
7.8 Blood Sampling for Drug Level and Biomarker Analysis  
Blood samples were collected two minutes after termination of each infusion step for 
compounds 1 and 3 (at 12 and 32 minutes; and for dog the male dog in addition at 62 
minutes in the experiment with compound 1). As compound 2 was administered orally, 
samples were collected according to clinical symptoms 30, 50, 90, 480 minutes after 
compound administration. In all experiments, one last sample was drawn 24 hours after 
dosing. Samples for determination of drug levels were collected in a K3 EDTA S-Monovette® 
(Sarstedt AG & Co) and centrifuged to get plasma. Plasma samples were then stored -20°C 
until test item concentrations were analyzed. Serum samples were collected in a Z-Gel 
Monovette® (Sarstedt AG & Co). After allowing 30 minutes of clotting time at room 
temperature, samples were centrifuged (10 minuntes, 3000 U/min). Serum samples were 
then stored at -80°C prior to further use for biomarker research. 
 
7.9 CSF Sampling for Biomarker Analysis  
 
 
 
 
 
 
 
 
 
 
Figure 13: Materials used for collection of CSF via implanted port (1) different disinfectants (Kodan®, 
Braunol®, Braunoderm®); (2) sterilized gauze (3) autoclaved collection needles; (4) pain medication 
(Metacam® 1.5 mg/mL ad us. Vet, Boehringer Ingelheim GmbH), only in case of multiple sampling 
sessions per day; (5) local anesthetic (Emla®, AstraZeneca GmbH), (6) local antibiotic ointment; (7) 
electric razor (e.g. Aesculap® Vega/ Isis B. Braun Melsungen AG); (8) sterile cannula 20G; (9) sterile 
covers (e.g. CuraVet); (10) sterile gloves (e.g. KruTex Vet-Gel surgical gloves). 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
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Male dogs used in this study had previously been implanted with CSF ports. Prior to 
punctuating a CSF port, a field on the animal’s head was clipped. 30 minutes prior to sample 
collection, a liniment containing a local anesthetic was applied (Emla®, AstraZeneca GmbH). 
Directly prior to sampling, the field on the head was disinfected wearing sterile gloves. Three 
different disinfectants were used and each of them was applied three times (Braunol®, B. 
Braun, Braunoderm®, B. Braun, Kodan®, Schülke). After these preparations, a sterile 30G 
cannula was used to puncture the skin over the port. For sample collection, sterile custom-
made stainless steel cannulas were used. Their lengths were previously determined 
according to the anatomical position of the lateral ventricles of each dog. Collection of CSF 
was done by inserting the cannula through the port with the dog’s head in an upright 
position. Next, the stylet was removed and the person holding the dog bended its neck so it 
looked in a downward direction. CSF then was collected in autoclaved Eppendorf® tubes (1.5 
mL, Eppendorf AG). The first drop was discarded as blood contamination from superficial 
vessels can occur. Prior to removing the cannula, the dog’s head was brought to an upright 
position and the stylet was inserted. After instrument removal, an antibiotic ointment is 
administered. CSF samples were then stored at -80°C until biomarker analysis.  
 
8 Biomarker Analysis  
Aim of the biomarker analysis was identification of changes in the metabolomic profile as 
early indicators of neurotoxicity. Serum samples were collected two minutes after 
completion of each infusion step from each dog in the experiments with intravenous 
administration. In the experiments with compound 2, time points were according to clinical 
signs. Baseline serum samples from each dog had been collected at an earlier time point, 
simultaneous with samples for the health check prior to each experiment. For dogs treated 
with compound 1, baseline samples were not analyzed to enable inclusion of additional 
quality controls. As the number of CSF samples was limited, statistical analysis of serum 
sample measurements was prioritized The analysis of serum samples for biomarkers was 
done in cooperation with the department of DMPK, AbbVie, GmbH & Co.KG, Ludwigshafen. 
The statistical analysis of the high-dimensional metabolomics data was done by the data and 
statistical science (DSS) department, AbbVie GmbH & Co.KG, Ludwigshafen.  
 
8.1 Technical Methods 
Serum and CSF samples were frozen at -80°C. They were thawed once for aliquot 
preparation. 15 µL of serum were distributed to protein-low bind Eppendorf® tubes (1.5 mL, 
Eppendorf AG). After finalization of the last EEG experiment, they were submitted to the 
DMPK department for metabolomics phenotyping with the Absolute IDQ® p180 Kit 
(Biocrates Life Sciences, Insbruck, Austria). This kit analyzes up to 188 endogenous 
metabolites of different classes (acylcarnithines, aminoacids and biogenic amines, 
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monosaccharides, sphingolipids and glycerophospholipids) (see: List of Metabolites: 
http://www.biocrates.com/images/ListofMetabolites_p180.pdf; (BIOCRATES, 2017)).  
 
8.2 Statistical Methods 
Software for statistical analysis was R version 3.3.2 run in RStudio version 1.0.143. The 
package "limma" was used to stabilize the variance across metabolites and reduce the 
influence of outliers. Time points between animals were not exactly identical, so the time 
points with the most similar exposure levels were chosen. With compound 2 and compound 
3, pre- and post-treatment levels of all metabolites were compared using a paired t-test for 
each post-treatment time point. For compound 1, no baseline metabolite levels were 
available from the same animals, so baseline data from other dogs were used and a 2-
sample unpaired t-test was performed for each time point. A Benjamani-Hochberg 
procedure was used to control the false-discovery rate (FDR). Results are presented for 
significant differences at an FDR of q < 0.05 and, in some cases, for p < 0.05. Significantly 
changed metabolites were compared amongst the three treatments for potential overlaps 
by creating a Venn diagram. The relation of identified metabolites for a specific pathway was 
then investigated. Results are presented with fold changes, which are the ratios of the 
metabolite values from treated samples to untreated samples.  
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V. Results 
1 Animal Selection: Assessment of General and Neurological Health  
All dogs were of good general health and had no neurologic abnormalities before surgical 
EEG implantation and after recovery. Body temperature before surgery ranged between 
37.8°C and 38.7°C. Capillary refill time was below two seconds in all dogs. Heart rate was 
variable, ranging from 87 to 112 bpm. Hematological and clinical chemistry parameters 
before and after surgery were within normal limits. The thyroid function of all dogs was 
normal.  
 
2 Surgical Implantation of EEG Transmitters 
 Pilot Study: Intra-surgical EEG Evaluation and Removal of CSF Implants 2.1
Implantation of EEG electrodes in addition to existing CSF ports was possible. The 
coordinates were adapted and the EEG recorded during the pilot study was evaluated by 
two researchers. Good EEG signal quality was observed (Figure 14).  
 
 
Figure 14: EEG recorded during the pilot study. Signal quality was evaluated by two different 
researchers. 
 
Removal of EEG and CSF implants in this dog was possible. Duration of the procedure was 
three hours from induction of anesthesia till extubation. Neurological examination of the 
dog was normal after the procedure. The dog was kept for an additional 6 weeks for 
recovery, then it was submitted successfully to an adoption program. Control X-rays were 
made four weeks after surgical implant removal (Figure 15 and Figure 16). In the ventro-
dorsal recording (Figure 15, to the left), a round brightening on the right side could indicate 
the former position of one of the CSF ports, but is too large compared to the actual screw 
size. Also, no corresponding spot is visible on the other side. Therefore, good healing of the 
implantation sites was diagnosed. Former implantation sides of the EEG electrodes are not 
visible in the x-ray. 
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Figure 15 (left) and Figure 16 (right): Ventro-dorsal and latero-lateral control X-rays 4 weeks after 
surgical removal of CSF ports and EEG electrodes of the dog used in the pilot study.  X-rays 
indicate a good healing process. 
 
 Implantation of EEG Transmitters in Dogs with and without CSF Ports 2.2
DSITM does not recommend electro cautery during implantation of telemetry devices and will 
not account for proper device functioning if this is disregarded. We used electro cautery 
prior to transmitter implantation to stop bleeding of superficial vessels and no negative 
effects on device functioning were observed. EEG implants are well tolerated and have kept 
patency for 18 months so far.  
Duration of implantation was 1.8 hours (mean, range 1.30 hours – 2.03 hours). All dogs 
resumed sternal recumbence within 20 – 40 minutes after extubation. Female dogs 
recovered better from anesthesia and were transferred to their home cages faster (mean: 
4.6 hours; range 3.5-6hours). One male dog had self-resolving vertical nystagmus for a 
period of five hours following surgery and was transferred to his home cage after six hours. 
Surgery of male dog 2001 was in the afternoon, and it was decided to keep him in the 
waking box overnight. Male dog 3001 was transferred to his home kennel after 10 hours.  
As recovery of all dogs was good, buprenorphine (Buprenovet® Multidose 0.3 mg/mL,Bayer 
Vital GmbH) was discontinued after four administrations (three on the day following surgery, 
one on the second day following surgery). Caprofen and enrofloxacin were continued for 
seven days following surgery. Clamps were removed after 14 days. The post-surgical clinical 
chemistry and hematology parameters were within normal limits and indicated good 
recovery. Control-EEGs after removal of clamps were normal. 
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3 EEG Experiments 
 Baseline Recordings  3.1
 Visual Analysis 3.1.1
During the second week after surgery, function of the EEG transmitters was controlled and 
15 - 20 minutes of EEG were recorded from each dog. By visual analysis, no abnormal 
transient EEG patterns could be identified. Recording quality varied, depending on the grade 
of activity of the dog which corresponded to an increase in artefact incidence. Best 
recordings were obtained when the dog was left alone and sat or lied down. The 
predominant pattern in wake dogs was beta activity, with average amplitude of 30 µV and a 
frequency of 20 Hz (Figure 17). Alpha activity indicated a reduction in the vigilance level 
(Figure 18). 
 
Figure 17: 10 seconds baseline EEG of an awake dog: no artefacts, beta activity is confirmed by FFT 
analysis (beta = orange). 
 
 
Figure 18: 10 seconds of baseline EEG: no artefacts, beta and alpha activity, indicating a reduced 
vigilance level. 
 
Artefacts were present in all EEG recordings. Movement artefacts were the most common 
ones and often exclusion of up to several minutes of EEG data was necessary. Movement 
artefacts are not only a result of muscle activity, but turning of the dog’s head causes the 
cables underneath the skin to bend and thereby the electric input is altered. This could be 
observed with normal dog movements or when the dog was handled. Artefacts were 
distinguished from normal EEG activity by relating the animals’ activity recorded by the 
transmitter and the video to abnormal EEG patterns. Paroxysmal EEG activity simultaneous 
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to increased animal movements or certain behaviors was considered as artefact. In Figure 
19, the correlation between increased movements and occurrence of EEG artefacts is 
illustrated.  
The implanted accelerometer detects movements of the whole animal along the three axes 
of the room. Movements of single body parts are not reflected on the activity trace but can 
induce changes in the EEG, e.g. when the whole body moves along with tail movements and 
causes bending of cables. On the contrary, animal movement does not always induce overt 
EEG artefacts. This can be seen in Figure 19 as well.  
 
Figure 19: 10 minutes of baseline recording  Movement artefacts marked red. The arrow points at 
the activity trace; a good correlation of increased movements to EEG artefacts is illustrated. In 
addition, the influence of artefacts on spectral analysis is demonstrated: in unaffected regions, beta 
activity dominates whereas there is an increase in delta activity during animal movements. 
 
 
Artefacts from muscle activity were also amongst the most common ones. Muscle potentials 
have a high voltage up to millivolts. This distinguishes them from brain activity which is in 
the microvolt range. Muscle activity can completely hide brain potentials. High-voltage 
activity in the EEG with no behavioral correlation was estimated to result from activity of the 
m. masseter or tongue movements. Occurrence of such artefacts could be provoked when 
the dogs were fed (Figure 20) or drinking. 
In some cases, the video does not show a clear origin of the artefact. This is the case with 
eye movements that cause slow waves in the EEG (Figure 21). The eye ball functions as a 
dipole and eye movements therefore are reflected in the EEG. In human EEG recordings, an 
EOG is therefore often recorded along with the EEG. This was not done in the studies for this 
thesis and it was found that video is not sufficient to monitor eye movements. 
 
Increased activity 
Artefacts 
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Figure 20: Muscle artefacts (4 seconds EEG, 
male dog). Dog was fed so artifacts are from 
jaw muscles and the tongue. 
 
Figure 21:Eye movements  (2.5 seconds EEG, male 
dog). 
 
EEG artefacts can also be caused by the electric activity of the heart muscle and are a 
common finding in clinical EEG recordings. Therefore an ECG is often written simultaneously 
with the EEG to monitor appearance of artefacts simultaneous with QRS complexes. No 
abnormal EEG patterns that could be due to ECG artefacts were identified in all of the 
recordings. In one study, an ECG was written simultaneous to the EEG but was not timely 
synchronized and could therefore not be used to identify artefacts.  
Isolated signal drop outs occurred in most recordings. Their duration varied between several 
seconds to some minutes at maximum. Signal drop-outs occurred predominantly at the 
beginning of the recording period and their cause could not be determined. They were 
excluded for qEEG analysis.  
 
 
Figure 22: Signal drop out  (6 seconds EEG, 
female dog). Some seconds of normal EEG 
activity can be distinguished.  
 
 Quantitative Analysis of Baseline Recordings 3.1.2
To control whether quantitative EEG analysis was possible, two baseline recordings were 
selected from each dog to check for inter-animal variability. After removing artefacts, a 
Kolmogorov–Smirnov test was run on each individual baseline to check for normal 
distribution (95%) and the result was that neither relative nor absolute power were normally 
distributed. Then, medians of the individual power bands from the two separate baseline 
recordings were calculated for each dog. Results are shown in Figure 23. The medians for 
each relative power band are similarly distributed in two individual baseline recordings for 
all the dogs. No further statistical tests were run, due to the small animal numbers. 
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However, with these results it was assumed that baseline qEEG parameters were stable 
enough to enable detection of possible treatment effects.  
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Figure 23: Median relative power of 2 individual baseline recordings from each dog 
 Sleep Recordings 3.1.3
In overnight recording sessions, different sleep stages were recorded. A hypnogram, as in 
Figure 24, shows the transition between the different sleep stages over time. Sleep stages 
can be defined differently, depending on species or focus of a study. Neuroscore (DSITM) 
allows differentiation of six different stages in large animals, that are displayed on the y-axis 
of the hypnogram (top-down: active wake = A, wake = W, REM = R, 1, 2, 3). In preclinical 
research, the differentiation between two deep sleep stages (2 and 3) is often not done, e.g. 
if only changes in REM duration in treated animals relative to control animals is investigated.  
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For creation of the hypnogram (Figure 24), the sleep stages 1 (light slow-wave sleep), 2 
(deep slow wave sleep) and REM (rapid eye movement sleep) were differentiated from 
“wake”. A decrease in vigilance is paired with an increase in the slower frequency 
components of the EEG (theta, delta, alpha > sigma, beta, gamma). In light (Figure 26) and 
deep (Figure 27) sleep, spindles could be identified as well as K-complexes. Spindles had an 
average amplitude of 100 µV. REM sleep (Figure 28) visually resembles the wake state as the 
background is dominated by faster activity. However, theta activity is present at the same 
time and can be used to identify this sleep stage.  
 
Figure 24: 4 hour hypnogram w=wake, 1=light sleep, 2=deep sleep, REM=rapid eye movement sleep. 
 
Figure 25: 10 seconds of EEG of a wake dog.  The hypnogram (4 hours) is shown above. ↑ indicates 
the position of the EEG in the hypnogram. FFT analysis shows a predominance of beta activity.  
. 
Figure 26: 10 seconds EEG during light sleep:  ↑indicates where the excerpt is in the hypnogram. 
 
Hypnogram 
 
EEG 
 
w 
1 
2 
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Figure 27: 10 seconds of EEG from a dog in deep sleep.  Sleep spindles (red ↑), K-complexes (blue ↑)  
The light blue ↑indicates where in the hypnogram the 10 seconds of EEG are located. 
 
Figure 28: 10 seconds of EEG from a dog in REM sleep. ↑indicates where in the hypnogram the 10 
seconds of EEG shown are located.  
 
 Comparison of EEGs Recorded with Subcutaneous and Implanted 3.1.4
Electrodes 
Simultaneous recording of the EEG from implanted and subcutaneous needle electrodes was 
possible. Amplitudes of the subcutaneously recorded signal differed by a factor 3-5 to the 
signal recorded with implanted electrodes. Peak voltages are 50 µV at implanted electrodes 
compared to 10 µV at subcutaneous electrodes. Number of artefacts is higher in the 
recording from the subcutaneous needle electrodes than in the recording from the 
implanted electrodes. Some artefacts were present in both EEG traces and appeared 
simultaneously (Figure 29). In the subcutaneously recorded EEG, artefacts caused the 
baseline to oscillate with very high amplitudes. In cases in which artefacts were limited to 
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the EEG from subcutaneous needle electrodes, they were probably caused by movement of 
the needles or the transmitter.  
 
 
Figure 29: Simultaneous recording of EEG from implanted and s.c. needle electrodes.  The upper 
trace is from implanted electrodes, below is the recording from s.c needle electrodes. Artefacts are 
present in both with s.c. > implanted, but sometims seem to be “mirrored” (rectangles).  
 
Propofol anesthesia resulted in a decreased frequency and higher amplitude in the EEG trace 
recorded with the implanted electrodes. Also, typical transients like spindles could be 
identified. In the recording from the subcutaneous needle electrodes, an increase in 
amplitude to 20 µV was induced by the anesthetic. The increase inamplitude and the 
elimination of artefacts lead to similar graphical appearance of both traces. Frequency 
seemed to be unaffected (Figure 30). 
 
Figure 30: EEG from implanted and subcutaneous electrodes under propofol anesthesia. A slowing of 
background activity is evident in the upper trace (implanted electrode). With the subcutaneous 
needle electrode (lower trace), only an increase in amplitude can be observed compared to baseline 
recordings.  
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 Reference Compounds 3.2
 Midazolam 3.2.1
Clinical Observations  
After intravenous midazolam, the male and the female dog showed an initial mild sedation 
lasting less than one minute which was followed by a paradox reaction involving increased 
sniffing and excitation. This effect was more prominent in the female dog than in the male 
and lasted for approximately 10 minutes. There were no other clinical observations. 
 
EEG Results: Visual Analysis 
No abnormal EEG activity was noted during baseline recordings (Figure 31).  
 
Figure 31: Baseline prior to midazolam adminstration (10 seconds, male dog). 
 
A mild slowing of the EEG occurred temporarily with peak amplitudes of 50 µV. Spindle-like 
patterns could be distinguished within the first 5 minutes after midazolam administration 
(Figure 32). They had a low incidence (3-4 per dog after midazolam administration) and their 
amplitude was around 80 µV. A transient slowing of background activity appeared within 
one minute after intravenous administration of midazolam that lasted 20 seconds (Figure 
33). Similar episodes were identified at irregular intervals during the next ten minutes.  
 
 
Figure 32: 10 seconds of EEG recording (female dog) with spindle-activity after midazolam 
administration.  Spindles (marked) were present within the first five minutes after midazolam 
administration. 
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Figure 33: 10 seconds of EEG recording (female dog) with sinusoidal, slow waves: This pattern 
appeared within the first minute after intravenous midazolam administration and lasted 20 seconds. 
Similar episodes were observed for the next ten minutes following midazolam administration.  
 
 
EEG Results: Quantitative Analysis 
In the male dog, an increase in relative delta power was observed after administration of 
midazolam. In the female dog, the slower frequencies showed a slight decrease while faster 
frequencies increased. Results for both dogs are shown in Figure 34. No homogenous 
changes were seen. Raw data plots are provided in the supplementary data (Appendix 4).  
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Figure 34: Median relative power changes in male and female dog after administration of midazolam.  
 Propofol 3.2.2
Clinical Observations  
Intravenous injection of propofol resulted in rapid loss of consciousness. Breathing rate and 
responses to external stimuli, e.g. lid reflexes, were regularly controlled by a veterinarian. 
When the lid reflex could be induced, a subsequent dose of propofol was administered and 
thereby anesthesia was maintained for 20 minutes. After the last dose was administered, 
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both dogs regained consciousness rapidly within five minutes. They were returned to their 
home kennels after approximately another 30 minutes.  
 
EEG Results: Visual Analysis 
EEG during baseline recording was normal (Figure 35). Changes after propofol 
administration were as expected from literature reports (Bergamasco et al., 2003). The low 
amplitude (around 50 µV) and high frequency that are characteristics of beta activity 
changed and delta activity became predominant. This consisted of low frequencies coupled 
with high amplitudes around 100 µV (Figure 36 and Figure 37). Sleep spindles (Figure 37), K-
complexes and vertex low waves could be identified. A hypnogram was created (Figure 38) 
to reflect the varying levels of anesthesia, namely the progression to lighter plane before 
administration of a subsequent dose. 
 
 
Figure 35: Normal baseline EEG (10 seconds, male dog). 
 
 
Figure 36: Delta waves present after administration of propofol (6 seconds, male dog). 
 
 
Figure 37: Delta waves and spindle activity (marked) after administration of propofol, (10 seconds, 
male dog). 
 
 
Figure 38: Hypnogram during propofol anesthesia.  A lighter anesthetic plane can be detected with 
the EEG and the EEG depressant inflence of the subsequent dose of propofol can be illustrated.  
 
 
 
1st dose: induction ↓ 2nd 
dose ↓ 
3rd 
dose ↓ 
4th 
dose ↓ 
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EEG Results: Quantitative Analysis  
Median relative power was calculated for the baseline and during propofol anesthesia. 
Frequency changes of both dogs show the same trend for all power bands. After propofol, 
an increase in the lower frequencies (delta, theta, alpha) is evident for both dogs. Relative 
beta and gamma power were reduced during propofol anesthesia (Figure 40). Raw data 
plots are provided in the supplementary data (Appendix 4).  
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Figure 39: Median relative power changes in male and female dog after administration of propofol. 
 
 
Figure 40: qEEG two minutes after propofol administration: dominant slow (delta, theta) frequencies.  
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 Apomorphine  3.2.3
Clinical Observations  
Subcutaneous apomorphine administration caused repeated emesis approximately 15 
minutes after administration in both dogs, lasting approximately 30 minutes. Increased 
licking and swallowing were observed prior to vomiting. After 30 minutes, antiemetic 
medication (Cerenia maropitant, 10 mg/mL Zoetis Belgium SA) was administered and no 
further emesis was observed. Dogs were returned to their home kennels after a total 
recording time (BL + after apomorphine treatment) of one hour.  
 
EEG Results: Visual Analysis 
Visual EEG changes after apomorphine administration were not pronounced. An increase in 
amplitude to 150 µV with increased synchrony could be observed. These episodes lasted 
between 2 and 20 seconds and did not remarkably differ from baseline recordings. 
 
  
Figure 41: Normal Baseline EEG (2.5 seconds, 
male dog). 
Figure 42: Transient increase in amplitude after 
apomorphine administration (2.5 seconds, male 
dog).  
   
 
No EEG changes preceded emesis. After emesis, EEG muscle artefacts (amplitude >150 µV), 
most probably from swallowing and tongue movements (licking), appeared in the EEG.  
 
 
Figure 43: EEG after emesis  (↑). 
 
 
As tongue movements or activity of the jaw muscles are known to induce artefacts in the 
EEG, an increase in the artefact coverage was one of the expected outcomes in this 
experiment. In contrast, neither emesis itself nor the prodromal signs resulted in a total 
increase in the artefact rate compared to baseline. Even an opposite trend could be 
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observed, as the movement activity of the dogs, especially running and jumping, was 
markedly reduced which led to an increase in EEG quality. 
 
EEG Results: Quantitative Analysis 
The median of the relative power bands of two dogs was calculated for each spectral band. 
Then, baseline relative power was plotted against relative power post treatment. An 
increase in delta power was seen in the male, but not in the female. Also a decrease in 
gamma power could be observed in the female, whereas in the male no change from 
baseline was induced by apomorphine injection. Results of qEEG differ between dogs in this 
case, which does not correlate to clinical symptoms. The raw data plots of the two dogs are 
provided in the supplementary data (Appendix 4).  
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Figure 44: Median relative power changes in male and female after administration of propofol. 
 
 Quinpirole 3.2.4
Clinical Observations  
Intravenous administration of quinpirole caused decreased activity and emesis in both dogs, 
starting 10 minutes after administration. The male was resting for five hours after compound 
administration. Due to this effect, the dose was reduced to 0.1 mg/kg for the female. Poor 
coordination and ataxia were observed in the female after administration of quinpirole. 
Body temperature of both dogs dropped below physiological values (37.5-39.0°C).  
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Figure 45: Changes in body temperature after quinpirole administration (↑), (female dog). 
 
 
Figure 46: changes in body temperature after quinpirole administration (↑), (male dog). 
 
EEG Results: Visual Analysis 
No marked EEG changes could be identified after quinpirole administration. Artefacts after 
emesis could be identified that had the same appearance as shown after apomorphine 
administration. Within 10 minutes of recording, EEG voltage increased and frequency 
decreased, indicating a decrease in vigilance state (Figure 48). 
 
 
Figure 47: Baseline EEG (6 seconds, male dog). 
 
 
Figure 48: Slowing of background activity after administration of quinpirole (10 seconds, female dog). 
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EEG Results: Quantitative Analysis 
Median relative frequencies were calculated for both dogs for the baseline and the post-
dosing period. Delta power of both dogs decreased after compound administration, whereas 
gamma power increased. The other medians are changed in the same direction in both dogs, 
but these changes are more subtle. The raw data plots, showing the medians +/-SD for each 
dog and each frequency band individually, are provided in the supplementary data 
(Appendix 4).  
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Figure 49: Quantitative changes after quinpirole administration in dogs (median of BL – post 
treatment for each individual frequency band). 
 
 In-House Compounds  3.3
 Compound 1 3.3.1
Clinical Observations and Exposure in the Male Dog 
Intravenous administration of the first dose (12 mg/mL over 10minutes) of compound 1 was 
well tolerated and resulted in plasma levels of 2362.3 ng/mL which was close to the targeted 
concentration of 2500 ng/mL. During the following 20 minutes of observation time, the only 
finding was transient lip licking. The second dose (27 mg/kg, administered over 10min) 
achieved a plasma concentration of 5894.4 ng/mL which was lower than the targeted 7500 
ng/mL. Symptoms observed during infusion and during the following 20 minutes observation 
time were salivation, emesis, unstable gait and repeated urination. The third infusion of 
compound 1 (29 mg/kg over a 10 minutes) resulted in a total plasma exposure of 7667.1 
ng/mL which was lower than the target concentration of 11500 ng/mL. Clinical symptoms 
during infusion were facial twitches, a mild tremor of the hind limbs and progressive ataxia. 
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Also, the dog appeared agitated. During sample collection for PK analysis, a tonic convulsion 
occurred. The tonic phase with signs of lost consciousness lasted approximately 15 seconds. 
Then, tonic-clonic limb movements started during which autonomic signs were present 
(salivation, urination, and defecation). Anticonvulsive treatment (midazolam, 0.2 mg/kg i.v.) 
was administered immediately after start of the tonic phase. Treatment was efficacious 
within seconds and total duration of the convulsion was below one minute. Symptoms after 
the convulsion were increased respiration rate, constricted pupils and emesis. Subcutaneous 
metoclopramide (1 mg/kg; Emeprid®, cewa) was administered and observation and EEG 
recording were continued for another seven hours during which no further clinical signs 
were noted. Clinical symptoms and correlating exposures are summarized in Table 10.  
 
Dose 
(mg/kg) 
Volume 
(mL) 
Infusion 
Rate 
(mL/h) 
Sample 
Time 
(min) 
Target 
Exposure 
(ng/mL) 
Plasma 
Concentration 
Male (ng/mL) 
Neurological (and 
autonomic) Symptoms 
12 7.1 42.4 12 2500 2362.3 None 
27 15.9 95.4 42 7500 5894.4 Urination, salivation, (emesis) 
29 17.15 102.9 62 11500 7667.1 
Tremor, facial twitches, 
limb twitches, tonic, 
then tonic- clonic 
convulsion 
n/a n/a n/a 1440 n/a 3009.3 None 
Table 10: Comparison between target exposure, measured exposure, and symptoms after compound 
1, male dog . Actual exposure was lower than calculated values. n/a= not applicable. 
 
Clinical Observations and Exposure in the Female Dog  
The dosing scheme for the female dog was adapted in order to reduce the incidence of 
emesis and the experimental time, thereby lowering the burden for the animal. A higher 
initial dose was chosen (30 mg/kg over 10 minutes) which resulted in a plasma concentration 
of 6966.21 ng/mL. This was lower than the target of 7500 ng/mL. Clinical symptoms 
observed during dose administration and observation time were salivation and emesis. The 
second dose (40 mg/kg over 10 minutes) induced neurological symptoms which were ataxia, 
a fine tremor of the head, facial jerks and hypersensitivity to touch. In addition, the female 
seemed to be agitated. A tonic, then tonic-clonic convulsion occurred eight minutes after 
start of the second infusion while the dog was still connected to the infusion line. 
Anticonvulsive treatment (midazolam, 0.2 mg/kg i.v.) was administered immediately, so 
total duration of the convulsion was less than two minutes. A subsequent dose of midazolam 
(0.1 mg/kg i.v.) was administered 90 seconds after the first dose, as it was unclear if the 
convulsion might reoccur. Blood for compound level determination was sampled within two 
minutes after the convulsion and analysis showed that the exposure at that time was 
13292.6 ng/mL. This was higher than the targeted 11500 ng/mL. The dog had tachycardia 
(160 bpm) and tachypnoe (40/min) directly after the convulsion, lasting for 10 minutes. 
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Other symptoms were poor coordination, constricted pupils and a fine head tremor. 1.5 
hours after the convulsion, no clinical symptoms were observed and the dog appeared 
normal. Observation was continued for the next five hours and no further treatment was 
necessary.  
 
Dose  
(mg/kg) 
Volume 
(mL) 
Infusion 
Rate 
(mL/h) 
Sample 
Time 
(min) 
Target 
Exposure 
(ng/mL) 
Plasma 
Concentration 
Female (ng/mL) 
Neurological (and 
autonomic) symptoms 
30 16.98 102 12 7500 6966.21 Salivation, emesis 
40 22.64 135 42 11500 13292.6 
Ataxia, tremor (head), 
facial jerks, increased 
sensitivity to touch, 
tonic, then tonic-clonic 
convulsion 
24h n/a n/a 1440 n/a 4511.26 none 
Table 11: Plasma exposure of compound 1 and clinical symptoms, female dog) n/a= not applicable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50: Total plasma exposure of compound 1. Doses were not the 
same for the two dogs (male: 12 mg/kg, 27 mg/kg and 29 mg/kg; 
female: 30 mg/kg and 40 mg/kg). The sample time point closest to 
convulsion is highlighted.  
 
 
Symptoms observed in the EEG study were compared with symptoms recorded in earlier 
toxicology studies in dogs. Studies with multiple dosing (5 days, 2 weeks, 13 weeks) were 
chosen. Table 12 lists the symptoms and indicates, whether they were also observed with 
intravenous dosing of compound 1 in the dog EEG study. 
 
 
Total Plasma Conc. Comp. 1
8 16 32 64 128 256 512 1024 2048
0
5000
10000
15000
2001 3002 Convulsion
Minutes
ng
/m
L
Results 
 
- 76 - 
 
Symptoms in dog 
toxicology studies 
Symptoms in 
EEG studies? Comment 
Activity Decreased Not clearly  
Activity Increased Yes Excitation/ agitation in both dogs in the EEG study 
Ataxia Yes Grade in toxicology studies: severe Grade in EEG study: mild - moderate 
Aggressive Behavior (Yes) Male dog in EEG study: growling after 3rd dose 
Convulsions Yes Convulsion type in toxicology study: tonic; in EEG study: tonic, evolving to tonic-clonic 
Dissociative behavior Yes EEG study: sniffing, trying to hide 
Emesis Yes / 
Head Movements Yes Female dog  
Jerks Yes / 
Salivation Yes / 
Sedation (Yes) 
After convulsion and midazolam treatment, dogs were calm 
for the rest of the afternoon, possible influence of 
midazolam 
Sensitivity to noise 
increased Yes 
Evident when dogs outside were barking; in addition: 
sensitivity to touch increased in the female dog 
Tremor (mild) Yes / 
Table 12: Symptoms with compound 1 in dog toxicology studies and EEG studies.  
 
Compound 1 has previously been tested in a NHP infusion study. Samples in this study were 
also collected after clinical convulsion. Figure 54 shows total plasma concentration of 
compound 1 in the NHP infusion study (145000 ng/mL, 135000 ng/mL and 146000 ng/mL) 
and in the dog EEG study (7667.1 ng/mL and 13292.6 ng/mL). In Figure 55, free plasma levels 
are shown. Due to the large difference in plasma protein binding (dog 0.3, NHP 0.012), free 
concentrations are similar in both species (NHPs 1740 ng/mL, 1620 ng/mL, 1752 ng/mL and 
dogs 2300.13 ng/mL, 3987.78 ng/mL). 
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Figure 51: Total plasma concentration of compound 1 at 
which convulsions occurred in dogs and NHPs. 
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Figure 52: Free plasma concentration of compound 1 at 
which convulsions occurred in dogs and NHPs. When 
total exposure is considered, the dog appears to be more 
sensitive. This is reverted when free compound levels are 
evaluated. 
 
EEG Results: Visual Analysis 
The EEG from the baseline period was normal in both dogs (example from the male dog, 
Figure 53). Incidence of artefacts was high during baseline. After start of the first dose, 
emesis was the first observed symptom and each event was accompanied by EEG artefacts 
as observed with apomorphine or quinpirole. After administration of the first intravenous 
dose, an increase in synchrony was observed in the EEG (Figure 54). This effect was even 
more expressed and accompanied by voltages of up to 200 µV during administration of the 
second dose (Figure 55). 
 
 
Figure 53: Baseline recording (10 seconds, male dog).  
 
 
Figure 54: EEG recorded at the end of the first infusion step of comp. 1 (8 seconds, female dog).  
Synchronized background activity with peak amplitudes of 100 µV. 
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Figure 55: EEG recorded during the second infusion of compound 1 (8 seconds, female dog).  
Synchronized background activity with peak amplitudes of 200 µV can be seen.  
 
In the male dog, transient paroxysmal activity started during administration of the third dose 
approximately two minutes before the onset of clinical convulsion. In the female, two 
minutes of paroxysmal activity preceded the convulsion, too. Due to signal loss and 
artefacts, it was not possible to identify this during live-view of the EEG but only 
retrospectively during offline-analysis.  
 
 
Figure 56: EEG, two minutes prior to the onset of convulsion (10 seconds, female dog).  Spikes can be 
identified, peak amplitude is 300 µV.  
 
The paroxysmal activity in both dogs was characterized by an increase in synchronization 
and mean amplitude of around 150 µV. Single spikes as well as spike trains with peak 
amplitudes of 300 µV could be identified. The first spikes were not correlated with muscle 
contractions; however, prior to the onset of convulsions, spikes were overlaid by high-
frequency muscle potentials that corresponded to visible jerks in the video. During 
generalized convulsion, peak amplitudes in the EEG were 1.3 mV which also indicates that 
most probably muscle activity overlies brain potentials.  
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Figure 57: EEG with muscle activity (10 seconds, female dog) Amplitudes above 1 mV indicate that 
muscle activity overlies the EEG (marked blue). 
 
In the male, the first paroxysmal spikes appeared about one minute prior to the onset of 
convulsion. Duration of the clinic convulsion was 30 seconds. Midazolam administration was 
effective to stop the convulsions (Figure 58).  
 
 
Figure 58: Convulsion timeline  (2 minutes, male dog). Starting one minute prior to clinic convulsion, 
spikes can be identified in the EEG. The high amplitude, corresponding to peak amplitudes during 
convulsions indicates that muscular twitches overly EEG activity. Midazolam administration stops the 
convulsion. Duration of convulsion according to EEG is 15-30 seconds.  
 
In the female, the signal was lost for a period of 3.8 seconds directly prior to the onset of 
convulsion for unclear reasons (Figure 59). The time of the seizure was approximately one 
minute but was difficult to determine, as artefacts, originating from handling of the dog, 
overly its end (Figure 60) and hinder EEG analysis for a time of 30 seconds. After an artefact-
free signal was restored, amplitude still averaged 70 µV, with peaks of 100 µV for another 20 
seconds. Then, very low amplitudes appeared, with mean amplitude of 20 µV. 
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Figure 59: EEG at onset of convulsion (30 seconds, female dog). EEG signal was lost for approx. 3.8 
seconds (marked). Single spikes can be identified prior to convulsion. Peak amplitude during 
convulsion was 2 mV, indicating muscle activity contributes to the signal.  
 
 
 
 
 
 
 
 
 
Figure 60: Artefacts in EEG at the end of convulsion.  High amplitude activity masks EEG; cause 
could be handling of the dog (60 seconds of EEG, female dog). 
 
After the generalized convulsion, amplitudes fell below baseline values in both dogs (Figure 
61). Amplitudes were below 20 µV, respectively for both dogs.  
 
 
Figure 61: EEG after tonic-clonic convulsion and midazolam treatment (10 seconds, male dog). The 
axis line is set to 20 µV. This is below baseline values that usually range between 30 µV and 70 µV.  
 
EEG results: Quantitative Analysis  
Median relative power was calculated from baseline and post-dosing relative frequencies. 
Plasma levels of both dogs were compared and time points at which exposure was 
comparable between both dogs were selected for FFT analysis. E1 for the male is 5894.4 
ng/mL and for the female it is 6966.21 ng/mL. E2 qEEG data were derived from the time 
when the male dog had a drug plasma exposure of 7667.1 ng/mL and the female had 
30sec 
Signal 
loss 
Spiking Clinic Convulsion 
Signal 
loss 
60sec 
Clinic Convulsion Artefacts 
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13292.6 ng/mL. In both dogs, an increase in the beta and theta frequency band was 
observed, along with a decrease in gamma. Raw data plots are provided in Appendix 4.  
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Figure 62: Median power of the male and female dog at baseline, at the time of E1 (5894.4 ng/mL 
and 6966.21 ng/mL) and E2 (7667.1 ng/mL and 13292.6ng/mL).  
 
 Compound 2 3.3.2
Clinical Observations and Exposure  
Oral administration of compound 2 at a dose of 14 mg/kg via gelatin capsule induced tremor 
of the head. In the male dog this symptom was observed starting 30 minutes after 
administration, in the female it was first noted after 50 minutes. The neck muscle 
contractions appeared to be transmitted to the rest of the body, as seen by swinging 
movements. The tremor was more pronounced and longer lasting in the male than in the 
female. This relates to plasma exposure, which reached higher levels in the male than in the 
female with a measured peak plasma concentration of 1357.85 ng/mL 50 minutes after 
compound administration. In the female, peak concentration was 950.71 ng/mL in the 50 
minutes sample. The plasma concentrations were therefore in the range and above the 
target plasma concentration of 1000 ng/mL. An additional plasma sample was collected from 
the female at 1.5 hours as the clinical expression of the symptom was higher at that time 
point than at the 50 minutes sample. In the male, the intensity had remained the same at 
that time point. The female was also able to control the head movements, for example when 
study personnel were present in the animal room. Duration of the tremor in the female dog 
was four hours. Additional symptoms in the male were salivation and stereotyped behavior 
such as biting the bars of his kennel. Both dogs appeared conscious during the whole 
observation time as they responded to external stimuli and were able to eat and drink. As 
the symptoms were still present in the male dog in the evening, EEG and video recording 
were continued during the night. Analysis of the video showed that the dog remained lying 
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and got up in the morning. Then, the head tremor had disappeared and the dog moved 
normally. Blood samples for evaluation of clinical pathology and hematology parameters 
were collected approximately 22 hours after dosing and were within normal limits for both 
dogs.  
In previous toxicology studies, the symptoms observed in dogs were similar to those 
detected in the EEG study. The sex difference had already been observed with oral dosing. In 
the NHP studies, head tremor was not observed (Table 14).  
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Figure 63: Total plasma concentration of compound 2 in 
the male (blue) and female (red) dog. 
 
 
Table 13: Total plasma concentrations of compound 2  The target exposure of 1000 ng/mL was 
reached in the male but not in the female dog.  
 
 
 
 
 
 
 
 
Dose Capsule 
(mg/ kg/day) 
Sample Time Point 
(hrs after dosing) 
Plasma Concentration 
(ng/mL) Male 
Plasma Concentration 
(ng/mL) Female 
14 
0.5 1206.91 493.90 
1.0 1357.85 950.71 
1.5 Not sampled 937.55 
7.5 779.37 357.,75 
24 151.60 70.62 
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Dose 
(mg/kg) Route Clinical signs NHP 
Cmax (day 1) 
(ng/mL) Clinical signs Dog 
Cmax (day 1) 
(ng/mL) 
10 p.o. 
stereotypical behavior 
(gnawing, circling), pupils 
dilated, eyelids 
partially/completely 
closed 
M: 643 
F: 653 
Head tremor, 
imbalance, 
salivation (female) 
pupils dilated 
M:1208 
F:1086 
30 p.o. 
All signs observed at 10 
mg/kg, in addition: 
excessive grooming, 
increased activity/hyper-
reactivity, hunched 
posture, aggressive 
behavior 
M: 1420 
F: 1510 
Head tremor, 
Ataxia (female), 
Salivation, pupils 
dilated 
M: 3758.2 
F:3103.2 
100 p.o. 
Signs observed at lower 
doses, in addition: 
decreased activity, 
ataxia, tremors, 
stereotypy (forepaw 
padding), inappetence 
M: 4260 
F: 4810 Not tested Not tested 
Table 14: Clinical symptoms and pharmacokinetics observed after 10 mg/kg, 30 mg/kg and 100 
mg/kg oral doses of compound 2 in NHPs, compared to the dog. 
 
Body temperature of the male increased to over 39.5°C in the late afternoon (6 hours after 
dosing) and is presented in (Figure 64). Maximal temperature was 39.7°C. A consequent fall 
to physiological values happened during the night. The time frame from 17.30-18.15 was not 
measured, as recording was interrupted then to secure the data collected during the day.  
 
 
Figure 64: Body temperature changes with compound 2  (measured by implant, male dog). Shown is 
the time from the start of the experiment till the next morning (17.30-18.15 not measured: 
interruption of recording for data saving). 
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The female did not react with changes in body temperature as shown in Figure 65. Values 
were within physiological limits during the experiment and video showed that behavior of 
this dog was normal during the night.  
 
 
Figure 65: Body temperature changes with compound 2  (measured by implant, female dog). Shown 
is the time from the start of the experiment till the evening. 
 
EEG Results: Visual Analysis 
Normal EEG activity was observed in both dogs during the baseline period (example from the 
female dog, Figure 66). Abnormal EEG activity was present in both dogs at the onset of 
clinical symptoms. For the male, this was about 30 minutes after oral compound 
administration. The female had a later onset of paroxysmal EEG activity, around 50 minutes 
after dosing. In both dogs, the first change in EEG was an increase in amplitude to peak 
values of 170 µV, coupled with a high degree of synchronization (Figure 67). 
 
 
Figure 66: Baseline recording of the female dog (6 seconds). 
 
 
Figure 67: EEG after compound 2 administration (10 seconds, female dog). Peak amplitudes are 
higher than the average in baseline recordings, with peaks of 170 µV. 
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EEG changes in the male consisted of the appearance of rhythmic, synchronized sharp 
transients resembling bilateral triphasic waves, one hour after compound administration. A 
low amplitude wave builds up into a high-amplitude upward spike that is then followed by a 
symmetrical downward deflection (Figure 68). Peak amplitude of these waves was 130 µV. 
Duration of these episodes was up to two minutes and they were interrupted by baseline-
like EEG rhythms. In the female dog, fast activity with peak amplitudes over 200 µV was 
present 1.5 hours after compound administration (Figure 69). These intervals lasted up to 
two minutes each and were also interrupted by activity resembling baseline activity.  
 
 
Figure 68: Paroxysmal activity, appearing in intervals of up to two minutes starting one hour after 
administration of compound 2 (10 seconds, male dog); Peak amplitude 130 µV.  
 
 
Figure 69: EEG activity 1.5 hours after compound 2 (10 seconds, female dog); amplitude >200 µV.  
 
Seven hours after compound administration, an oscillating, symmetrical pattern was 
observed in the male dog. Peak amplitudes were above 200 µV: periodiogram and FFT 
analysis showed that these slow oscillations were predominantly in the range of 4-8 Hz 
which is in the theta band (Figure 70).  
 
 
 
 
 
 
 
Figure 70: Sinusoidal oscillations five hours after compound 2 (10 seconds, male dog)  Amplitudes are 
above 200 µV and frequency is 10 Hz. The FFT power bands confirm that the EEG has a dominant 
frequency in the theta band.  
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Another, faster variant of symmetrical EEG paroxysms after administration of compound 2 in 
the male dog were high amplitude, fast, oscillating deflections. They also appeared in 
intervals eight hours after compound administration. Peak amplitude was 200 µV. This was 
observed at several intervals during the first eight hours of the night-time recording.  
 
 
Figure 71: Paroxysmal activity after compound 2  (10 seconds, male dog); peak amplitude 200 µV. 
 
In the female dog, the EEG had a normal appearance five hours after compound 2 had been 
administered. Latency to sleep for dog 1002 was five hours, but sleep was frequently 
interrupted during the first half of the night.  
In the male, EEG symptoms lasted almost the whole night. Appearance of slow background 
activity superimposed with spindles around 14 hours after compound administration 
indicated progression to sleep (Figure 72). The first episode of sleep lasted less than two 
minutes, but sleep reoccurred at shorter intervals and in increasing lengths during the night-
time. They were interrupted by episodes of normal waking background activity and intervals 
with a markedly increased amplitude and high synchrony (Figure 74). 
 
 
 
Figure 72 (above) and Figure 73: Examples of EEG activity during the night-time recording after 
compound 2 (10 seconds, male dog).  These episodes first appeared at 2 a.m. and the first ones 
lasted around two minutes. Consequent similar episodes were recorded with rising lengths and 
increased frequency during the rest of the night.  
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Figure 74: Highly synchronized EEG after compound 2 (10 seconds, male dog). This EEG was recorded 
during the night. Peak amplitudes are above 100 µV.  
 
 
EEG results: Quantitative Analysis  
Time points for calculation of FFT relative power were chosen based on exposure: E1 is the 
peak exposure of both dogs respectively (male: 1357.85 ng/mL and female: 950.71 ng/mL). 
E2 is the evening time point (7.5 hours after compound administration: male 779.37 ng/mL; 
female 357.75 ng/mL). Quantitative analysis of EEG showed no remarkable changes for the 
female when baseline values were compared to post treatment values. In the male dog, a 
marked increase in relative theta power was observed during the duration of the recording. 
The difference between the dogs also correlates to clinical symptoms.  
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Figure 75: Median power changes with compound 2. An increase in theta power is the most 
prominent finding in the male dog (blue). In the female dog (red), no obvious changes were induced 
in the quantitative EEG power by compound 2.  
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 Compound 3 3.3.3
Clinical Observations and Exposure in the First Experiment  
Compound 3 was administered by continuous intravenous infusion to one male and one 
female dog on the same day. First, the experiment with the male dog was conducted. The 
first symptoms, appearing three minutes after the start of the infusion (8.0 mg/kg over 10 
minutes), were licking, smacking and a careful gait. Then, reddening of the oral mucosal 
membranes and a rise in respiration and heart rate (160 bpm) were noted. At the end of the 
first infusion, the male was resting in a lying position. Plasma level of compound 3 after 
termination of the first infusion was 1116.54 ng/mL in this dog which was above the 
targeted exposure of 750 ng/mL.  
The female dog kept standing during the first infusion (8.0 mg/kg over 10 minutes), but her 
gait seemed unstable. The increase in heart rate was minor compared to the male dog (120 
bpm). The plasma exposure of compound 3 in the female measured 12 minutes after the 
start of the infusion was 710.84 ng/mL and was below the targeted 750 mg/mL.  
In both dogs, eye squinting was observed, while all ocular reflexes remained normal. Red 
oral mucosal membranes and an increase in the pulsation intensity of the femoral vessels 
were observed in both dogs during the first infusion. During the observation time between 
infusions, reduced activity was noticed as well as tense facial muscles and erected ears. 
Observation time was increased from 20 to 30 minutes for the male dog to ensure recovery 
from cardiovascular symptoms. Prior to the start of the second infusion (6.0 mg/kg over 10 
minutes), the heart rate had normalized and the dog had resumed a standing position.  
Symptoms in both dogs during the second infusion were lip licking, fine tremors of the hind 
legs, tachypnoe and tachycardia. During infusion, the male dog rested in sternal recumbence 
with hunched posture and retracted tail while the female remained in a standing position.  
After the stop of the infusion, the male dog was lying and appeared to be sedated. The 
nictitating membrane was prolapsed and the pupils reacted slightly delayed. Cardiovascular 
parameters normalized after 15 minutes. The dog was located on a mattress and appeared 
to be sedated for a period of three more hours. In the female dog, sedation was also present 
for two more hours but there were no ocular findings. The second infusion resulted in 
plasma concentrations of 1527.87 ng/mL in the male and 1295.48 ng/mL in the female dog 
respectively. Both values were above the targeted 1000 ng/mL. The third dose was not 
administered due to the unexpected cardiovascular symptoms.  
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Dog Dose (mg/kg) 
Volume 
(mL) 
Infusion 
Rate 
(mL/h) 
Sample 
Time 
(min) 
Target 
Exposure 
(ng/mL) 
Measured 
Exposure Symptoms 
M 
8 14.54 87.27 12 750 1116.54 
licking, smacking, 
careful gait, red oral 
mucosal membranes, 
tachypnoe, tachycardia, 
eye squinting, tense 
facial muscles, erected 
ears 
6 10.9 65.45 52 1000 1527.87 
lip licking, fine tremors 
hind legs, tachypnoe 
tachycardia, resting, 
hunched posture 
n/a n/a n/a 60 n/a 806.87 sedation 
n/a n/a n/a 1440 n/a 18.19 none 
F 
8.0 9.69 56.0 12 750 710.84 
unstable gait, 
eye squinting, 
tachypnoe tachycardia, 
tense facial muscles, 
erected ears 
6.0 7.27 43.63 42 1000 1295.48 lip licking, fine tremors, tachypnoe tachycardia 
n/a n/a n/a 60 n/a 576.53 sedation 
n/a n/a n/a 1440 n/a 5.76 none 
Table 15: Total plasma concentration of compound 3 and clinical symptoms of the male (M) and 
female (F) dog in the first experiment with compound 3.  
 
 
 
 
 
 
 
 
 
Figure 76: Total Plasma Exposure of compound 3 (male: blue, 
female: red) after the first experiment. 
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Administration of compound 3 resulted in a drop in body temperature in both dogs. 
Minimum temperature of the male was 35.87°C six hours after the first infusion; for the 
female dog minimum was 36.42°C approximately three hours after start of the first infusion. 
EEG and temperature recording were not continued overnight, but the temperature for both 
dogs was within physiological limits on the next day.  
 
 
Figure 77: Body temperature after compound 3  (male dog, measured by implant). The left arrow 
marks the approximate start of the 1st infusion; the right arrow marks the start of the 2nd infusion.  
 
Figure 78: Body temperature after compound 3 (female dog, measured by implant). The left arrow 
marks the approximate start of the 1st infusion; the right arrow marks the start of the 2nd infusion.  
Clinical Observations and Exposure in the Second Experiment  
Due to unexpected cardiovascular symptoms, it was decided to repeat the experiment with 
compound 3 with one dog and include ECG recording. As the male dog appeared to be more 
sensitive and due to the possibility to collect CSF via port, it was decided to use this dog after 
a wash out time (12 weeks). The ECG was obtained via external telemetry (DSITM JET) and the 
dog was habituated to wearing the jacket prior to the experiment. Baseline ECG was normal, 
with a mean heart rate of 125 bpm (calculated over 20 minutes of baseline recording, SD +/-
21.13). 
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Figure 79: ECG, recorded with external telemetry, during baseline recording (7 seconds, HR 77 bpm, 
sinusarrhthmia). 
 
During the infusion (16.5 mg/kg over 10 minutes), the first signs were stiffness of the limb 
muscles and unstable gait. Hind legs showed muscle twitches and their severity increased 
throughout the infusion. A tonic contraction of the legs, paired with ophistotonus was 
observed towards the end of the infusion. Then, tonic-clonic movements, predominantly of 
the hind legs, appeared. Midazolam was administered intravenously within 20 seconds and 
stopped the involuntary muscle movements. When lifted up for blood sampling, the dog 
behaved aggressively and did not tolerate handling. This lasted for 20 minutes, after which 
he was calm again. Mean heart rate over 20 minutes from the start of infusion was 199 bpm 
(SD 10.73). This increase in heart rate was accompanied by vanishing of the sinusoidal 
arrhythmia (Figure 80). The ECG at the time point of convulsion could not be interpreted due 
to movement artefacts. One hour to one hour and twenty minutes after the infusion, mean 
heart rate was 155.9 bpm (SD 6.408). QTcv interval was not prolonged by administration of 
compound 3. Mean QTcv time in baseline was 237 msec (SD 8.952), within the twenty 
minutes after the start of the infusion the mean QTcv was 226.6 msec (SD 7.235) and one 
hour after start of the infusion it was 241.7msec (SD 5.669). All these values are within the 
reference ranges published for Marshall Beagle dogs (Hanton & Rabemampianina, 2006).   
 
 
Figure 80: Increased heart rate and vanishing of sinusarrythmia 6 minutes 
after start of the first infusion. 
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Figure 81: ECG Artefacts at the time of clinical convulsion with compound 3. 
 
 
 
Figure 82: Heart rate change during 20 minutes of baseline (blue), at the 
beginning of the first infusion (red) and one hour after dosing start (black). 
 
 
 
Figure 83: QTcv from the male dog in paseline, during 20 minutes starting 
with the infusion of compound 3 and one hour after start of the infusion 
(Median +/-SD). 
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Two and a half hours after the convulsion, a CSF sample was collected. The dog appeared to 
be sedated for a total of five hours. Exposure 20 minutes after the convulsion was 1600.7 
ng/mL. He ate all food offered five and a half hours after compound administration. The 
drop in body temperature was observed again. Minimum temperature was 36.15°C, 7 hours 
after start of the infusion. 
 
 
Figure 84: Temperature of the male dog after administration of compound 3  (measured by implant).  
 
Clinical symptoms were compared to those observed in earlier NHP toxicology studies with a 
duration of more than one day (five days, two weeks). Route of administration in these 
studies was oral gavage. In NHPs, salivation and emesis were observed which were not seen 
in the dog. Also ocular signs (dilated pupils, bilateral nystagmus) were not present in dogs. 
As opposed to NHPs, dogs had an increased heart and respiration rate. Reddening of the 
mucosal membranes and increased pulsation of femoral vessels could indicate a rise in blood 
pressure, although this was not monitored specifically.  
 
Symptoms in NHP 
toxicology studies  
Symptoms 
present in EEG 
dog studies? 
Comment 
Activity Decreased Yes / 
Convulsions Yes / 
Dilated Pupils No / 
Emesis No / 
Jerks Yes 
Severity NHP study: mild 
Severity in dog study: mild, progressing to moderate and 
then convulsions 
Nystagmus No Was considered a premonitory sign for convulsions in NHP  
Salivation No Emesis was also present in NHP 
Tremor (fine) No “Shivering” in NHP  Decrease in body temperature in dog EEG study 
Table 16: Symptoms in NHP toxicology studies and EEG dog studies. 
 
Compound 3 had also been tested in a NHP primate study with intravenous infusions. 
Differences to the infusion scheme as opposed to the dog EEG study were that first a higher 
bolus was administered and then, infusion rate was held constant until convulsions 
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occurred. Free plasma concentration of compound 3 in this study is shown in Figure 85. Time 
points at which convulsions occurred are marked (*). In three out of six NHPs, convulsions 
were seen at administration of the initial dose. In one animal, no convulsion was seen 
despite very high plasma exposure. In two NHPs, time point of convulsions was during the 
infusion. Plasma exposure at which the dog in the EEG study had a convulsion is also 
indicated. As the sample was collected approximately 20 minutes after the symptom, the 
actual drug plasma concentration was higher. Still, the exposure in the dog is within the 
range of that in the NHPs.  
 
Free Plasma Concentration NHP vs. Dog
0 50 100 150
64
128
256
512
1024
2048
105 M
106 M
107 M
Dog 3001
101 M
102 M
103 F
104F
time (hrs)
 
Figure 85: Exposure (Cfree) NHP and dog. Time points marked with * indicate 
convulsions. Doses for NHP 101, 102 and 103 (not naïve) were determined 
by modeling to achieve a target of 2000 ng/mL total. Target exposure for 
NHP 105, 106 and 107 (naïve) was 1500 ng/mL total.  
 
EEG Results: Visual Analysis (First Experiment) 
EEG recordings of both dogs were normal in the baseline period (example female, Figure 
86). During the first infusion of compound 3, a slowing of background activity was observed 
in both dogs. This effect was not persistent and normal background activity appeared 
regularly. Episodes of slow EEG activity, interrupted by normal background patterns, were 
observed during the both infusion steps and in the observation period.  
 
 
Figure 86: Baseline recording (example female dog). 
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Figure 87: Slowing of background activity 8 minutes after the start of the first infusion of compound 
3  (10 seconds, female dog). 
 
 
Figure 88: Example of the slowing of background activity during the 20 minutes observation period  
(8 seconds, female dog). The axis line is set to 50 µV, indicating the peak frequencies at that time.  
 
 
Figure 89: Slowing of background activity after administration of the 2nd dose of compound 3 (10 
seconds, female dog). 
 
After the second dose, spike-like patterns appeared in the EEGs of both dogs. In the female, 
amplitudes between 50 µV and 70 µV predominated. In two episodes 10 minutes and 15 
minutes after termination of the infusion, amplitude reached 100 µV. In the female, the last 
such event in the EEG was 20 minutes after stop of the infusion. In the male dog, amplitudes 
consistently were higher than 100 µV. These episodes had a low incidence and disappeared 
within 10 minutes after completion of the second infusion. Video recordings showed no 
definite cause of artefact at that time but still, it cannot be ruled out that e.g. swallowing 
was the reason for this EEG sign.  
 
 
Figure 90: Spike-like patterns (marked blue) five minutes after completion of the 2nd infusion (5 
seconds, female dog). The amplitude is low (60 µV). 
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Figure 91: Spikes of above 100 µV amplitudes (marked blue) approximately five minutes after 
administration of the 2nd infusion of compound 3  (10 seconds, male dog). 
 
EEG Results: Visual Analysis (Second Experiment) 
Baseline EEG of the male was normal. After the start of the infusion, no distinct EEG changes 
were noticed. Artefact rate was higher than in other recordings, which might be due to the 
jacket touching the subcutaneous transmitter. Isolated spikes-like EEG signs and episodes 
with a higher degree of synchronization could be identified, but it was not clear if they were 
artefacts or real symptoms. Before and during clinic convulsion no paroxysmal activity was 
present in the EEG. High frequencies with peak amplitudes of 200 µV predominantly in a 
downward deflection appeared after start of clinical symptoms. Midazolam had already 
been administered at that time.  
Figure 92: Normal EEG background activity, at the time point of clinic convulsion (10 seconds, male 
dog). 
 
 
 
Figure 93: High-frequency synchronized EEG activity, one minute after midazolam treatment  (10 
seconds male dog). 
 
EEG Results: Quantitative Analysis  
The median relative power was calculated and for both dogs and it was found that increases 
in the delta and theta frequencies were induced by administration of compound 3. The other 
frequency bands were not affected in the same direction or degree in the two dogs. The 
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increase in the delta band was also observed in the second experiment, whereas the change 
in the theta band was not. All other medians values were not influenced by treatment in the 
second experiment.  
 
 
 
 
 
 
 
 
 
 
 
Figure 94: Changes of median relative power with compound 3. 
 
Figure 95: Changes of median relative power with compound 3 in the male dog. 
 
4 Biomarker Analysis  
Raw data from the biocrates analysis (Biocrates Absolute IDQ® p180 Kit (Biocrates Life 
Sciences, Insbruck, Austria)) were summarized in an Excel Sheet by the department of 
DMPK, AbbVie GmbH & Co. KG, Ludwigshafen, and submitted to the Data and Statistical 
Science (DSS) department at AbbVie GmbH Co. KG, Ludwigshafen. For each treatment, the 
set of metabolites with q < 0.05 at all time-points is presented in Figures 96 to 98. From a 
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total of 178 metabolites and 43 pre-calculated ratios of interest that were detected with the 
kit, a total of 0, 14 and 0 metabolites were significantly changed at all time points for 
compounds 1, 2 and 3 respectively. Most significant changes at a q < 0.05 were detected 
with compound 2.  
The Venn diagram (Figure 99) shows the overlap between treatments for all metabolites 
that changed with an FDR of q < 0.05 at any of the time points. One outcome was changed in 
all three experiments at q < 0.05, and this was the SDMA/ Arg ratio (Figure 99).  
At a less stringent threshold of p < 0.05, 36 overlapping metabolites with an altered 
expression after treatment were detected (Figure 100). The 36 common metabolites that 
changed after all 3 treatments are listed in Table 17.  
 
 
 
Figure 96: Volcano plots showing the false discovery rate (y-axis) vs. the effect size (log base-2 of the 
FC) for each of the three time points after treatment with compound 1. Blue dots represent results 
with q < 0.05. The table shows the number of significantly changed metabolites at each time point, as 
well as the number of unique metabolites that were significantly changed at any time point. 
 
 
 
 
 
Time (min) # sig (q<0.05) 
12 0 
42 11 
1440 0 
All times 0 
Compound 1, 12min    Compound 1, 42min 
Compound 1, 24hrs  
  Compound 1, 
42min 
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Figure 97: Volcano plots showing the false discovery rate (y-axis) vs the effect size (log base-2 of the 
FC) for each of the three time points after treatment with compound 2. Blue dots represent results 
with q < 0.05. The table shows the number of significantly changed metabolites at each time point, as 
well as the number of unique metabolites that were significantly changed at any time point. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 98: Volcano plots showing the false discovery rate (y-axis) vs the effect size (log base-2 of the 
FC) for each of the three time points after treatment with compound 3. Blue dots represent results 
with q < 0.05. The table shows the number of significantly changed metabolites at each time point, as 
well as the number of unique metabolites that were significantly changed at any time point. 
 
Time (min) # sig (q<0.05) 
30 25 
50 48 
1440 21 
All times  14 
Time (min) # sig (q<0.05) 
12 31 
42 / 52 0 
1440 0 
All times 0 
Compound 2, 30min     Compound 2, 50min 
Compound 2, 24hrs
 Compound 1, 42min 
Compound 3, 12min     Compound 3, 42 min (f), 52 min (m) 
Compound 3, 24hrs 
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Figure 99: Number of overlapping metabolite 
changes (q < 0.05) at any time point 
Figure 100: Number of overlapping metabolite 
changes (p < 0.05) at any time point 
 
 
Metabolite 
Class/ Ratio Metabolite 
Time point 1 
C1 – C2 – C3 
Time point 2 
C1 – C2 – C3 
24hrs 
C1 – C2 – C3 
Acylcarnithines 
(n=6) 
C14.1.OH 
Hydroxytetradecenoylcarnitine 
↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ -↑ - ↑ 
C14.2 
Tetradecadienylcarnitine 
↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑- ↑ - ↑ 
C16 
Hexadecanoylcarnitine 
↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
C18 
Octadecanoylcarnitine 
↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
C18.1 
Octadecenoylcarnitine 
↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
C5.DC.(C6.OH) 
Glutarylcarnitine 
(Hydroxyhexanoylcarnitine) 
↑- ↑ - ↑ ↑ - ↑- ↑ ↑ - ↑ - ↑ 
Amino Acids 
Methionine (Met) ↓ - ↓ - ↓ ↓ - ↓ - ↓ ↓ - ↓- ↓ 
Proline (Pro) ↓ - ↓ - ↓  ↓ - ↓ - ↓ ↓ - ↑ - ↓ 
Nitro-Tyrosine ↓ - ↓ - ↓ ↓ - ↓ - ↓ ↓ - ↓ - ↓ 
Glycerophos-
pholipids 
lysoPC.a.C16.1 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
lysoPC.a.C26.0 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
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 lysoPC.a.C26.1 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.aa.C28.1 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.aa.C30.0 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.aa.C34.1 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.aa.C38.1 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.aa.C40.1 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.aa.C40.2 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.aa.C40.4 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.aa.C42.5 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.ae.C34.2 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.ae.C34.3 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
PC.ae.C42.2 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↓ - ↑ - ↑  
PC.ae.C44.3 ↓ - ↑ - ↑ ↓ - ↑ - ↑ ↓ - ↑ - ↑  
Sphingolipids 
SM..OH..C22.2 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
SM.C20.2 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑- ↑  
SM.C24.0 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
SM.C24.1 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
SM.C26.1 ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑  
Amino Acids 
and biogenic 
Amines (ratios) 
ADMA...Arg  ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
MUFA..PC ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
SDMA...Arg ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↓ - ↑ 
Total.DMA...Arg ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
Tyr...Phe ↓ - ↓ - ↓ ↓ - ↓ - ↓  ↓ - ↓ - ↓ 
Sphingolipids 
Total non-OH 
SM 
Total.SM ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
Total.SM.non.OH ↑ - ↑ - ↑ ↑ - ↑ - ↑ ↑ - ↑ - ↑ 
Table 17: Results of the metabolomic analysis: Altered metabolites with compound 1, 2 and 3, based 
on a unadjusted p-value < 0.05. Decreases (↓) or increases (↑) in metabolite level between baseline 
and the two post treatment time points are indicated; = means that metabolite level was similar to 
baseline (similar defined as a change less than). Red are non-significant changes, green are significant 
changes (p<0.05). “C x:y”: C=Carbon atome, x=carbon number, y=number of double bonds; SM= 
Sphingomyelin, PC= Phosphatidylcholines; ADMA= Asymmetric dimethylarginine; SDMA= Symmetric 
dimethylarginine; Met= Methionine; Arg= Arginine; DMA=Dimethylarginine; aa= both moieties at the 
sn-1 and sn-2 position are fatty acids and bound to the glycerol backbone via ester bonds; ae= one of 
the moieties, either in the sn-1 or at sn-2 position is a fatty alcohol and bound via an ether bond 8: 
lyso-PC.a= Lyso – Phosphatidyl-cholines – acyl; PC.aa=Phosphatidyl-choline acyl-alkyl; 
PC.ae=Phosphatidyl-choline diacyl 2. 
                                                     
2 (http://www.biocrates.com/images/List-of-Isobaric-and-Isomeric-Lipid-Species.pdf, accessed 07.Aug 2017) 
and (http://www.biocrates.com/products/research-products/absoluteidq-p180-kit, accessed 07.Aug 2017)  
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Figure 101: Example plot of the Biocrates results for the individual compounds.  Results for the 
other overlapping metabolites are provided in the supplementary data. An increase in the level of 
phosphatidylcholine from baseline to time point 1, 2 and 3 (=24hrs) is evident for all treatments. 
 
The 34 metabolites that were altered in all the three different treatments belonged to the 
class of acylcarnithines (n=6), glycerophospholipids (n=15); sphingolipids (n=5) and amino 
acids (n=3, methionine, nitro-tyrosine, proline). Also, the total DMA / arginine ratio, total 
sphingomyelin, total not-hydroxylated sphingomyelin and the tyrosine / phenylalanine ratio 
changed significantly on treatment.  
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VI.Discussion 
The aim of this thesis was to evaluate use of EEG data for improved assessment of 
neurological symptoms, especially convulsion liability. Four reference and three in-house 
compounds with different modes of action were tested for this purpose. Several methods 
exist for evaluation of seizure liability, but the EEG has been identified as the most sensitive 
one (Easter et al., 2009). Additional video recording supported correlation of symptoms to 
EEG, identification of artefacts and increased observation time. In addition, these 
experiments should generate new data to allow direct comparison of dog and NHP regarding 
their species specific sensitivity for neurological symptoms.  
 
1 Question 1  
By using the EEG, can premonitory signs of convulsions be identified that facilitate 
prophylactic anticonvulsive treatment and avoid the occurrence of convulsions in 
toxicology studies, thereby reducing the burden of animals? 
The possibility to administer anticonvulsive treatment upon the first detection of paroxysmal 
EEG activity would potentially reduce the burden of seizure liability testing by preventing 
progression of a seizure into a convulsion. Authier et al. (2009) reported a possible 
treatment window of four minutes in NHPs in a study using PTZ as convulsive agent whereas 
Dürmüller et al. (2007) described a latency time of 60 seconds prior to the onset of PTZ – 
induced convulsions in dogs. These differences probably resulted from route and mode of 
application (Authier et al., 2009). Whereas in the NHP study, PTZ was administered 
subcutaneously at fixed doses in 15-minutes intervals (Authier et al., 2009), the dogs 
received a continuous intravenous infusion (Dürmüller et al., 2007). With subcutaneous 
dosing the latency between paroxysmal activity and convulsions was prolonged by a factor 4 
(Authier et al., 2009). Both authors considered these periods sufficient to allow intravenous 
administration of anticonvulsive drugs (Dürmüller et al., 2007; Authier et al., 2009).  
In our experiments, compound 1 and compound 3 induced convulsions. With compound 1, 
paroxysmal activity was present in the EEG of two dogs prior to onset of clinical convulsion 
as reported for PTZ induced convulsions (Dürmüller et al., 2007; Authier et al., 2014b). 
Compound 3 induced clinical convulsions in the second experiment in one dog without clear 
paroxysmal EEG activity prior to and during clinical convulsion. Spikes in the EEG could not 
definitely be related to either real EEG symptoms or artefacts. The EEG at onset and during 
most of the clinical convulsion was normal. An abnormal EEG was seen later, and lasted 
longer than the clinical symptom. DSITM’s technical support was contacted to identify a 
potential error in the synchronization between video and EEG. As all settings were correct, it 
was concluded that this was a real phenomenon. Fonck et al. (2015) point out that there are 
behaviors with a clinical presentation that can be mistaken for a seizure and recommend 
EEG for confirmation of the electroencephalographic origin (Fonck et al., 2015). The dog 
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responded to midazolam treatment and autonomic signs were also present during muscle 
contractions. From a clinical point of view, the diagnosis of a convulsion was therefore clear.  
The time needed for the treatment of a convulsion was below one minute, so in theory, EEG-
based prophylactic treatment should be possible. After reviewing the literature it seems that 
this has not been done successfully in preclinical research so far.It has to be added that 
certain preparations need to take place prior to start of dosing: inserting an intravenous 
port, placing the anticonvulsant drug ready-to inject at the dose appropriate for the animal 
in a syringe within easy reach and preparing a second syringe with a flushing fluid.  
One reason for the difficulty to detect epileptiform activity prior to the onset of convulsions 
is the quality of the raw, unprocessed, EEG signal, at least in the program used here (DSITM 
Ponemah, Version 5.2). Although providing a live-view on the EEG, it did not facilitate 
meaningful interpretation of the unfiltered signal during the EEG studies. The EEG signal 
passes over the screen at high speed, so differentiation of real paroxysmal events from 
artefacts was not possible. For retrospective analysis, the first step was application of a high 
pass filter to stabilize the baseline. Also, unclear events were reviewed several times in 
relation with the video recording. A definite differentiation of true paroxysmal EEG activity 
from artefacts therefore only was possible after careful retrospective assessment, using 
filters and requiring more time than available in real-time analysis.  
The absence of definite EEG symptoms before and during clinical convulsion induced by 
compound 3 is surprising. In an earlier rat EEG study, compound 3 induced spike-wave 
discharges (SWD) in two out of six rats from one hour post dose (60 mg/kg oral dose, 1170 
ng/mL) without visible convulsions. These SWDs are shown in Figure 102. At 120 mg/kg, 
convulsions were observed in three out of six rats. In the EEG, two of the remaining three 
rats had SWD activity without behavioral changes. One rat did not demonstrate SWDs. 
Therefore, clinical symptoms without paroxysmal activity were not seen in the rat as in the 
dog EEG study. Paroxysmal events of increased amplitude and synchrony were seen in EEGs 
of both dogs after the second infusion during the first experiment without convulsion.  
 
Figure 102: Rat EEG after 60 mg/kg oral dose of compound 3 Spike 
and wave discharges were not accompanied by clinical signs of 
convulsions. 
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In NHPs, nystagmus was seen prior to occurrence of convulsions. In dogs, this was not 
observed with any of the two compounds that induced convulsions in the EEG experiments. 
Also, in the NHP infusion study with compound 1, no prodromal nystagmus was described. 
The incidence of nystagmus in toxicology studies was found to be higher in NHPs than in 
dogs (Backes, 2016). Backes (2016) suspected that differences in handling practice can 
explain this as dogs can usually move freely in their kennels whereas NHPs are commonly 
restrained in a chair and therefore closer to human observers (Backes, 2016). In humans, 
Husain et al. (2003) observed that abnormal eye movements are a frequent sign in patients 
with non-convulsive status epilepticus and therefore, the nystagmus observed after 
administration of compound 3 could indicate the presence of a seizure prior to its 
generalization in the NHPs. In the rat the presence of non-convulsive seizures was confirmed 
with EEG, but assessment of nystagmus in rodents is difficult and presence of this symptom 
in rats could not be confirmed.  
For dogs with idiopathic epilepsy, Berendt & Gram (1999) investigated clinical signs of non-
convulsive seizures. They do not mention nystagmus and only note pupil dilation as ocular 
symptom (Berendt & Gram, 1999). However, their results are based largely upon owner 
descriptions and it can be suspected that an untrained person might miss this symptom. To 
sum up, nystagmus seems to be a potential sign of non-convulsive seizures, but its 
occurrence seems to depend on compound and species.  
Instead of nystagmus, compound 3 induced clinical signs in dogs not described in rat and 
NHP. These symptoms were tachycardia and red mucous membranes. Reflex tachycardia can 
occur after infusion of high volumes (“Bainbridge effect”, see (Vatner et al., 1975)) but as 
infusion rate and volume were appropriate for dogs and this was not observed with infusion 
of compound 1, a compound-specific effect was suspected.  
In the development of compound 3, cardiovascular safety was explored in the in vitro hERG 
(human ether-a-go-go related gene) and in the anesthetized dog model. hERG is a sodium 
channel on cardiomyocytes, responsible for the repolarization. The assay detects QT 
prolongation which is a measure of pro-arrhythmic drug effects. Results of the hERG assay 
corresponded well to in vivo testing in the anesthetized dog. There, the QT interval was only 
prolonged at a very high exposure level (2870 ng/mL). QT interval in our study was also not 
affected by administration of compound 3 at exposure levels up to 1600.7 ng/mL. A slight 
increase in QT length one hour after administration of the first dose could be related to the 
decrease in body temperature(Van der Linde et al., 2008; El Amrani et al., 2016).  
In the anesthetized dog, a drop in mean arterial pressure and dP/dt was noted at 810 ng/mL. 
This exposure level is below the one achieved in the EEG study, and effects on the 
cardiovascular system were seen. Clinically, a rise in blood pressure was suspected but could 
not be objectively assessed as no blood pressure monitor was available. The role of central 
serotonin and related molecules on the cardiovascular system has been reviewed by Kuhn et 
al. (1980). Blood pressure effects seem to be species dependent and in dogs, a depressant 
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action has mostly been reported, especially in anesthetized animals (Kuhn et al., 1980). One 
reference also reports blood pressure increases with 5-HTP in conscious dogs (Dunkley et al., 
1972). It is known that drugs can have opposite effects in anesthetized and conscious dogs, 
due to the absence of reflex responses in the anesthetized state (Sarazan et al., 2011).  
Decreased contractility, that has been detected in the safety pharmacology assessment of 
compound 3, leads to a reduction in heart performance and thereby to a reduced ability to 
adapt to stress (Sarazan et al., 2012). A drop in mean arterial pressure (MAP) could be 
accompanied by a compensatory increase in heart rate which corresponds to the 
tachycardia observed in the EEG study. Therefore, both, a rise or a drop in blood pressure 
can explain the symptoms observed and objective pressure measurements would be needed 
for a final conclusion. 
A cardiovascular symptom that has a clinical appearance that can be mistaken for seizures is 
syncope. EEG effects of syncope in humans have been described by Brenner (1997). 
However, they differ from the appearance of the EEG recorded during administration of 
compound 3: in syncope, an initial slowing of background activity is followed first by high-
amplitude delta activity, progressing into subsequent flattening (Brenner, 1997). In our 
study, the EEG background activity slowed down during the first experiment with compound 
3 in both dogs. This correlated to the clinic, as both dogs seemed to be slightly sedated. In 
the second experiment, no such EEG effect was observed. The ECG recorded via external 
telemetry simultaneous to the convulsion could not be interpreted, due to the high amount 
of movement artefacts. In conclusion, the possibility that the convulsions in NHP and dog 
were due to cardiovascular symptoms cannot be excluded. 
It needs to be added that the metabolism of compound 3 varies between NHP and dog: in 
NHP, main metabolites are carbamoyl glucuronides, whereas in dog, aliphatic parts of the 
molecules are hydroxylated, meaning another metabolite is formed in the dog. 
Pharmacologic activity of this metabolite has not been further investigated and might 
explain differences in clinical symptoms. 
Body temperature decreases are not typically regarded as premonitory sign of seizure 
(Markgraf et al., 2014). In a rat study with the selective 5HT2c agonist Org 306039, a 
decrease in body temperature was also noted, but started only on dosing day three 
(Markgraf et al., 2014). Another report describes that intrahypothalamic injection of 
serotonin causes hypothermia in rats (Cox & Lee, 1981). EEG changes accompanied by 
hypothermia were described by Ostojic et al. (2013) in models of absence seizures. He 
described that spike wave discharges were present at the same time as PTZ or gamma-
hydroxybutyrate (GHB) induced hypothermia, but also in the period of spontaneous 
rewarming (Ostojic et al., 2013). Therefore they concluded that mildly lowered core body 
temperature can cause non-convulsive seizures (Ostojic et al., 2013). The hypothermia 
induced by compound 3 therefore could have contributed to the occurrence of non-
convulsive seizures in the rat EEG.  
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Other premonitory signs of convulsions in the EEG studies were rather unspecific clinical 
neurological symptoms: ataxia, jerks, tremor, twitches of facial and/ or limb muscles, 
salivation, increased sensitivity to touch or noise, agitation and excitation. Twitches and 
myoclonic jerks were present prior to all compound induced convulsions described here and 
were accompanied by an abnormal EEG. Tremor was also observed, but Authier et al. (2017) 
reported that this symptom is not usually related with EEG paroxysmal activity and in the 
case of compound 3, could also be induced by hypothermia.  
The premonitory symptoms of drug induced seizures in dogs overlap with reports on 
prodromal signs in dogs with idiopathic epilepsy. Prodromal signs in epileptic dogs, as 
described by Berendt & Gram (1999), were e.g.: anxiety, restlessness, attention-seeking, 
limb twitches, tremor or head tremor, tonic jaw opening, incoordination, autonomic signs 
(emesis, salivation) and dilation of pupils. Also, Fonck et al. (2015) noted that pre-convulsive 
symptoms are similar across preclinical species and also translatable to humans. However, 
Berendt & Gram (1999) report that occurrence of such symptoms does not necessarily mean 
a secondary generalization to convulsions. This is also true for toxicology studies, in which 
neurological symptoms are not always followed by convulsions.  
EEG was not included in the study on epileptic seizure types and their respective clinical 
symptoms in dogs conducted by Berendt & Gram (1999). From EEG examinations in humans 
it is known that the prodromal state preceding seizures can, but must not, be accompanied 
by EEG changes (Berendt & Gram, 1999). The EEG is the accepted gold-standard for seizure 
detection, but its use for identification of the prodromal state is therefore limited. 
The common term for the prodromal state is “aura”. This forewarning sensation is thought 
to originate from activation of a small group of neurons (Berendt & Gram, 1999). We used a 
bipolar montage with two electrodes. Depending on the location of the focal EEG changes 
relative to the electrodes, paroxysmal activity could be missed.  
Technical limitations could also explain the absence of clear EEG symptoms prior to and at 
the beginning of the convulsion in the second experiment with compound 3: Given 
completely synchronous activity of both hemispheres, the differentially amplified signal 
would equal zero in recordings from bilateral electrodes. Inclusion of a reference lead would 
be beneficial in future EEG studies.  
In conclusion, premonitory EEG signs are difficult to definitely diagnose during real-time 
viewing. They were only present within a short time frame prior to the convulsion. In one 
case, no clear premonitory EEG signs were identified prior to convulsion. Therefore, this 
method cannot help to prevent the occurrence of drug induced convulsions in animals that 
are monitored with EEG. Clinical prodromal signs vary between species and seem to not 
reliably forewarn of convulsions. Nevertheless, treatment decisions can rather be based on 
clinical symptoms than on EEG.  
Discussion 
 
- 108 - 
 
A dedicated study can, however, detect convulsion liability in a limited number of animals. 
As convulsions are a dose-limiting factor, early definition of the exposure levels correlated 
with convulsions could be a rationale for lower doses in long-term toxicology studies. 
Convulsive levels could be avoided in regulatory toxicological studies, thereby reducing the 
burden on these animals.  
 
2 Question 2 
Is combination of two procedures possible to enable simultaneous EEG recording and CSF 
sampling for analysis of potential biomarkers of seizure liability? 
CSF ports in dogs are an established method in preclinical drug development (Wilsson-
Rahmberg et al., 1998). These implants enable repeated CSF sampling from conscious dogs. 
Samples are usually not contaminated by blood and of good quality (Wilsson-Rahmberg et 
al., 1998). As implants are covered by skin, group housing is possible and natural behaviors 
of dogs are not impaired. Group housing is the recommended method for dog husbandry 
(Hawkins et al., 2004). Also, it has been shown that the quality of measurements is better 
compared to single-housing conditions (Klumpp et al., 2006). Next to the animal welfare 
perspective, group housing is also advantageous for detection of neurological symptoms: 
earlier evaluation of internal data showed that the detection rate for neurological symptoms 
is higher if an animal can move freely compared to restraint conditions (Backes, 2016). 
Therefore, completely internalized devices were also selected for EEG recording.  
In this thesis, it was first investigated in a pilot study if EEG signals of good quality can be 
obtained from dogs with pre-implanted CSF ports. As results from intra-surgical evaluation 
were positive, dogs with and without CSF ports had EEG electrodes implanted. Neither in 
baseline recordings nor in experiments with CNS-active compounds, were differences in 
recording quality noticed between dogs with and without CSF ports.  
For establishment of an assay, a set of reference compounds was selected as has been 
described in literature (Winter et al., 2008; Easter et al., 2009; Zhang et al., 2011). For EEG 
recordings, especially the use of PTZ as a positive control agent has been described 
(Dürmüller et al., 2007). This was not done due to the following reasons: first, for validation 
of equipment functioning, a positive control is not necessary, also not according to current 
guidelines (FDA, 2001). Also, testing PTZ as a positive control would mean an extra burden 
for the dogs and restrict their use in further experiments for ethical and legal reasons.  
To allow for simultaneous implantation of CSF ports and EEG transmitters, bilateral 
coordinates were selected. This was based on external advice from a contract-research-
organization (CRO). However, the transmitters provided by DSITM do not have a reference 
lead, so only a bipolar montage with one channel could be realized with the equipment 
available. Standard application of the M01 transmitter (DSITM) is measurement of 
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cardiovascular parameters; therefore they have a solid tip lead with a more rigid wire by 
default. During implantation, removal of the insulation and bending of the wire was more 
difficult with this lead. A query to the vendor showed that they had not been aware of this 
and it seemed this was the first time that this implant type was used for EEG recordings. 
Results show that baseline recordings at different vigilance states compared well to 
literature references so the transmitter and implantation scheme seem to be suitable for 
dog EEG recordings. In case of follow-up experiments with this transmitter, it is 
recommended to order it with two regular leads and, if possible, one reference lead.  
In human and veterinary clinics, multiple electrodes are usually used to identify focal EEG 
changes and the use of only two electrodes is a limitation. Two electrodes have been shown 
to be a number sufficient for the detection of generalized EEG changes (Parmentier et al., 
2006; Dürmüller et al., 2007). This was confirmed in our experiments as appearance of 
baseline and sleep patterns corresponded well to literature reports. However, EEG analysis is 
limited when only one channel is available: Focal EEG changes cannot be localized or even 
missed, connectivity analysis is not possible and artefact identification is more difficult.  
The most common artefact in the EEG resulted from movement and muscle activity and this 
was also described by Authier et al. for NHPs (Authier et al., 2009). In theory, the dental 
cement that covers the electrodes serves as insulation thereby preventing occurrence of 
artefacts in the EEG. However, the voltage of muscles is high enough to still be captured by 
implanted electrodes. This could be demonstrated by offering food. Artefacts appear 
simultaneously to jaw movements and can be distinguished from EEG activity due to their 
high frequency and amplitude. However, the relation between artefacts in the EEG and 
muscle activity is not always clear. Reasons can be video quality which was not sufficient to 
show subtle movements as from ears and eyelids. Also, some behaviors can be invisible for 
an external observer, such as movements of the tongue or increases in muscle tone. 
Artefact prevention could have been done with the use of sedative agents, general or local 
anesthetics as it has been described by various clinical veterinarians  (Fox & Stone, 1967; 
Klemm & Hall, 1970; Holliday & Williams, 1999). Local anesthetics were applied in the 
experiment evaluating the compatibility of subdermal needle electrodes with the DSITM 
recording system. In the other experiments, use of accompanying pharmaceutics was not 
considered appropriate, as drug-drug interactions could occur and behavioral observations 
would be confounded. Facial twitches, for example, would have been concealed if the 
muscles were paralyzed.  
Another approach in the veterinary clinic is the use of a poorly lit room with sound-
attenuating walls for EEG recordings (Brass, 1959; Jones & Greufe, 1994; Holliday & 
Williams, 1999). This was not feasible in the EEG experiments, as poor light conditions 
reduce video quality and make detection of symptoms more difficult. More importantly, 
with convulsions being expected, poor light conditions would hinder administration of 
anticonvulsive treatment.  
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Taken together, the experiments showed that combination of CSF ports and EEG telemetry is 
possible and that the signal quality does not differ to that of dogs without pre-implanted 
CSF-ports. Both implant types do not influence normal animal behavior and therefore are 
acceptable methods with regards to animal welfare. As no reports on one-channel bilateral 
EEG recordings have been found in the literature, the impact of this is not clear. Comparison 
of recordings obtained with unilaterally placed electrodes would be necessary to confirm 
applicability of bilateral electrode placement for preclinical safety studies. The use of 
additional electrodes for EOG and EMG could increase validity of results, especially to assist 
artefact recognition and enable polysomnography in sleep studies.  
 
 Biomarker Analysis  2.1
Collection of samples for biomarker analysis at the time point of neurological symptoms was 
possible during the EEG experiments. 36 significant changes from baseline to post-treatment 
time points were observed with unadjusted p values < 0.05. Studies by Moser and Freeborn 
et al. (2015) investigated consequences of pesticide exposure (permethrin, deltamethrin, 
imidacloprid, carbaryl, triadimefon, fipronil) in rats on biomarker profiles (Moser et al., 2015) 
and on the EEG (Freeborn et al., 2015). They analysed rat plasma with different biomarker 
kits including the same biokrates kit selected for the EEG study (Absolute IDQ® p180 Kit 
Biocrates Life Sciences, Insbruck, Austria). Groups of rats each received a single dose of one 
of the treatments, and two different dose levels were selected from each pesticide 
(Freeborn et al., 2015; Moser et al., 2015). In addition, fipronil was also tested in repeated 
dosing conditions (Freeborn et al., 2015; Moser et al., 2015). 
Overall, the amount of altered metabolites was similar in their study: 20% of the total 186 
metabolites were significantly altered under their statistical criteria (Benjamini-Hochberg 
adjusted p-value < 0.05; absolute fold-change > 1.3) (Moser et al., 2015). In the dog EEG 
studies, 36 metabolites (19.36%) were significantly altered in the three different treatments, 
using a q-value > 0.05. 
Moser et al. (2015) observed a dose-dependency of metabolite changes, as “either only the 
high does showed changes or else, both low and high doses were significantly different from 
control” (Moser et al., 2015). Dose dependent changes could be suspected in the dog study 
with most metabolites as well. Analysis of the 24 hour sample, which was not included in the 
study by Moser et al. (2015) however showed that many metabolites were altered for a 
prolonged time. Especially, some levels had further increased 24 hours after administration 
of the first dose. Therefore, changes in metabolite levels between the first and the second 
dose cannot be related to either a dose effect or a time effect after an initial insult.   
Amongst the altered metabolites, three amino acids were affected in the dog EEG study and 
these were methionine, proline and nitro-tyrosine. A reduction indicates an increased 
turnover (Moser et al., 2015). With increased formation of reactive oxygen species (ROS), 
methionine is oxidized to methionine sulfoxide (MetO, MeSOX, MetSO or MsX) (Hoshi & 
Heinemann, 2001). A reduction in methionine levels could therefore indicate increased 
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oxidative stress. Increase of nitrotyrosine is a marker for many diseases, including 
neurodegenerative diseases and neuronal injury (Greenacre & Ischiropoulos, 2001), so the 
meaning of a decrease is not clear. A decrease in plasma proline has been observed in rats 
after traumatic brain injury (Louin et al., 2007). In their study, Louin et al. (2007) saw the 
decrease in proline at the 24 and the 72 hour time point and found that it correlated to 
reduced neurological scores of the animals. The fall in proline at the early time points was 
observed also in dogs. At the 24 hours’ time point, the levels either showed an upward trend 
(compound 1), had returned to or were higher than baseline (compound 2), or were 
decreased (compound 3). The prolonged decrease in proline levels with compound 3 did not 
correlate with neurological symptoms in dogs, so the proposed use of proline as indicator of 
severity of neurological deficit (Louin et al., 2007), is not supported here. 
Lysophosphatidylcholines, phosphatidylcholines and sphingomyelines were altered with all 
three compounds. In the study by Moser et al. (2015) only Fipronil had an influence on these 
metabolites. Fipronil increased levels of diacyl and acyl-alkyls phosphatidylcholines and 
sphingomyelines but lowered lysophosphatidylcholines (Moser et al., 2015). 
Phosphatidylcholines are important for membrane structure and signal transmission 
(Farooqui et al., 2000; Lim & Wenk, 2009). From phosphatidylcholines, 
lysophosphatidylcholines are formed after partial hydrolysis (Farooqui et al., 1997). 
Alterations in plasma levels of these glycerophospholipids have been associated with 
neurodegenerative diseases (Farooqui et al., 2000; Klavins et al., 2015; Li et al., 2016). A 
relation between increased sphingomyelins and neurodegeneration in normal aging and 
disease has also been found (Farooqui et al., 2000).  
The overlap of the metabolite changes between the EEG study and the studies by Moser et 
al. (2015) and Louin et al. (2007) indicates that metabolomics profiling could detect 
neurologic insults. Further work would be needed to investigate which of the changes are 
specific for neurotoxicity.  
 
3 Question 3 
Can intravenous administration of escalating doses reduce inter-animal variability so that 
use of fewer animals is justified? 
After oral dosing a significant variability of exposure levels between individual animals has 
been found (Backes, 2016) due to varying ADME (Absorption, Distribution, Metabolism, 
Excretion) properties. With intravenous dosing, there are no differences in absorption. In 
addition, emesis, which is frequently seen in toxicology studies, and gender differences 
influence exposure after oral dosing. This was seen with compound 2: Data from a previous 
toxicology study (PK data collected on day 1 after a single dose) with an oral dose of 10 
mg/kg and from the EEG study with a dose of 14 mg/kg are shown in Figure 103. Plasma 
drug exposure is similar across studies, with the lowest levels achieved in the female in the 
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EEG study despite a higher dose. Tmax in female dogs seems to be longer than in males with 
the same dose levels, and also Cmax seems to be lower, especially in the EEG study. 
Compound 2 could not be administered intravenously as solubility was too poor to reach 
targeted exposure levels with reasonable infusion volume. 
 
 
 
 
 
 
 
 
 
Figure 103: Comparison of plasma exposure in the EEG study to data from previous 
toxicology studies. Exposure levels are similar across studies and show a higher gender 
difference in the EEG study. 
 
Compound 1 and compound 3 were administered intravenously. Variability was seen 
concerning the convulsive exposure level with compound 1. Plasma samples were collected 
within two to five minutes after clinical convulsion from both dogs. The total dose that 
induced convulsions in the male dog was 68 mg/kg, corresponding to a plasma 
concentration 7667.1 ng/mL. The female dog had convulsions eight minutes after the start 
of the second infusion while still being connected to the infusion line. Considering this, a 
total dose of 61.8 mg/kg corresponding to a plasma concentration of 13292.6 ng/mL induced 
convulsions in the female. The slightly higher compound need for the male dog is probably a 
result of the longer experimental time. This was 70 minutes for the male opposed to 38 
minutes until clinical convulsion in the female, as dose level and infusion rate were higher in 
the second study. During the longer experimental time, some amount of compound 1 might 
have been already metabolized.  
The lower total dose however resulted in higher plasma drug concentrations of 13292.2 
ng/mL in the female as opposed to 7667.1 ng/mL in the male. In the male dog, the 
convulsion occurred during blood collection for TK analysis. The dog was lifted up and set on 
a table for this purpose. It is possible that in this case the convulsions were triggered by 
handling. In the female dog, an increased sensitivity to touch was also noted, but as opposed 
to the male dog, blood was collected directly within the recording kennel in this experiment 
and the female was handled less. A possible relation between sampling time points and 
occurrence of convulsions has also been reported elsewhere (Authier et al., 2017). The 
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variability in convulsive exposure could in this case result from external manipulation. 
Therefore, all surrounding factors need to be well controlled and standardized amongst 
studies. 
Infusion rate could also contribute to variability with intravenous infusions. In the 
experiment with compound 1, infusion rate for the female was 2.25 mL/min to reach the 
highest dose whereas for the male, it was 1.71 mL/min (31.6% higher). The relationship 
between infusion rate and exposure at the time point of clinical effect has been investigated 
by Ramzan & Levy (1985) with intravenous infusion of PTZ to rats: they run two experiments, 
with the endpoint in the first one being appearance of the first myoclonic twitch and in the 
second being generalized convulsions. They found that no significant difference existed 
between plasma, brain and CSF concentrations of PTZ as a consequence of infusion rate in 
rats (Ramzan & Levy, 1985). This was different to earlier results of a study investigating 
consequences of different infusion rates on exposure, dose required and latency to loss of 
righting reflex in rats (Danhof & Levy, 1984). In this experiment, phenobarbital levels in 
blood and brain at occurrence of the behavioral endpoint increased with increasing infusion 
rate in rats (Danhof & Levy, 1984). Also in humans, Marsch et al. (2001) found that a faster 
infusion rate of morphine led to significantly higher plasma levels”. Ramzan & Levy mention 
that PTZ has only very little (2.5%) plasma protein binding (Ramzan & Levy, 1985). Opposed 
to this, phenobarbital was bound to plasma proteins at 36.2 ± 7.6% (Danhof & Levy, 1984) 
and morphine at 34% - 37.5% (Olsen, 1975). Differences in plasma protein binding could be a 
factor contributing to the differential influence of infusion rate on plasma exposure.  
Plasma levels after intravenous infusion of compound 3 (8 mg/kg in the first infusion, 6 
mg/kg in the second one), were very similar in the male and the female. Exposure in the 
male dog was higher (first time point: 1116.53 ng/mL, second time point: 1527.87 ng/mL) 
and clinical symptoms were more pronounced in this dog. Thus, exposure correlates to 
clinical symptoms. One cause could be the difference in body conditioning score (BCS) of 
both dogs: The male had a BCS of 3 and the female a score of 2. Due to the higher weight, a 
higher infusion rate was necessary to administer the complete dose to the male dog within 
the pre-defined 10 minutes of infusion time (55.91% faster in the first infusion step, 29.16% 
in the second infusion step). Therefore, with this compound, an influence of infusion rate on 
exposure is also possible.  
Apart from reduced variability due to differences in absorption or metabolism, another 
advantage of an intravenous infusion study is the direct exposure and resulting shorter 
experimental time. In the EEG studies with intravenous infusion, plasma exposure levels at 
which symptoms occurred were reached within a maximum of two hours. The dogs were 
supervised through clinical examinations and video-EEG for the rest of the day after the 
experiment and neither were additional neurological symptoms observed nor did the 
severity of symptoms increase.  
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This was different in the oral study with compound 2: in this study, the male dog showed 
stereotyped behavior only in the afternoon and the symptoms lasted until the next morning, 
so overnight observation via video EEG was done. In conclusion, the study design using 
intravenous administration reduced the experimental burden for animals through shortened 
procedural time and shorter time during which neurological symptoms were present.  
In the EEG study with compound 1, most neurological symptoms that were observed in 
longer-duration toxicology studies with oral administration in dogs (see results section, Table 
12). Compound 3 was not tested in dogs, but in NHPs, and symptoms observed in oral 
toxicology NHP studies and in the NHP infusion studies overlap as well. Through the faster 
rise in exposure levels with intravenous dosing, active compound brain levels are also 
reached quicker. This could have been confirmed by measuring compound brain levels or 
analyzing CSF, as surrogate of brain tissue. Therefore, with the accelerated study design, 
relevant neurological symptoms can be detected and longer study durations do not alter the 
readout with regards to these symptoms. 
With dedicated infusion studies, neurological symptoms could be induced in a short 
experimental time of two hours at maximum and determination of plasma substance levels 
was possible simultaneously to occurrence of symptoms. Exposure after intravenous 
administration of compound 1 and 3 was less variable than exposure after oral 
administration of compound 2. This is in line with previous findings from toxicology studies 
with compound 1 and other drug candidates (Backes, 2016). Some variability was still 
observed with intravenous dosing. Higher exposures were seen with increased infusion 
rates. The magnitude of this influence factor is probably compound related, as the effect 
was observed with morphine (Marsch et al., 2001) and phenobarbital (Danhof & Levy, 1984) 
but not with PTZ (Ramzan & Levy, 1985). This study design therefore enables continuous 
observation for improved detection of neurological symptoms, sample-collection according 
to clinical signs and instant treatment of the animals if severe symptoms are observed.  
Theoretically, lowered variability is a rationale for reducing animal numbers, but there are 
practical considerations: authorities require that a candidate drug’s action is investigated in 
a study that uses the same route of administration that is intended for human use. In most 
cases, this is “per os” administration. Also, the design of toxicology studies in non-rodents is 
standardized. For example, a default number of three non-rodents per gender per dose 
group is usually used in 2-week dose range finding GLP studies. This is considered to be the 
minimum number necessary to appropriately investigate adverse effects.  
Several authors have stressed the importance to identify neurological liabilities early in the 
drug development process (e.g. (Easter et al., 2009)). Intravenous administration of 
escalating doses led to reduced exposure variability compared to toxicological studies 
thereby allowing the use of only two animals. Such studies can be included in early phase 
safety assessments when compound availability is usually limited. Recommendation 
therefore would be, in cases where seizure liability is a concern, to conduct such dedicated 
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studies prior to toxicological studies. In addition, the whole range of neurological symptoms 
that occurred in long term toxicology studies were also seen in the EEG studies. The 
possibility to collect samples for exposure analysis simultaneous to the occurrence of 
symptoms in such short studies can improve calculation of safety margins. Dose selection for 
toxicology studies with large animal numbers could be adapted accordingly to avoid reaching 
exposure levels at which severe neurological symptoms occur. 
 
4 Question 4  
Is the dog a relevant animal model for seizure liability assessments and how does the dog’s 
sensitivity for neurological symptoms compare to other preclinical species? 
Regulatory requirements for CNS testing of developmental drugs are limited to behavioral 
observations by Irwin test or FOB, which are usually done in rodents (FDA, 2001). As 
convulsions are often only observed in toxicology studies (Easter et al., 2009), these 
experiments are not sufficient to detect seizure liability for all compounds. Multiple assays 
for seizure liability detection have been developed but none of them is regarded to be 
sufficiently sensitive and a combination of tests is usually selected. There is a general 
difference between these assays: some are considered as early screening tools for a medium 
to large amount of compounds, like computational methods (Zhang et al., 2011), brain slices 
(Easter et al., 2007) or the zebrafish locomotor assay (Winter et al., 2008; Cassar et al., 
2017). Others are used to answer more specific questions about dose-relation or seizure 
type. Ethical reasons oppose to the use of the dog in the first category. For detailed 
assessments of seizure liability, this species has already been successfully used (Dürmüller et 
al., 2007; van der Linde et al., 2011b; Authier et al., 2014b).  
Dogs are regarded by some authors (Redman & Weir, 1969; Edmonds et al., 1979; Easter et 
al., 2009; Hasiwa et al., 2011; Authier et al., 2013; Authier et al., 2014b) to be overly 
sensitive for convulsions, but retrospective analysis of internal data showed that this is not 
supported by exposure-based evidence (Backes, 2016). However, only few substances were 
tested in more than one non-rodent species and therefore, evaluation of species-specific 
sensitivity is limited (Backes, 2016). The choice of compound 1 and compound 3 for the EEG 
experiments enabled comparison with data previously collected in NHPs in a comparable 
study design and improved the data basis for evaluation of species sensitivity.  
As previously reported (Backes, 2016), it is important to consider free plasma concentration 
for comparing exposure-related symptoms amongst species. The free concentration is the 
amount of substance unbound in plasma and is calculated by using species-specific plasma 
protein binding. The free concentration in plasma is the fraction of the total concentration 
that can reach its site of action within the brain. The example of compound 1 illustrates that 
the difference between NHP and dogs in convulsive threshold is reverted when free instead 
of total concentrations are considered. NHP had convulsions at a total exposure of 135000 
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ng/mL – 146000 ng/mL whereas dogs showed this symptom at 7667.1 ng/mL and 13292.6 
ng/mL. Considering the unbound fraction in plasma in the dog (fu 0.3) that is higher than in 
the NHP (fu=0.012), convulsive exposure levels are very similar. Cfree for the dog at the time 
of convulsion was 2300.13 ng/mL and 3987.78 ng/mL and for the NHP Cfree was 1620-1752 
ng/mL. Therefore, the dog is not more sensitive than the NHP with this compound.  
The case of compound 1 is also an example how different outcomes can be seen in different 
assays: in the PTZ seizure threshold test this compound had anticonvulsive effects in rats, 
but actually it is convulsive at high doses in other species: first, convulsions occurred in 
toxicology studies in dogs and then in dedicated infusion studies in NHP and dog. Similar 
effects have been described for bupropion (Tutka et al., 2004). 
In the testing of compound 3, convulsions were observed in one dog. The corresponding 
sample was taken 20 minutes later due to post-ictal aggressive behavior of the animal. 
Therefore exact exposure at the time point of convulsions can only be estimated based on 
computational modeling. The difference between total and free exposure is not as marked 
as with compound 1, as the fraction unbound in plasma is more similar between dog and 
NHP (fu dog: 0.121 – fu NHP: 0.155). In NHP studies, there was one animal that had a very 
high exposure (9570 ng/mL) but did not show convulsions. The other NHPs convulsed at 
total plasma levels between 979 ng/mL and 1970 ng/mL (mean: 1588 ng/mL). Total plasma 
level in the dog 20 minutes after the convulsion was 1600.7 ng/mL, so the dog is close to the 
NHP mean. Considering free plasma concentration, the mean NHP exposure with 
convulsions is 238.6 ng/mL (range 151.7 ng/mL – 335.4 ng/mL) and the dog had a free 
plasma concentration of 193.68 ng/mL 20 minutes after the convulsion. The results from the 
testing of compound 3 therefore do also not confirm the hypothesis that the dog is more 
sensitive to convulsions than the NHP.  
Concerning compound 2, the dog showed high sensitivity for head tremor. In NHPs, this 
symptom was not observed (compare results section). Oral bioavailability of compound 2 in 
NHP is only 12.6%, compared to 78.4% in the dog. A 10 mg/kg oral dose induced the head 
tremor in dogs and resulted in a Cmax 1208 ng/mL (males) and 1086 ng/mL (females). In NHP, 
the same dose led to a Cmax of 643 ng/mL in males and 653 ng/mL in females. Considering 
the plasma protein binding of 0.49 in dog and 0.41 in NHP, free concentrations at Cmax (10 
mg/kg oral dose) were 591.92 ng/mL (dog male), 532.14 ng/mL (dog female), 263.63 ng/mL 
(NHP male) and 267.73 ng/mL (NHP female). A dose of 30 mg/kg results in a free exposure in 
NHPs that is related with head tremor in dogs (582.2 ng/mL males; 619.1 ng/mL females). No 
head tremor was observed at this dose in NHP, but stereotypies, e.g. self-mutilation through 
chewing on body parts, circling, gnawing and picking at gums. A 5-fold higher CSF/ plasma 
ratio at Cmax was observed in dogs compared to NHPs (0.2 in dogs; 0.04 in NHP after a 1 
mg/kg oral dose) and can together with the higher bioavailability partially explain the higher 
sensitivity of this species. In rats, stereotyped behavior was also seen (walking on tip-toes).  
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The origin of the head tremor in dogs was not clear; partial seizures with motor signs were 
one explanation. This was not explored in more detail for to several reasons: the occurrence 
of partial seizures without generalization was considered rare; the finding had the same 
intensity over different dose ranges and midazolam was not effective in halting the tremors. 
In addition, the level of consciousness of dogs was not or only mildly impaired, they were 
responsive to external stimuli and no autonomic signs were observed. EEG recordings did 
not show definite seizure characteristics. The occurrence of triphasic waves in the male dog, 
has been described as a general sign of CNS toxicity that is not indicative for a single 
compound class or seizure (Blume, 2006). With compound 2, the dog EEG therefore served 
to exclude seizures as cause of the symptom.  
In summary, comparison of exposure at the time point of neurological symptoms between 
two non-rodent species showed, that no difference existed between the dog and the NHP 
regarding sensibility for convulsions with compound 1 and compound 3. As opposed to NHP 
infusion studies, in dogs these studies can be performed with relatively freely moving 
animals and therefore, a broader range of symptoms can be detected. The dog is generally 
suited as an animal model for seizure liability testing and its use in seizure liability 
assessments in drug development has also been performed successfully by other 
researchers (Dürmüller et al., 2007; van der Linde et al., 2011b; Authier et al., 2014b; Authier 
et al., 2017). For development of antiepileptic drugs, use of the dog has been specifically 
proposed due to similarity of human and dog epilepsy (Potschka et al., 2013). Studies using 
dogs have the advantage of a higher detection rate of neurological symptoms. One reason 
for this is larger body size compared to rodents which allows better identification of subtle 
symptoms. Also, the higher grade of domestication means the dog shows symptoms more 
readily and caretakers recognize them easier. Lastly, due to a larger blood volume, the 
possibility for repeated sample collection for exposure and biomarker analysis exists. In 
general, the use of the dog in seizure studies that have potentially a high burden for the 
animals must be carefully considered.  
 
5 Question 5  
Can quantitative and automated analysis of dog EEG support investigation of CNS effects 
of development drugs? 
Quantitative EEG analysis has been recommended for detection of background EEG changes 
that are not evident upon visual analysis (Moore et al., 1991). One advantage of quantitative 
over visual EEG analysis is its objective nature as a measure of drug effect (Jones & Greufe, 
1994) and the possibility for statistical analysis (Eccles, 1988). Quantitative EEG analysis has 
found clinical application in anesthesia monitors in human (Kissin, 2000) and to some degree 
also in veterinary medicine (Otto & Short, 1991; March & Muir, 2005; Campagnol et al., 
2007; Ribeiro et al., 2008). With regards to drug development, qEEG enables data 
management and data quality control suited to comply with GLP requirements (Jones & 
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Greufe, 1994). Also, as opposed to behavioral observations, qEEG effects have been 
considered to be better translatable from preclinical species to clinical trials in humans to 
assess adverse CNS effects (Fonck et al., 2015). However, it has also been pointed out, that 
the psychological state has an influence on the EEG and that this factor might limit inter-
species translatability (Eccles, 1988; Freeborn et al., 2015).  
Several researchers tried to find specific drug fingerprints on the EEG (reviewed by (Van 
Riezen & Glatt, 1993)). Quantitative EEG patterns have been investigated with drugs from 
the same indication but from different chemical classes and with several modes of action 
(Frankenheim, 1982; Dimpfel et al., 1988; Dimpfel, 2003). Another approach was the analysis 
of pathway-specific drug effects using e.g. cholinergic (Dimpfel, 2005) or dopaminergic 
(Dimpfel, 2008) compounds. The promise of qEEG categories is that the efficacy of a 
development candidate in a certain indication can be determined and ideally translated to 
the clinic. However, according to Porsolt et al. (2002) “there is debate as to whether qEEG, 
by virtue of the different profiles observed, is capable of identifying specific classes of 
psychotropic agent (…)”(Porsolt et al., 2002). Also, Wilson et al. (2014) mention that there is 
a paucity on reports that evaluate translatability of pharmacologically induced qEEG changes 
(Wilson et al., 2014).  
One difficulty with interpreting qEEG data is that a dose and time dependency of effects has 
been found with different compounds and different doses or time points have been selected 
leading to differential results. Also, comparison of qEEG results reported by different authors 
amongst each other and with data from the dog EEG studies was found to be limited. Direct 
comparison would first necessitate a consistent definition of frequency bands and their 
respective bandwidths. This premise is not given, for example the gamma band is not always 
considered (e.g.(Jones & Greufe, 1994; Dimpfel, 2003; Dimpfel, 2008)) and a differentiation 
of lower and upper alpha and beta bands has been proposed by some authors in human 
medicine (e.g. (Herrmann et al., 1979)) and preclinical research (e.g. (Dimpfel, 2003), 
(Dimpfel, 2008)). Also definition of the sigma power band is commonly done for sleep 
studies (Authier et al., 2014a). In addition, species and the respective recording and analysis 
techniques vary between experiments. For example, route of administration and 
pharmacologic properties of a compound should be considered when selecting time points 
to derive qEEG data. Some authors present their results with a focus on selected brain areas. 
Lastly, measures taken to control vigilance state and the behaviors induced by 
administration of different drugs are often not mentioned. To sum up, different 
experimental designs make it difficult to find a conclusion regarding a compound’s qEEG 
fingerprint.  
This is not only true for drug-induced qEEG effects, but also for reference values that have 
been published e.g. for the dog by Moore et al. (1991) and Jones & Greufe (1994): These 
reference values were established using scalp electrodes rather than implanted telemetry. It 
is known that the voltage of the electric brain activity is reduced by the skull and the 
overlying muscle layers. Thereby, absolute power values of different frequency bands vary 
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between methods, species and even dog breeds. Changes in relative power are therefore 
more suitable to compare results obtained in different studies.  
One example, for which dose- and time dependent effects have been described are 
dopaminergic substances (Dimpfel, 2008; Wilson et al., 2014). This dose-dependency affects 
behavior and concomitant on qEEG parameters (Dimpfel, 2008; Wilson et al., 2014). Also, 
Dimpfel describes differential changes in hippocampus, striatum, reticular formation and 
frontal cortex (Dimpfel, 2008). Wilson et al. reported results of the effects on rat EEG after 1 
mg/kg subcutaneously administered apomorphine (Wilson et al., 2014). They reported an 
increase in the relative power in the gamma band, which they defined from 30-70Hz, 30 and 
60 minutes after apomorphine administration in quiet waking conditions (Wilson et al., 
2014). Quantitative EEG changes in humans after a low dose of apomorphine (total 0.75mg 
s.c.; 0.01 mg/kg given an average weight of 70 kg) were increases in relative and absolute 
beta 3 (they differentiated beta 1, 2 and 3 with beta 3 ranging from 21 to 32 Hz) power 
localized over frontal-central scalp areas 30 minutes after apomorphine (Luthringer et al., 
1999). In general, an “EEG activating effect” is related with apomorphine. In the dog study, 
there were no significant changes in the gamma or beta power in both dogs, but the dog is 
also different to other species, regarding the emetic effects of apomorphine. A time point 
around 30 minuntes after apomorphine administration was selected to enable comparison 
to the results reported by Wilson et al. (2014). Quinpirole, which is an agonist at D2 
receptors, increased gamma and reduced delta power. Compound 1 induced qEEG changes 
mainly consisted of a rise in delta and theta and a decrease in gamma in both dogs. This 
effect was not clear by visual EEG analysis only. To sum up, dopaminergic compounds 
induced differential changes in dog EEG. A relation to this specific pathway therefore cannot 
be made.  
In drug safety testing, the specific EEG fingerprint of a dug class is of less interest than 
identification of potential patterns that indicate CNS liabilities. This application of EEG has 
been investigated (Benignus, 1983; Eccles, 1988; Jones & Greufe, 1994; Jones et al., 1995). 
Fonck et al. (2015) mention that their own results show that qEEG has the potential to be 
used as a translatable safety biomarker. In humans, it has been observed that increases in 
delta and theta as well as triphasic waves, that were present with compound 2, are an 
unspecific sign of neurotoxicity. Interestingly, the increase is already obvious at the first time 
point, whereas visual EEG interpretation could only detect this pattern change during the 
late afternoon and the night. In the female dog, no remarkable qEEG changes were present, 
but a mild increase in theta at the first time point could also be identified. This difference 
between male and female dog was also present in their clinical behavior and explained by 
the lower exposure reached in the female dog despite being administered the same dose. 
These EEG symptoms have been identified in relation to drug toxicities or metabolic 
encephalopathy (Blume, 2006). In dog EEG, increase in theta and/ or delta were the most 
significant changes in qEEG. These parameters therefore could be used as identifiers of 
neurotoxicity.  
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However, administration of propofol also increased delta, theta, alpha and sigma band while 
beta and gamma showed a marked decrease. Similar effects have also been reported in 
literature: Bergamesco (2003) describes that propofol anesthesia significantly increased 
both, absolute and relative power of delta. This increase in delta was dose-related, whereas 
the other frequency bands were not affected by the amount of anesthetic administered 
(Bergamasco et al., 2003). The increase in the lower frequency bands under general 
anesthesia was significant in several reports whereas changes in the higher frequency bands 
were not (Itamoto et al., 2001; Jeserevics et al., 2007). The influence of general anesthetics 
on the canine EEG could be confirmed, with the EEG telemetry setup, but opposed to the 
findings reported by Bergamesco (2003), all lower frequency bands were increased and 
higher frequencies were decreased.  
Changes in qEEG therefore need to be interpreted in relation to behavior and cannot be 
used as an indicator of neurotoxicity alone. As clinical symptoms were present at the time of 
qEEG effects, the practical utility of these measures as predictor of neurotoxicity prior to 
induction of severe symptoms is limited. Also, for correct assessment of qEEG changes, 
artefacts have to be excluded and the vigilance state needs to be considered (Wilson et al., 
2014) as each state has been linked to a specific qEEG pattern (Freeborn et al., 2015). In 
humans, the level of consciousness can be controlled by either recording resting state EEGs 
(eyes closed) or setting a task that ensures a stable level of wakefulness (Wilson et al., 2014). 
The vigilance level in animals can be held constantly high by making them walk on a 
treadmill (Krijzer et al., 1993; Porsolt et al., 2002). Alternatively, episodes with reduced 
wakefulness need to be excluded from qEEG analysis. This approach was chosen in this 
thesis, as visual evaluation of recordings was also needed for exclusion of artefacts. In 
practice it was found that due to the testing conditions in which the dogs were constantly 
observed, decreases in their vigilance level were only observed in baseline and overnight 
recordings (with the exception of drug-induced sedation with compound 3).  
In summary, qEEG levels were altered after compound administration, but only at the same 
time as neurological symptoms and did not enable detection of neurological symptoms prior 
to their clinical occurrence. Also, accurate qEEG analysis is time intensive due to the need to 
manually review the EEG traces. In conclusion, this parameter is not recommended as a 
useful safety biomarker for neurotoxicity.  
 
6 Additional Outcomes   
 EEG Recording with Subcutaneous Needle Electrodes  6.1
A telemetry transmitter was connected to stainless-steel needles to test whether this would 
enable recording minimal-invasive EEGs with the same equipment used for the implanted 
telemetry. It was possible to record an EEG with this method, the quality however did not 
compare to EEGs recorded with implanted telemetry. First, electrode movements were an 
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additional source of artefact and second, the method failed to show subtle EEG transients 
like spindles under propofol anesthesia. In general, signals obtained with non-invasive 
electrodes were of lower voltage than those recorded with implanted electrodes. This 
difference in amplitude had already been observed by Redding & Colwell, who 
simultaneously recorded signals from implanted electrodes and alligator clamps to evaluate 
performance of the non-invasive clamps (Redding & Colwell, 1964). They concluded, that 
both recordings were generally comparable but that amplitudes differed significantly 
between cortical and scalp electrodes, with lower voltages at scalp electrodes, which could 
potentially dampen high frequencies (Redding & Colwell, 1964). 
A limitation in our experiment was that no electrophysiology needle electrodes were used 
due to technical problems in connecting the cables to the electrodes. As the method has 
been successfully tested by Authier et al. (2015), it is possible that this is the reason for the 
poor performance of the subcutaneously recorded EEG compared to the EEG recorded from 
implanted electrodes.  
The majority of reports on dog EEG in the veterinary clinic describes the use of subdermal or 
clip electrodes. The use of subcutaneous needle electrodes in dogs in a preclinical research 
setting has been described (Jones & Greufe, 1994; Authier et al., 2015). Advantages of this 
approach are the relatively lower effort and reduced costs: the devices for EEG acquisition 
from subcutaneous electrodes can be reused and no surgery is needed. From an animal 
welfare perspective, the risk and stress associated with surgery are avoided using this 
method. However, so far, only acute studies with physical restraint have been described 
with the use of needle electrodes and telemetry remains so far the best option if long-term 
studies are planned. Experience from the veterinary clinic has shown that sedation or 
anesthesia often cannot be avoided in order to record high quality EEGs with needle 
electrodes. In safety studies, simultaneous application of other substances and the drug 
candidate is usually avoided due to possible drug-drug interactions or confounding effects 
on symptoms.  
An EEG recording system utilizing 15 subcutaneous needle electrodes has recently been 
introduced to the veterinary clinic for monitoring epileptic dogs at home and in clinics 
(Wielaender et al., 2017; Wielaender et al., 2018). It needs to be evaluated, if this approach 
is suitable for use in drug development as well. The use of a larger montage permits 
visualization of the EEG signal in different montages. For shorter duration studies (up to 24 
hours) it can be an alternative to implanted telemetry. Probably, animals need to be 
separated as long as the electrodes are inserted and this would discourage its use in longer 
duration studies. One general disadvantage of a jacket is the risk of concealing certain 
symptoms, like isolated muscle twitches on the trunk or piloerection.  
Risk of non-invasive electrodes is, next to the higher artefact coverage that loss of electrodes 
can occur during a study. If unnoted or at a time point when replacement is not possible, e.g. 
due to symptoms, this would mean that an animal was dosed without getting the intended 
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readout. Repetition of experiments or use of additional animals is not in line with 3R 
principles; therefore the risk of data loss after equipment failure and the concomitant need 
to repeat experiments needs to be weighed against the burden (and the costs) of surgical 
implantation of telemetric devices.  
One major application for long-term EEG in drug development is for sleep studies. The dog 
has been recognized as a model for sleep research with good translatability to humans: in 
the course of domestication, dogs adapted to human day- and night rhythms (Parmentier et 
al., 2006; Kis et al., 2014). Traditionally, rodents are used for sleep studies, but their sleep 
cycle is different to the human one to a greater degree than the dogs, that has adapted to 
humans during the domestication process. Therefore results from dog sleep studies have 
been proposed to have a higher degree of translatability to humans (Parmentier et al., 
2006). In addition, there are some sleeping disorders that naturally occur in both, humans 
and dogs, (narcolepsy) or that have been induced in dogs (obstructive sleep apnoe) and like 
with epilepsy, dogs have been discussed as a translational model for this disease (Horner et 
al., 1998).  
To conclude, the use of non-invasive electrodes for EEG studies can be an alternative to 
implanted telemetry in acute studies. In order to avoid restraint of dogs that can confound 
symptoms, training would be necessary. For long-term monitoring and especially sleep 
studies, use of implanted telemetry is advantageous due to higher signal quality, reduced 
risk of data loss, data quality and animal welfare.  
 
 Video-EEG Analysis  6.2
Toxicological studies are not ideally designed for the assessment of seizures: Clinical 
observations are usually only done at pre-defined time points (Backes, 2016), and as the 
average duration of a seizure was estimated to be less than three minutes (Metea et al., 
2015), occurrence of such an event can be missed. In such cases, safety margins would not 
be calculated correctly. Video observation can increase the probability of detection of 
convulsive episodes and allow detailed description of the event (Elander, 2013). Limitations 
of video recordings are that they do not allow detection of subtle changes in behavior (e.g. 
ocular symptoms) or partial seizures that do not lead to clear symptoms (Williams et al., 
2006). Also, large amounts of data are generated during several days of video recording and 
analysis takes long or requires large personnel efforts. There are software solutions that 
support video analysis for some species and would be a possibility to increase convulsion 
detection rate.  
Blinded analysis, as it has been recommended by Jeserevics et al. (2007), was not possible in 
the exploratory pilot studies described here as the same person was responsible for study 
planning, study conduct and video - EEG interpretation. If such studies are performed in the 
context of regulatory studies in future, blinding of the EEG interpreter or EEG analysis by a 
second person would be necessary.  
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Recordings were acquired using DSITM Ponemah. Synchronization with video was enabled 
with the Noldus Media Recorder. One major disadvantage of this software solution is that 
only one camera can be selected per animal at a time meaning that 360° views of a freely 
moving dog are not supported. The solution to include one not-implanted transmitter in 
each recording enabled saving a synchronized video. However, the program does not display 
this video in the same window as the one allocated to the animal. In practice, the second-
angle videos were only used in rare cases to confirm suspected artefact sources.  
Analysis of recordings was done using DSITM NeuroScore software version 3.2. This program 
has been developed for preclinical applications and has been used by other authors in the 
field as well (Authier et al., 2009). The default settings of the automated seizure detector 
had a high false positive detection rate (low specificity). This was reduced when a custom-
made protocol was run, but visual analysis was still necessary to exclude false detected 
episodes. On the other hand, sensitivity was high, meaning that all real seizures were 
detected by the program. This has been observed by other authors as well (Authier et al., 
2009). The automatic seizure detection tool has one major disadvantage: it presupposes the 
presence of a seizure in a recording, in order to align the settings to the individual EEG 
traces. To my knowledge, there are no reported universally applicable identifiers of seizures 
recorded with implanted telemetry in dogs, so the customization of detection protocols also 
depends on the preliminary identification of a seizure. However, the protocol is still useful, 
especially when long recordings need to be analyzed, as a search function is available after 
the seizure detection protocol has been carried out. This allows the analyzer to jump from 
one detected episode to the next one, thereby reducing the time necessary for visual 
analysis.  
 
  
Abstract 
 
- 124 - 
 
VII. Abstract 
Preclinical safety is an important part of drug development in animals and humans. In 
toxicology studies, seizure liability can be detected at high doses as convulsions. Non-
convulsive seizures induce only subtle behavioral changes and their assessment in animals is 
challenging. Electroencephalography (EEG) is the only method to correlate animal behavior 
to seizure activity and video-EEG is the current gold-standard for preclinical seizure liability 
assessments (Authier et al., 2014b). In most cases there are no clear premonitory signs that 
forewarn of convulsions but epileptiform EEG activity prior to clinical manifestation has been 
reported during a period potentially sufficient for prophylactic anticonvulsive treatment 
(Dürmüller et al., 2007). 
Aim of this thesis was investigation of a study design for assessment of neurological 
symptoms in dogs. This design should optimize detection of neurological signs while 
minimizing study duration and animal numbers. Video-EEG was used to increase symptom 
detection rate and to explore the possibility to refine seizure liability testing by enabling 
EEG-based anticonvulsive treatment. For establishment of the EEG system in our facility, 
reference substances were tested first. Then, three in-house drug candidates with different 
modes of action and known neurological side effects were chosen. Two telemetered beagle 
dogs were used per experiment. Substance effects on clinical symptoms and on the EEG 
were investigated. CSF and blood samples for analysis of drug exposure and biomarkers 
were collected simultaneous to symptoms. Results were compared to previous toxicological 
studies thereby enabling evaluation of non-rodent species differences in sensitivity for 
neurological symptoms.  
Results showed that combination of implants for CSF collection and EEG recording is 
possible. In this study design, intravenous administration was superior to oral dosing as it led 
to a reduced variability in exposure levels. Also, experimental time was significantly reduced 
compared to standard toxicology studies while the same neurological symptoms were 
induced. This shortened duration enabled continuous clinical observations for a better 
evaluation of CNS effects and immediate veterinary assistance in the spirit of animal welfare. 
The EEG was not superior to clinical observations in forewarning of convulsion risk and did 
not enable convulsion prevention. This was due first to the short latency between onset of 
abnormal EEG activity and convulsions which was below one minute with in-house 
compounds. Secondly, accurate interpretation of the unfiltered EEG signal was limited, 
especially differentiation of artefacts and epileptiform activity.  
In conclusion, a study design using intravenous infusions is suitable for the characterization 
of neurological symptoms. All the symptoms, which were already known from studies with a 
longer duration, were also seen. This allowed better correlation of neurological symptoms to 
exposure and immediate veterinarian treatments. For substances with a high risk to induce 
severe neurological symptoms, such studies can guide dose selection for longer regulatory 
toxicological studies to prevent occurrence of severe neurological symptoms.  
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VIII. Zusammenfassung 
Im Rahmen der Entwicklung von Human- und Veterinärarzneimitteln wird die 
Anwendersicherheit neuer Medikamente in präklinischen Sicherheitsstudien erforscht. 
Zentralnervöse Nebenwirkungen werden häufig erst in toxikologischen Prüfungen erkannt, 
wenn bei hohen Dosierungen Krampfanfälle bei den Versuchstieren auftreten. Epileptische 
Anfälle können allerdings auch subtilere Symptome, deren Erkennen in Tieren schwierig ist, 
verursachen. Die Elektroenzephalographie (EEG) bietet in Tierstudien die einzige 
Möglichkeit, nicht-konvulsive Anfälle zu diagnostizieren. Daher ist die Kombination von 
Videoüberwachung und EEG in der präklinischen Arzneimittelentwicklung gegenwärtig der 
Goldstandard für die Sicherheitsbewertung einer Substanz im Hinblick auf ihr Risiko, Anfälle 
auszulösen (Authier et al., 2014b). Meist gibt es keine klinischen Warnzeichen vor dem 
Auftreten von Krampfanfällen. Allerdings wurde das Auftreten epileptiformer EEG-Aktivität 
vor klinischen Symptomen beobachtet. Das beschriebene Zeitfenster ist potentiell 
ausreichend für prophylaktische antikonvulsive Behandlung (Dürmüller et al., 2007). 
Ziel dieser Arbeit war es, in Pilotstudien ein neues Studiendesign für die Charakterisierung 
neurologischer Nebenwirkungen zu evaluieren. Dieses Studiendesign sollte die 
Erkennungsrate neurologischer Nebenwirkungen optimieren und dabei gleichzeitig eine 
Reduktion der dazu nötigen Tiere und der Studiendauer ermöglichen. Der Einsatz von EEG 
und Videoüberwachung sollte es ermöglichen, Substanz-induzierte Anfälle im Frühstadium 
zu erkennen und ihr klinisches Auftreten zu verhindern. Um das EEG-System in der 
Forschungseinrichtung neu zu etablieren und um zu evaluieren, ob Implantate für Liquor-
Entnahme und EEG-Aufzeichnung kompatibel sind, wurden zuerst Referenzsubstanzen 
getestet. Zur Beantwortung der eigentlichen Fragestellung wurden drei 
Arzneimittelkandidaten mit unterschiedlichen Wirkmechanismen ausgewählt, von denen 
bekannt war, dass sie neurologische Symptome verursachen. Je Substanztest wurden zwei 
Hunde mit implantierten EEG-Sendern verwendet. Zwei der Substanzen wurden in 
eskalierenden intravenösen Dosen verabreicht, die dritte wurde als einzelne orale Dosis 
gegeben. Effekte der Substanzen auf klinische Symptome und auf das EEG wurden evaluiert. 
Parallel wurden Blut- und Liquor-Proben zur Bestimmung der Substanzspiegel und 
potentieller Biomarker genommen. Die Auswahl der Substanzen bot zusätzlich die 
Möglichkeit, die Empfindlichkeit der beiden regelmäßig in Arzneimittelprüfungen 
verwendeten Nicht-Nager Spezies Hund und Affe für neurologische Symptome vergleichend 
zu bewerten.  
Die Ergebnisse zeigen, dass die Kombination von Implantaten für EEG-Aufzeichnung und CSF-
Probennahme möglich ist. Die intravenöse Applikation war der oralen Substanzgabe 
vorzuziehen, da die Variabilität der Substanz-Plasmaspiegel geringer war. Alle Symptome, 
die aus früheren toxikologischen Studien mit längerer Dauer bekannt waren, wurden ebenso 
beobachtet. Durch das Dosierungsschema war ihr Auftreten allerdings auf eine verkürzte 
Zeitspanne reduziert. Die kurze Studiendauer ermöglichte durchgehende klinische 
Beobachtung, somit die Erkennung aller Symptome und zeitnahe veterinärmedizinische 
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Behandlungen, was im Sinne des Tierschutzes einen Vorteil darstellt. Für eine frühzeitige 
Erkennung von Krampfanfällen war das EEG nicht besser geeignet als klinische Beobachtung, 
da die Interpretation des ungefilterten EEG Signals durch das Auftreten von Artefakten 
erschwert war.  
Das Studiendesign, in dem das EEG angewendet wurde, ist zur Charakterisierung 
neurologischer Nebenwirkungen geeignet, da alle Symptome, die aus Studien mit längerer 
Dauer bekannt waren, ebenso beobachtet wurden. Durch die verkürzte Dauer wurde 
ermöglicht, Symptome und Substanzplasmaspiegel zu korrelieren und zeitnahe tierärztliche 
Behandlungen durchzuführen. Bei Substanzen, die ein hohes Risiko für neurologische 
Nebenwirkungen haben, kann dieses Studiendesign genutzt werden um im Vorfeld von 
behördlich geforderten toxikologischen Studien Dosierungen zu bestimmen, bei denen keine 
schweren neurologischen Nebenwirkungen zu erwarten sind.  
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IX. Appendices  
1  Medication: Surgery 
Active Agent Trade Name Vendor Dose Administration  Route 
Enrofloxacin Baytril® Flavour 50 mg/ 15mg 
Bayer Vital 
GmbH 5 mg/kg 
Starting 1 day prior 
to surgery, daily for 
a total of 7 days 
p.o. 
Enrofloxacin Baytril® - 2,5% Injektionslösung 
Bayer Vital 
GmbH 5 mg/kg 
On the day of 
surgery  s.c. 
Caprofen Rimadyl®20mg Tabletten  
Zoetis 
Deutschland 
GmbH 
4 mg/kg 
Starting 1 day prior 
to surgery, daily for 
a total of 7 days 
p.o. 
Caprofen Carprieve® 
Zoetis 
Deutschland 
GmbH 
4 mg/kg 
On the day of 
surgery instead of 
the oral dose 
s.c. 
Buprenor-
phine Buprenovet® 
Intervet 
Deutschland 
GmbH 
0.02(mg/
kg) 
30 min prior to 
midazolam; every 6 
hours for 3-4 days 
i.m. 
Midazolam 
Midazolam-
ratiopharm® 
15mg/3ml  
Ratiopharm 
GmbH 
0.2 
(mg/kg) 
On the day of 
surgery, 
premedication 
i.v. 
Propofol  Propovet™ Multidose 
Abbott 
Laboratories Ltd 
initial: 6.6 
mg/kg 
then after 
effect 
prior to intubation i.v. 
Dexpanthenol  
Bepanthen® 
Augen- und 
Nasensalbe 5 %  
Bayer Vital 
GmbH 
to cover 
both eyes 
after loss of 
consciousness, 
repeated if needed 
corneal 
Isofluran Isofluran CP CP Pharma GmbH 
approx. 
2.0-3.5% during surgery 
per 
inhala-
tionem 
Lidocaine Xylocain® Pumpspray 
AstraZeneca 
GmbH 
One 
pump 
spray 
Prior to insertion of 
ear bars 
ear 
canals 
Bupivacain - 
hydrochloride 
Bupivacain 
0.25% 
Jenapharm®  
Mibe GmbH 
Arzneimittel 
Approx. 
2-5mL during surgery 
on 
muscles  
Dexametha-
sone 
Dexamethasone 
Injektionslösung 
ad us. Vet. 
2mg/mL  
CP Pharma 
GmbH 1 mg/kg  
during surgery, 
prior to drilling i.v. 
Ringerlactat 
Ringer Lactat 
Hartmann B. 
Braun Vet Care 
B. Braun 
Melsungen AG  
8-10 
ml/kg/h  during surgery i.v. 
Povidon-Iod  Braunovidon® Salbe 10%  
B. Braun 
Melsungen AG  
to cover 
wound 
after wound 
closure topic 
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2 Materials for Implantation of Electroencephalography Transmitters in Dogs 
Instruments Specifications 
Adson-Forceps, straight, serrated n=2 
Adson-Brown tissue forceps, straight, with 
teeth n=2 
Allis tissue clamps n=2 
Dental elevator n=1 
Medium/large gelpi retractors (fine) n=2  
Weitlaner retractor 2 x 3 with wide spread n=1 
Kelly hemostat forceps, curved n=1-2 
Kelly hemostat forceps, straight n=1-2 
Halsted mosquito forceps, curved n=2 
Halsted mosquito forceps, straight n=2 
Debakey forceps n=2 
Mayo-scissors straight, 15cm n=1-2 
Metzenbaum scissors, curved, 14.5 cm n=1-2 
Olsen-Hegar needle holder/ Webster needle 
holder n=1 
Backhaus towl clamps n=6 
Trocar n=1 
Screwdriver n=1 
Drill handpiece and motor; motor on i.v. stand; with footpiece 
Drill bits 1.18mm 
Drill holder for manual drilling n=1 
Bur 1.4mm, n=1-2 
10 blade with scalpel handle n=1 
Screw-holding forceps, curved n=1 
Skin stapler n=1 
Plate to mix dental cement, n=1 
Spatula to mix dental cement, n=1 
Lineal n=1 
Allen Wrenches 
 n=3 (5/32", 2", 3") 
Others Specifications 
Stereotaxic with ear bars n=1, e.g. Stoelting Co. 
Screws n=2; Plastics One®, Size 0-80 (Shaft 3.2mm/ head diameter 2.5mm/ shaft diameter 1.57mm) 
Sterile covers 
MTP- Medical Technologies GmbH; camera cover folded 
with paper insertic aid, 13x242cm, sterile; to cover the 
drill 
Cidex® OPA Advanced Sterilization Products®, Johnson + Johnson 
Cidex® OPA Test Strips Advanced Sterilization Products®, Johnson + Johnson 
Large sterilization bin with lid n=1-2 
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Bowl to rinse the transmitter in sterile saline prior to implantation 
Cotton tip applicators Several sterilized in surgical pack, additional packs 
Gauze Several sterilized in surgical pack, additional packs 
small towels n=5-6; to place around stereotaxic 
Skin marker Mediware Skin Marker, servoprax GmbH 
Electro-cautery If necessary, use only prior to implantation of transmitter 
Bone cement Smartset GHV, DePuy CMW, Johnson+Johnson 
Electric razor Aesculap® Vega/ Isis B. Braun Melsungen AG 
Sterile gloves KruTex Vet-Gel surgical gloves 
Endotrachealtubus Rüsch® Super Safety Clear Trachealtubus, size appropriate for the respective dog 
SMI-Spoon Resorbierbarer Gelatineschwamm SMI AG 
Surgical Glue 3M VetbondTM 
Sutures 3/0 Dafilon®, B. Braun Melsungen AG 3/0 Monosyn®, B. Braun Melsungen AG 
Syringes different sizes; e.g. 1mL, 5mL, 10mL 
Sterile cannulas Different diameters   
Sterile bag-in-bag In case of multiple days of surgery: to sterile pack the drill handpiece 
 
3 Medication: Experiments  
Active Agent Trade Name Vendor Dose (mg/kg) Route 
Midazolam 
Midazolam-
ratiopharm® 15mg/3ml 
Injektionslösung 
Ratiopharm GmbH 0.2 i.v. 
Apomorphine Emedog 1 mg/mL Laboratoire TVM 0.8 s.c. 
Propofol Propovet™ Multidose Abbott Laboratories Ltd initial: 6.6; after effect i.v. 
Metamizol Natrium 
500mg/ml Metamizol WDT 
Wirtschaftsgenossenschaft 
deutscher Tierärzte eG 20-50 i.v. 
Metoclopramide Emeprid® Injection Cewa 1 s.c. 
Maropitant Cerenia® ad us. vet Zoetis GmbH 1 s.c. 
Lidocainehydrochloride 
20mg/mL 
Lidocainehydrochloride 
2% 
Bela-Pharm 
Arzneimittelfabrik 
1mL per cm 
skin field s.c. 
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4 Supplementary Data  
 Biomarker Analysis  4.1
 
  
Figure 104: Hydroxytetradecenoylcarnitine 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 105: Tetradecadienylcarnitine changes 
from baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
  
Figure 106: Hexadecanoylcarnitine changes from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 107: Octadecanoylcarnitine changes from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Appendices 
 
- 131 - 
 
  
Figure 108: Octadecenoylcarnitine changes from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 109: Glutarylcarnitine changes from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
  
Figure 110: Methionine changes from baseline to 
time points 1, 2 and 3 after administration of 
compound 1 (above), 2 (middle) and 3 (bottom). 
Figure 111: Proline changes from baseline to 
time points 1, 2 and 3 after administration of 
compound 1 (above), 2 (middle) and 3 (bottom). 
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Figure 112: Nitro-Tyrosine changes from baseline 
to time points 1, 2 and 3 after administration of 
compound 1 (above), 2 (middle) and 3 (bottom). 
 
Figure 113: Lyso-Phosphatidylcholine a.C16:1 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
  
Figure 114: Lyso-Phosphatidylcholine a.C26:0 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
Figure 115: Lyso-Phosphatidylcholine a.C26:1 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
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Figure 116: Phosphatidylcholine a.aC28:1 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 117: Phosphatidylcholine a.aC30:0 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
  
Figure 118: Phosphatidylcholine a.aC34:1 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
Figure 119: Phosphatidylcholine a.aC38:1 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
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Figure 120: Phosphatidylcholine a.aC40:1 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 121: Phosphatidylcholine a.aC40:2 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
  
Figure 122: Phosphatidylcholine a.aC40:4 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 123: Phosphatidylcholine a.aC42:5 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
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Figure 124: Phosphatidylcholine a.aeC34:2 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 125: Phosphatidylcholine a.aeC34:3 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
  
Figure 126: Phosphatidylcholine a.aeC42:2 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
Figure 127: Phosphatidylcholine a.aeC44:3 
changes from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
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Figure 128: Sphingomyelin-OH-C22:2 changes 
from baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 129: Sphingomyelin C20:2 changes from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
  
Figure 130: Sphingomyelin C24:0 changes from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
Figure 131: Sphingomyelin C24:1 changes from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
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Figure 132: Sphingomyelin C26:1 changes from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 133: Changes in the ADMA/Arg ratio from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
  
Figure 134: Changes in MUFA.(PC) from baseline 
to time points 1, 2 and 3 after administration of 
compound 1 (above), 2 (middle) and 3 (bottom). 
Figure 135: Changes in the SDMA/Arg ratio from 
baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
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Figure 136: Changes in the total DMA/Arg ratio 
from baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
 
Figure 137: Changes in total sphingomyelins 
from baseline to time points 1, 2 and 3 after 
administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
  
Figure 138: Changes in total non-OH 
sphingomyelins from baseline to time points 1, 2 
and 3 after administration of compound 1 
(above), 2 (middle) and 3 (bottom). 
Figure 139: Changes in the Tyrosin/ Phenylalanin 
ratio from baseline to time points 1, 2 and 3 
after administration of compound 1 (above), 2 
(middle) and 3 (bottom). 
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Figure 140: Correlations between the 34 detected metabolites 
(final time point, n=6). 
 
 
Figure 141: fold changes across time points for compound 1. 
 
 
Figure 142: fold changes across time points for compound 2. 
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Figure 143: fold changes across time points for compound 3. 
 
 
Figure 144: Fold changes across time points for all 3 compounds. 
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 qEEG Data  4.2
The following scatter plots show the changes from baseline to post treatment values in each 
frequency band for each dog respectively. Mean +/-SD are displayed. The medians that were 
calculated for comparison of both dogs are close to mean levels.  
 
 Midazolam 6.2.1
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Figure 145: Changes in relative EEG power after midazola treatment (dog 1001). 
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Figure 146: Changes in relative EEG power after midazola treatment (dog 1002). 
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 Propofol 6.2.2
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Figure 147: Changes in relative EEG power after propofol treatment (dog 2001). 
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Figure 148: Changes in relative EEG power after propofol treatment (dog 2002). 
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 Apomorphine 6.2.3
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Figure 149: Changes in relative EEG power after apomorphine treatment (dog 1001). 
 
 
Relative Power BL - Apomorphine
De
lta
 BL
De
lta
 Ap
om
orp
hin
e
 Th
eta
 BL
Th
eta
 Ap
om
orp
hin
e
Alp
ha
 BL
Alp
ha
 Ap
om
orp
hin
e
Sig
ma
 BL
Sig
ma
 Ap
om
orp
hin
e
Be
ta 
BL
Be
ta 
Ap
om
orp
hin
e
Ga
mm
a B
L
Ga
mm
a A
po
mo
rph
ine
0
20
40
60
Dog 1002
%
 E
EG
 
Figure 150: Changes in relative EEG power after propofol treatment (dog 2002). 
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 Quinpirole 6.2.4
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Figure 151: Changes in relative EEG power after quinpirole treatment (dog 2001). 
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Figure 152: Changes in relative EEG power after quinpirole treatment (dog 2002). 
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 Compound 1  6.2.5
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Figure 153: Changes in relative EEG power after compound 1 (dog 2001). 
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Figure 154: Changes in relative EEG power after compound 1 (dog 3002). 
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 Compound 2 6.2.6
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Figure 155: Changes in relative EEG power after compound 2 (dog 1001). 
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Figure 156: Changes in relative EEG power after compound 2 (dog 1002). 
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 Compound 3  6.2.7
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Figure 157: Changes in relative EEG power after compound 3 (dog 3001). 
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Figure 158: Changes in relative EEG power after compound 3 (dog 2002). 
 
 
 
Appendices 
 
- 148 - 
 
Relative power (%) Compound 3
EE
G 
De
lta
 BL
EE
G 
De
lta
 Co
mp
. 3
EE
G 
Th
eta
 BL
EE
G 
Th
eta
 Co
mp
. 3
EE
G 
Alp
ha
 BL
EE
G 
Alp
ha
 Co
mp
. 3
EE
G 
Sig
ma
 BL
EE
G 
Sig
ma
 Co
mp
. 3
EE
G 
Be
ta 
BL
EE
G 
Be
ta 
Co
mp
. 3
EE
G 
Ga
mm
a B
L
EE
G 
Ga
mm
a C
om
p. 
3
0
20
40
60
80
EEG Power Bands (BL - Treatment) Dog 3001
%
 E
EG
 
Figure 159: Changes in relative EEG power after compound 3, second experiment. 
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